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ABSTRACT 
 
Parenteral nutrition (PN) is an essential life sustaining therapy for premature and 
critically ill infants.  However, prolonged PN therapy can lead to life-threatening liver damage, 
and cause parenteral nutrition associated cholestasis (PNAC).  There has been some recent 
evidence that aluminum accumulation in the livers of PN-fed subjects may lead to hepatic 
damage leading to liver injury.  This dissertation aimed to investigate the role of aluminum as a 
toxic component of parenteral nutrition and as a risk factor in developing PNAC.   
The project composed of two main studies.  The objectives of the first study were:  
1) Evaluate the early morphological changes in piglet liver after intravenous  
  administration of aluminum chloride hexahydrate at a dose of 1500 µg/kg/d.; 2) Determine 
whether the morphological changes deteriorate further with increasing duration of exposure and 
whether these changes correlate with changes in biochemical markers of cholestasis; 3) Identify 
the appropriate imaging technique for studying the ultrastructural changes in the liver; 4) 
Determine if intravenous injection of high dose aluminum into neonatal piglets disrupts iron 
homeostasis in the liver.  
The results showed that intravenous infusion of aluminum in neonatal piglets led to 
marked elevation in serum total bile acids, and transmission electron microscopy-energy 
dispersive microanalysis (TEM-EDX) was suitable in detecting the site of Al deposition in the 
liver and in demonstrating histopathological changes associated with Al infusion.  
The objectives of the second part were to: 1) Investigate the role of aluminum as a toxic 
component of parenteral nutrition and as a risk factor in causing liver injury; 2) Evaluate the 
effect of reducing aluminum content of parenteral nutrition on liver iron homeostasis; 3) 
Investigate the effect of low aluminum PN and high aluminum PN (regular PN) on the mRNA 
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expression of Bsep and Mrp2.   
The results showed that administration of PN solution with lower Al content led to 
reduced levels of serum and hepatic Al in low Al PN group compared to regular PN group.  This 
reduction was associated with less histopathological changes in the liver. On the other hand, 
administration of regular PN in piglets led to decreased expression of transporter Mrp2.  
This work suggests that reducing Al content in PN may reduce the development and 
severity of liver injury in the piglets. 
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1.0 Introduction 
1.1 Rationale 
Parenteral nutrition (PN) is the intravenous administration of complete and balanced nutrition 
given to patients who are seriously ill and are unable to tolerate enteral feeding.  Since its 
introduction into clinical practice in the 1960s, parenteral nutrition has been associated with the 
development of parenteral nutrition associated cholestasis (PNAC).  Prolonged parenteral 
nutrition (usually ≥ 3 weeks) is associated with complications affecting the hepatobiliary system, 
such as steatosis and cholestasis.  While steatosis (fatty liver) is relatively more common in 
adults, cholestasis is more common in children (Payne-James and Silk, 1991; Quigley et al., 
1993; Kelly, 1998).  Parenteral nutrition associated cholestasis remains a significant problem in 
terms of not only incidence but also lack of effective treatment, the mortality, and morbidity 
associated with the illness.  The occurrence of the illness is more frequent and severe in infants 
than in adults (Allard, 2002).  The reported incidence of PNAC in children is quite variable from 
study to study.   Data from epidemiological study reported that 7.4% of the 624 infants 
developed PNAC (Bell et al., 1986).   Another study, the incidence of neonatal PNAC has been 
reported at 25% (Kubota et al., 2000), and associated mortality may range from 20% to 31% 
(Kubota et al., 2000; Ginn-Pease et al., 1985).  Sondheimer et al., reported that cholestasis 
developed in 28 (67%) of the 42 infants receiving parenteral nutrition (Sondheimer et al., 1998).  
The incidence of PNAC might be as high as 84% in a study conducted on 31 infants receiving 
PN (Cohen and Olsen, 1981). 
Although several biochemical parameters have been used to define this disorder for 
research purposes, a serum direct bilirubin ≥ 34 mol/L is considered the most commonly used 
marker after exclusion of other causes of cholestasis (Guglielmi et al., 2006).  The common 
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histopathological features of PNAC are intracanalicular cholestasis and periportal fibrosis.  Other 
histopathological findings include giant cell transformation, portal inflammation, acute 
cholangitis, hepatocellular damage and severe fibrosis (Benjamin, 1981; Hodes et al., 1982; 
Sokol, 1997; Kelly, 1998; Zambrano et al., 2004).   
Despite the well documented association between PN administration and cholestasis, the 
precise etiology of PNAC remains unclear.  Many researchers agree that the etiology of the 
disease is multifactorial.  A number of risk factors that predispose children to PNAC are age-
related risk factors including prematurity, lack of enteral feeding, and sepsis (Forchielli and 
Walker, 2003).  Other important risk factors related to the PN components themselves are 
nutrient deficiencies, caloric load, and toxicity of nutrients (Forchielli and Walker, 2003).   
Aluminum is a significant contaminant of PN component solutions such as calcium and 
phosphate salts (Sedman et al., 1985; De Vernejoul et al., 1985; Li et al., 2005).  More than 81% 
of aluminum contamination in neonatal PN can be attributed to calcium gluconate (Mouser et al., 
1998).  When parenterally administered, aluminum bypasses the protective barrier of the 
gastrointestinal tract and may become deposited in bone, liver, spleen, kidney, brain, and other 
tissues (Yokel and McNamara, 2001; Priest et al., 1998).  Approximately 40% of the 
intravenously infused aluminum is retained in adults and up to 75% is retained in neonates 
(Klein, 1995).  Kidneys are the major excretory organ for aluminum, thus patients with reduced 
renal function and premature infants are at greatest risk for aluminum toxicity (Yokel and 
McNamara, 2001; Sedman et al., 1985; Advenier et al., 2003).  Also, because of immature renal 
function, premature infants are more prone to aluminum toxicity due to their increased calcium 
and phosphorus requirements thus exposing them to more aluminum contaminants from the 
calcium and phosphorus salts (Advenier et al., 2003).   
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In addition to well established toxic effects of aluminum exposure on brain, liver, skeletal 
muscles, heart, and bone marrow (Galle, 1987; Bishop et al., 1997; Gilbert-Barness et al., 1998; 
Gonzalez et al.,  2007; Al-Hashem, 2009; Mahdy, 2009), aluminum has also been implicated in 
altering cellular iron homeostasis.  Disruption of cellular iron homeostasis can pose serious 
health problems.  Elevated cellular iron concentration can induce oxidative stress to the cell and 
is linked to the pathogenesis of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and 
heart-related diseases (Kell, 2009). 
Despite the attempts to reduce the aluminum contamination in the PN solution, aluminum 
toxicity is still reported in many studies (Poole et al., 2008).  Previous studies of aluminum 
exposure from PN solutions have reported aluminum intakes in the range of 10 - 60 µg/kg/day 
(Mouser et al., 1998; Popinska et al., 1999; Advenier et al., 2003), which significantly exceeds 
the recommendations set by the American Society for Clinical Nutrition, and American Society 
of Parenteral and Enteral Nutrition (ASCN/ASPEN) for safe aluminum infusion of 2 μg/kg/day 
(ASCN/ASPEN, 1991).  These intake ranges also exceed the safe upper limit of 5 μg/kg/day Al 
recommended by Food and Drug Administration (FDA, 2000) and Health Canada (2011).    
Research draws a correlation between aluminum loading and PNAC in neonates (< 28 
days).  Despite this relationship, the exact role of aluminum in the development of PNAC is 
unknown.  No consistent histopathological changes are seen in the liver after infusion of Al.  
Moreover, such studies used less ideal and animal models (Klein et al., 1987; Klein et al., 1988).   
Considering the significant aluminum contamination of the PN components, and the high 
risk of PNAC in neonates, the suggested relationship between aluminum contaminated PN 
solutions and the development of cholestasis needs further study.  In a retrospective study in 
Saskatchewan, 31% of hospitalized infants with gastrointestinal failure who received parenteral 
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nutrition (PN) for 21 days developed cholestasis (Li et al., 2004).  Although these PN solutions 
were contaminated with 21.6 µg/kg/d aluminum (compared to the recommended ‘safe’ level of 2 
µg /kg/d for adults), its causal relationship to PNAC remains speculative.   
In continuation of the previous work, a newborn piglet model was developed to study the 
effect of aluminum infusions on biochemical parameters and histopathological features of the 
liver.  The newborn piglet is an excellent model for the human infant because of the comparative 
anatomy, physiology and metabolism, especially the similarities of the hepatobiliary system 
(Pond and Mersmann, 2000).   In previous work conducted in our laboratory, piglets were orally 
fed and given daily intravenous injections of either a high dose (1500 µg/kg/d) or low dose (20 
µg/kg/d) aluminum for 3 weeks and were compared with saline and PN controls (Li, 2004).   
After 3 weeks, the high aluminum group showed biochemical and histologic signs of cholestasis.  
In the low dose aluminum group, piglets had increased serum bilirubin levels but no histologic 
signs of cholestasis.  In my work, I aimed to determine the early morphological ultrastructural 
changes in the liver that are associated with aluminum infusion and correlate those changes with 
biochemical markers of cholestasis namely the serum direct bilirubin and total bile acids. 
Furthermore, I aimed to identify an appropriate imaging technique(s) for the early detection of 
ultrastructural changes consistent with cholestatic changes of the liver.  However, to reproduce 
the hepatic changes, it was first necessary to conduct a study using the high aluminum dose 
(1500 μg/kg/d) previously shown to cause cholestasis in piglets.  This dose of aluminum was 
selected as being large enough to reproduce histologic and biochemical changes in the piglet’s 
liver (Klein et al., 1987; Li et al., 2004) and, hence, allow for the identification of an appropriate 
imaging technique. The findings from this first study would then lead to the second major study 
of my PhD thesis research involving a clinical model of total parenteral nutrition infusion 
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containing high and low aluminum content.  
The results obtained can better enable us to understand the morphological and 
biochemical changes during the infusion of aluminum as well as to determine the early changes 
associated with aluminum loading.  These results might help to develop a better understanding 
on the role of aluminum in causing PNAC.  This information would be very helpful in 
identifying the onset of the disease as well as reducing the incidence and severity of the disease. 
1.2 Hypotheses and Objectives 
The main hypothesis of my PhD thesis research was that high aluminum content PN 
causes early histopathological changes and elevated biochemical markers in the liver and 
lowering aluminum content would reduce the histopathological changes and lower the 
biochemical markers of tissue damage, and thus reduce the incidence and severity of PNAC.  
The primary objective of the present study is to evaluate the effect of low aluminum content PN 
compared to regular PN on the histopathological ultrastructure and biochemical markers in the 
piglet’s liver. My secondary objective is to investigate the aluminum-iron interaction in the liver 
tissue and their role in causing liver injury.  
This project is composed of two main studies; the first study is to examine the early 
morphological structural changes in the piglet’s liver after daily intravenous infusion of high 
aluminum doses (1500 µg/kg/d) and correlate these changes with biochemical changes.  Piglets 
will receive high aluminum dose for different durations of exposure and the degree of 
pathological changes in the liver and changes in biochemical markers of cholestasis will be 
correlated with the duration of aluminum exposure.  The high dose of aluminum was previously 
shown to cause cholestasis in the piglet and use of this dose will allow a determination of the 
imaging technique that best identifies the ultrastructural changes in the liver with aluminum 
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exposure.   
The second study will use a clinical model of total parenteral nutrition, the neonatal 
Yucatan piglet.  The piglets will be administered PN with high and low dose aluminum for two 
weeks and the development of PNAC will be evaluated using the biochemical markers and the 
imaging technique identified in the first study.  To test our hypothesis, this project utilizes a 
combination of morphologic and biochemical methods in order to elucidate the role of aluminum 
in causing liver injury in neonatal piglets.  
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2.0 LITERATURE REVIEW 
 
2.1 Parenteral nutrition associated cholestasis 
Since the introduction of parenteral nutrition (PN) in the 1960s, its use has become a vital 
tool in clinical practice.  Parenteral nutrition is used frequently for nutritional support of 
clinically ill individuals with disorders of the gastrointestinal tract who cannot tolerate enteral 
intake (Burrin et al., 2003; Baserga and Sola, 2004).  However, several studies have shown that 
prolonged use of PN is associated with liver and biliary system diseases including cholestasis, 
cholelithiasis, sepsis, and liver cirrhosis (Kelly, 1998; Briones and Iber, 1995).  Parenteral 
nutrition associated cholestasis (PNAC) is defined as cholestasis that is associated with a 
prolonged duration of parenteral nutrition administration more than 2 weeks (Drongowski et al., 
1989).   Elevated serum direct bilirubin, total bile acids, and transaminases are the common 
biochemical presentation of PNAC.  However, because this presentation is identical to other 
cholestatic liver diseases (Sokol, 1997; Kelly, 1998), therefore, PNAC can be accurately 
diagnosed only after other causes of extrahepatic cholestasis have been excluded, namely 
obstructive causes and metabolic liver diseases (Carter and Shulman, 2007; Guglielmi, 2008).  
The frequency of parenteral nutrition associated cholestasis varies in studies from 7.4–
84% (Beale et al., 1979; Cohen and Olsen, 1981; Bell et al., 1986; Sandhu et al., 1999).  A 
number of studies indicate that approximately 40–60% of children on long-term PN will develop 
hepatic dysfunction (Kelly, 1998).  In 1975, Rager et al. reported that nine of 15 premature 
infants who received PN have demonstrated cholestasis histologically.  The nine infants had a 
serum total bilirubin greater than 8 mg/dL, the normal value for total bilirubin ranging 0.2-1.9 
mg/dL (Catherine et al., 2003).  The results of a retrospective study of neonates who received PN 
for at least one week reported that 15% of infants developed PNAC (Drongowski and Coran, 
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1989).  In this study, the cholestasis was defined as a direct serum bilirubin greater than 2.0 
mg/dL during the course of PN therapy.  In another study, the overall incidence was 43% in 
infants receiving PN for 19 to 75 days (.Touloukian and Seashore, 1975).  The incidence of 
PNAC closely related to duration of PN.  For example, the overall incidence of cholestasis in 62 
premature infants on PN was 23%, but infants receiving PN for more than two months has an 
incidence of 80% increasing to 90% in those on PN for more than 3 months.  Serum direct 
bilirubin above 2.0 mg/dL was used as cut-off point to define cholestasis (Beale et al., 1979).  In 
a more recent study, the author found that 25% of neonates with intestinal pathology who 
received PN for a mean of 18 days developed parenteral nutrition associated cholestasis (Arnold, 
2002).   
After more than 30 years, despite the well-documented association between PN 
administration and cholestasis, the precise etiology of parenteral nutrition associated cholestasis 
remains mystery (Carter and Shulman, 2007).  Many researchers agree that the etiology of the 
disease is multifactorial.  A number of risk factors that predispose children to PNAC are age-
related risk factors including prematurity, lack of enteral feeding, low birth weight, sepsis, 
caloric overload, and toxicity of the PN components(Forchielli and Walker, 2003; Guglielmi et 
al., 2008) .   
2.1.1 Potential risk factors  
2.1.1.1 Prematurity and low birth weight 
A relationship has been identified between the development of cholestasis in infants who 
are premature and of low birth weight.  However, because many infants who need PN are likely 
to be premature and of low birth weight, it is difficult to decide whether prematurity and low 
birth weight are independent or associated risk factors.  Premature are  infants defined as those 
who are born before 37 weeks gestational age and are usually born with birth weight less than 
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2500 g.   Beale et al., found that 50% of premature infants (n=62) receiving parenteral nutrition 
with birth weight less than 1000 g had cholestasis (direct bilirubin > 1.5 mg/dL), and 18 % at 
birth weight between 1000-1499 g and only seven % had cholestasis with a birth weight greater 
than 1500 g (Beale et al., 1979).  The increased incidence of cholestasis in premature infants 
with low birth weight suggests that the disease may be related to the immaturity of neonatal 
biliary secretory system.  The decreased size of the bile acid pool due to both reduced hepatic 
uptake and synthesis of bile acids make premature neonates more susceptible to the development 
of cholestasis (Afdhal and Smith, 1990; Gleghorn et al., 1989).  Premature infants with a lower 
gestational age have shown to have elevated serum direct bilirubin concentrations (> 40 µmol/L) 
and developed cholestasis (Pereira et al., 1981; Beath et al., 1996).  Pereira et al. reported that the 
frequency of cholestasis was 1.4 % in the neonates who were born at a gestational age of > 36 
weeks, and increased to 5.3% in infants who were born between 32 and 36 weeks, and reached 
13.75 % for infants born before 32 weeks (Pereira et al., 1981).  Although some studies have 
linked the development of cholestasis in infants to prematurity and low birth weight, more 
research is needed to identify whether prematurity and low birth weight are independent or 
associated risk factors.  
 
2.1.1.2 Lack of enteral feeding 
Lack of enteral feeding has a crucial role in the development of PNAC.  The levels of 
cholecystokinin and other gastrointestinal hormones, such as glucagon, gastrin, and 
enteroglucagon are reduced in patients receiving parenteral nutrition compared to enterally fed 
(Greenberg et al., 1981).  These hormones are involved in stimulating bile flow and contraction 
of gallbladder.  A reduction in release of cholescystokinin, responsible for gallbladder 
contractility, resulted in formation of biliary sludge in the gallbladder, a common finding of 
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biliary stasis in infants with PNAC (Touloukian and Seashore, 1975).  However, the results of 
some studies reported that using enteral feeding and increasing the levels of cholecystokinin 
hormone did not significantly reduce the incidence of PNAC (defined as direct bilirubin level > 1 
mg/dL) (Teitelbaum, 2005; Demircan et al., 1998).  Also, lack of enteral feeding contributes to 
intestinal hypomotility, which has been reported to promote bacterial overgrowth in the small 
intestine (Lucas et al., 1983).  Bacterial overgrowth contributes to infections, bacterial 
translocation and endotoxin production, which in turn has the ability to downregulate bile acid 
transporting proteins (Trauner et al., 1998).  In addition, bacterial overgrowth has the ability to 
convert chenodeoxycholic acid into a hepatotoxic bile acid litocholic acid (Hofmann, 2004).  
However, in a retrospective study on 74 neonates received parenteral nutrition for more than 21 
days, the author reported that lack of enteral feeding did not promote cholestasis (Beath et al., 
1996), which implies that the importance of enteral feeding in the development of PNAC is still 
controversial and more research is need to be done.   
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2.1.1.3 Sepsis 
Sepsis is one of the most common complications of total parenteral nutrition infusion in 
infants (Rannem et al., 1986).  Beath et al. reported that surgical neonates had a 30 % increase in 
serum conjugated bilirubin concentrations during repeated episodes of sepsis (Beath et al., 1996).  
The mechanism of sepsis-induced cholestasis is unknown, but research has focused on the 
possible toxic effects of endotoxins on the hepatobiliary system.  Endotoxins are released from 
the gram-negative bacteria like Escherichia coli during systemic infections, or may translocate 
from the gut into the portal circulation by binding to specific sites of the intestinal membrane 
after their release by enteral bacteria (Gonnella et al., 1992).  In the liver, the amount of 
endotoxins may exceed the ability of Kupffer cells to detoxify them (Nolan, 1975), thus leading 
to their sequestration in hepatocytes (Utili et al., 1976; Gonnella et al., 1992) and causing direct 
hepatocellular injury.  In response to bacterial inflammation, higher level of cytokines tumor 
necrosis factor (TNF) and interlukines-6 (IL-6), have been found in the rats receiving parenteral 
nutrition compared to the control group (Zheng, 2004).  Moreover, treatment of animals with 
endotoxins or cytokines has been shown to cause down regulation of bile acid transporters 
(Green, 1996; Trauner et al., 1998; Denson et al., 2000), which are the crucial part of bile flow.  
However, in a study reviewing the medical records of 24 neonates with a clinical history of 
receiving PN who died at Yale –New Haven Children’s Hospital, the histological study of the 
liver samples found no significant relationship between parenteral nutrition induced-liver injury 
and sepsis (Zambrano et al., 2004).   
In summary, it is likely that sepsis may contribute to PNAC through the involvement of 
endotoxins.  However, the exact role of endotoxins as a causative factor in causing PNAC 
remains unclear.   
12 
 
2.1.1.4 Nutrients  
2.1.1.4.1 Taurine deficiency  
Taurine is an important amino acid for the conjugation of bile acids (Chesney et al., 
1998).   Premature infants have a decreased cystathionase level, an enzyme important for 
synthesis of taurine and cysteine from methionine (Zlotkin and Anderson, 1982).  The inability 
to produce enough taurine favours the formation of hydrophobic and toxic glycine-conjugated 
bile acids.  Taurine supplementation has been shown to maintain bile flow and bile acid secretion 
in guinea pigs (Guertin et al., 1993).  On the contrary, Cooke et al found that taurine 
supplementation in premature infants did not show any effect on hepatic function (Cooke, 1984).  
Moreover, no correlation has been found between low plasma taurine concentrations and 
cholestasis, and no strong evidence suggests that returning plasma taurine concentrations to 
normal would prevent PNAC (Btaiche and Khalid, 2002).  Recently, the formulation of some 
neonatal parenteral nutrition is now routinely supplemented with taurine (Forchielli et al., 1995; 
Adamkin et al., 1995; Thornton and Griffin, 1991).   However, no conclusive evidence has 
shown that supplemental use of taurine reduced the incidence of cholestasis (Teitelbaum, 1997).  
More studies are needed to demonstrate its true usefulness.  
2.1.1.4.2 Caloric load 
Overfeeding of energy substrates either in the form of dextrose, amino acids, or fats, 
individually or combined has been reported to cause hepatic steatosis and cholestasis (Messing et 
al., 1992; Wagner et al., 1983).  Excessive caloric intake is believed to promote fat deposition in 
the liver through stimulating insulin release, which in turn, promotes lipogenesis and inhibits the 
oxidation of fatty acids (Quigley et al., 1993).   Reduction in total calories of parenteral nutrition 
solutions leads to improved jaundice and histologic features of cholestasis in adult patients 
(Messing et al., 1992).  Excessive dextrose infusion may lead to steatosis but not to cholestasis in 
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adults (Btaiche and Khalidi, 2002).  The administration of excessive calories has been associated 
with elevated transaminase levels and hepatic steatosis in humans and animals (Sheldon, 1978).  
In addition, it is noteworthy that providing a balanced dextrose and fat source of calories in PN 
formulations would reduce the incidence of steatosis.  The recommended balanced PN should 
provide 70%-85% calories from carbohydrates and 15%-30% from fats (Miratallo et al., 2004). 
         However, now that dextrose-based PN formula is replaced with a more balanced dextrose-
fat PN formulation there has been a reduction in the incidence of steatosis (Quigley et al., 1993).  
The role of caloric load in the development of PNAC is still unclear and not much research has 
been done to clarify this relationship.  
2.1.1.4.3 Lipids 
The parenteral lipid emulsion, Intralipid
®
 (manufactured by Fresenius Kabi, Germany), a 
soybean-based lipid emulsion with egg yolk phospholipid, has been known for decades as the 
gold standard lipid emulsion in PN.  However, this intravenous soybean-based lipid emulsion has 
been implicated in the development of hepatic complications (Chen et al., 1996; Zaman et al., 
1997).  Phytosterols, naturally occurring sterols in plants, equivalent of cholesterol, are found in 
soybean-based lipids. Unlike cholesterol, phytosterols are not converted to bile acids and they 
are much faster excreted by the liver (Boberg et al., 1990).  Phytosterols has been postulated to 
have a deleterious effect on liver function (Clayton et al., 1993; Clayton et al.,1998).   Lyer et al. 
(1998) reported that administration of daily injection of sterol into neonatal piglets had caused a 
significant increase in the serum bile acid levels.  Furthermore, in isolated rat hepatocytes, 
phytosterols caused a significant inhibition in the secretory functions of the hepatocytes (Bindl et 
al., 2000).  In children with biochemical evidence of PNAC, high serum levels of phytosterols 
have been reported (Clayton, 1993).    
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Another critical component of soybean based lipid emulsion have been implicated to play 
a role in the development PNAC are ω-6 PUFAs (ω-6 polyunsaturated fatty acids), linoleic and 
arachidonic fatty acid (Camandola et al., 1996; Park et al., 2001; Dichtl et al., 2002).  The 
authors demonstrated that linoleic and arachidonic fatty acids increased the production of 
cytokines, inflammatory mediators, such as tumor necrosis factor (TNF) and interlukin-6 (IL-6).  
Also, arachidonic acid is a substrate for proinflammatory mediators such as leuktriens B4 and 
C4, Thromboxane A2 and eicosanoids prostaglandin E2 (Tilley et al., 2001).  These harmful 
effects led to the conclusion that increased levels of ω-6 PUFAs can cause inflammation (Calder 
et al., 2006).   
   Lately, Omeagven, fish oil based lipid emulsion receiving a lot of attention as a safe 
alternative intravenous lipid emulsion in PN.  This fish oil based lipid emulsion, still not 
approved yet in Canada and USA to be used in clinical practice. 
An animal study, using a fish oil-based lipid emulsion in PN instead of soybean-based 
lipid emulsion reported a reduced incidence of PNAC in neonatal piglets (Van-Aerde et al., 
1999).  The definition of PNAC was based on the bilirubin concentrations in serum.  The average 
serum bilirubin levels were 17.2 ± 2.4 µmol/L in the fish oil-based emulsion PN compared to 
soybean oil-based emulsion PN (123 ± 15.1 µmol/L).  In humans, case reports on the use of fish 
based lipid emulsions (i.e. Omegaven) reported significant improvements or complete resolution 
of cholestasis on the basis of histological features and serum direct bilirubin  (Gura et al., 2006).  
Retrospective studies also supported the finding that Omegaven has a reversal cholestatic effect.  
Diamond et al. found that Omegaven restored liver function, reduced serum direct bilirubin 
concentrations and led to complete recovery from cholestasis in 9 of the 12 patients on PN with 
PNAC (Diamond et al., 2009).  Also, in a case series study, the investigator observed that 
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Omegaven halted progressive PNAC in three of the four preterm infants with intestinal failure 
and PNAC (Cheung et al., 2009).  
 Although data evaluating the use of fish-oil based lipid emulsions in humans is limited, 
the fish oil-based emulsions are safer than soybean-oil based lipids and offer a promise in 
reducing the incidence of liver complications (Gura et al., 2006).   
2.1.1.5 Toxicity of nutrients  
Over the past decades, contamination of specific nutrients present or added to PN has 
been implicated in the pathogenesis of PNAC (Lavoie et al., 2005; Kelly, 2006).  The implicated 
components include aluminum, copper and manganese.   
2.1.1.5.1 Aluminum  
Since 1980s, Al has been known as a contaminant in PN solutions (Klein, 1982).  At that 
time, studies have estimated an increase in daily Al intake of 50-fold more than the present mean 
intake (Klein et al, 1984; Sedman et al., 1985; Klein, 1995).  During that time, however, some 
changes in the components of PN have been made to reduce the total load of Al in the PN 
solutions.  The casein hydrolysates, rich in Al, were replaced with crystalline amino acids that 
have lower Al content.  Although these changes have reduced the overall Al content in the PN 
solutions, Al remains present in a significant amount in several components of PN solution, 
including calcium and phosphate salts (Sedman et al., 1985; De Vernejoul et al., 1985).  Previous 
studies on Al exposure from PN solutions have reported that Al intakes in the neonates and 
children on PN range from 10 – 60 μg/kg/day (Mouser et al., 1998; Popinska et al., 1999; 
Advenier et al., 2003).   More recently, Poole et al found that the calculated Al exposure in 
neonatal PN solutions in the range of 30 - 60 μg/kg/day (Poole et al., 2008).  All of these studies 
exceeded the safe intake limit of 2.0 μg/kg/day of Al intake for adults recommended by the 
American Society of Clinical Nutrition/American Society of Enteral and Parenteral Nutrition 
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Joint Commission (ASCN/ASPEN 1991).  Research to date on aluminum contamination and the 
development of hepatic dysfunction suggests a strong relationship.  Much of the experimental 
research used non-neonatal models with aluminum doses far exceeding the level of 
contamination seen in PN.  Hence, further research into the relationship between aluminum 
contaminated PN solutions and the development of PNAC in neonates and infants is therefore 
necessary. 
 2.1.1.5.2 Manganese  
Manganese is an essential trace nutrient required as a catalytic cofactor for a variety of 
important enzymatic reactions in human physiolog, and it is one of the trace elements routinely 
added in parenteral nutrition admixture.   In recent years, there is a growing concern that chronic 
overexposure to manganese in long-term parenteral nutrition therapy may lead to manganese 
toxicity or “hypermanganesemia”, which is often associated with hepatic and cerebral 
complications (Dickerson, 2001).  A few studies have reported the effects of manganese toxicity 
in children receiving PN (Reynolds et al., 1994; Fell et al., 1996).  In a study by Fell et al., 45 
children (79%) of the 57 children receiving PN for more than two months had a higher plasma 
manganese level than the normal range.  In the same study, 11 children (19.2%) of 57 had both 
cholestasis and hypermanganesemia. Cholestasis in this group was defined as total serum 
bilirubin > 12 µmol/L (Fell et al., 1996).  On the contrary, Beath et al. found no significant 
difference in the frequency of cholestasis between two groups who received either high or low 
manganese dosage in parenteral nutrition solutions (Beath et al., 1996).  These results are 
supported by a recent study conducted on 54 infants receiving PN for four months.  Of the 54 
infants only 7 had high levels of serum conjugated bilirubin and manganese.  The author 
concluded that no correlation was found between high blood manganese levels and cholestasis 
17 
 
(McMillan et al., 2008).  No clear relationship between high levels of manganese and cholestasis 
has been established, and the existing data are contradictory.  It is unclear if the elevated 
manganese causes cholestasis or is it merely elevated because it is not well excreted in the face 
of cholestasis? 
2.1.2.5.3 Copper  
Copper is an essential trace mineral and an integral part of several crucial enzymes in 
metabolism (Linder and Hazegh-Azam, 1996).  Copper toxicity is very rare but chronic high 
intakes of copper are linked to Wilson’s disease and liver cirrhosis (Araya et al., 2003).  Copper 
is routinely included in the PN, and chronic high copper levels are hepatotoxic (Suita et al., 
1999) and may predispose patients on PN to hepatic injury.  A prospective study of children on 
PN found no correlation between cholestasis and copper levels (McMillan et al., 2008).  
Cholestasis was defined as a serum conjugated bilirubin ≥ 2 mg/dL.  Also, in a retrospective 
study of 28 cholestatic infants, their serum conjugated bilirubin > 2 mg/dL, who received PN and 
had 20 µg/kg/d copper added to PN, only 2 (7%) of the infants had elevated serum copper levels 
with no correlation in their high serum copper levels to liver disease progression (Frem et al., 
2010).  Reducing copper in PN however, may cause copper deficiency.  In 2004, Hurwitz et al. 
reported that an adult patient on PN with short bowl disease who devolved cholestasis (defined 
as serum conjugated ≥ 2 mg/dL) and had the copper removed from his PN.  The patient 
developed pancytopenia (reduction in red and white blood cells and platelets).  The copper was 
added back to PN and the pancytopenia was resolved (Hurwitz et al., 2004).  Copper is an 
important nutrient and it need to be added in adequate amounts to prevent hepatotoxicity or 
deficiency.  
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2.2 Anatomy of the liver  
The liver is the largest solid organ in the body, weighing about 1.5 kg in the adult 
(Lefkowitch, 2002).  It lies in the right upper quadrant of the abdomen, inferior to the diaphragm 
and anterior to the stomach.  The liver is unique amongst other organs.  In addition to the supply 
of arterial blood from the hepatic arteries, it also receives blood from the portal vein, which 
drains venous blood from the digestive tract, pancreas and spleen.  Thus, the liver is the main 
organ to metabolize all of the substances absorbed from the intestine.  It is also the first organ to 
be exposed to toxic compounds absorbed from the gastrointestinal tract.  The liver is an 
important metabolic organ; it acts as a transient nutrient store, transforms circulating metabolites 
and detoxifies harmful substances (Stieger and Meier, 1998; Suzuki and Sugiyama, 2000).  Also, 
the liver functions as an exocrine organ by producing bile and by secreting bile into the 
duodenum to facilitate lipid digestion and absorption (Guyton, 2006).   
The basic structural unit of the liver is the liver lobule (Figure 2.1), which is hexagonal in 
shape.  The lobule is composed principally of many hepatic cellular plates.  Each hepatic plate is 
usually two cells thick, and between the adjacent cells are the small bile canaliculi that empty 
into bile ducts (Guyton, 2006).  Branches of the hepatic artery, portal vein, and bile ducts are 
commonly found at the corners of the lobules.  In the center of the lobule, there is a central vein, 
which empties into the sublobular vein.  Several sublobular veins converge to form hepatic veins 
that empty into the inferior vena cava.  Plates of the hepatocytes radiate from the central vein to 
the perimeter of the lobule.   
Blood flows from the hepatic artery and portal vein through the sinusoids and drains into 
the central vein.  Sinusoids are lined by squamous endothelial cells and kupffer cells.  The lining 
is discontinuous, allowing direct contact of hepatic cells with soluble components of blood, and 
permitting the easy exchange of macromolecules between blood and the hepatocytes.  The 
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kupffer cells are derived from monocytes and are typical macrophages, capable of endocytosis of 
microbes and foreign particles (Guyton, 2006).   
 
 
              Figure 2.1. Composition of liver lobule. 
              (Source: Guyton, 2006) (Reprint permission obtained) 
 
 
Hepatocytes constitute about 80% of the total cells in the liver.  The multiple functions of 
the liver are primarily carried out by hepatocytes.  The cytoplasm of hepatocytes often contains 
glycogen.  Glycogen is mobilized when blood glucose concentrations are low.  Hepatocytes 
synthesize and secrete various plasma proteins, such as albumin, prothrombin, fibrinogen and 
lipoproteins.  Bile secretion is another important function of the hepatocytes.  It synthesizes bile 
salts from cholesterol and secretes the salts into bile canaliculi.  In addition to bile salts, 
cholesterol, phospholipids, bilirubin, water and electrolytes are co-excreted into the bile.  
Bilirubin is the metabolic waste of recycled red blood cells (Kuntz, 2006).  
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2.3 Bile formation, composition, and transport 
2.3.1 Bile formation  
Bile acids are synthesized from cholesterol in the liver.  They are classified as primary 
and secondary bile acids.  Primary bile acids are synthesized directly from cholesterol in the 
liver, and include cholic acid (CA) and chenodeoxycholic acid (CDCA), whereas, secondary bile 
acids, deoxycholic acid (DCA) and lithocholic acid (LCA) are formed by metabolism of primary 
bile acids by colonic bacteria.  The majority of the bile acids in humans are conjugated with 
taurine or glycine to form conjugated bile acids.  Bile acids are present as sodium salts and 
usually referred to as bile salts (Chiang, 1998).  These bile salts are then secreted across the 
canalicular membrane into bile canaliculi, which are small channels formed by half tubules from 
the apical surface of two adjacent hepatocytes (Guyton, 2006).  The bile canaliculi drain into bile 
ductules, which empty into the terminal branches called the terminal bile ducts (Saxena et al., 
1999).  Then, the bile flows into the right and left hepatic ducts that ultimately drain into the 
common hepatic duct (Boyer and Nathanson, 1999).  Bile is stored in the gallbladder and 
subsequently secreted into the common bile duct via the cystic duct.  In its course through the 
bile ducts, a second portion of liver secretion is added to the initial bile.  This additional 
secretion is a watery solution of sodium and bicarbonate ions secreted by secretory epithelial 
cells (cholangiocytes).  Cholangiocytes deliver fluids and electrolytes in response to hormonal 
secretion (primarily secretin) released by the duodenum into the portal bloodstream after 
stimulation by acidic pH, fatty acids, and bile acids (Kim et al., 1979).   
2.3.2 Composition of bile  
The normal adult liver secretes approximately 600 to 800 mL of bile a day.  Dissolved 
solids are 3% of bile by weight, and bile acids are the predominant organic solute at a biliary 
concentration of 20 to 30 mmol/L.  In addition to bile acids, phospholipids and cholesterol are 
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the next two most prevalent components, and they make up respectively 17% and 3% of the 
solutes in bile (Table 2.1).  Other components in the bile are present in small amount such as 
steroids, vitamins, drugs, and xenobiotics.  Bilirubin, present at a concentration of 0.2 mmol/L 
constitutes 1% of the bile volume.  Glutathione is present at relatively high concentrations of 5 to 
10 mmol/L in the cytosol of hepatocytes and used in many reducing reactions and glutathione 
and glutathione conjugates actively secreted into bile.  Inorganic salts are present in 
concentrations similar to those in plasma.  
 
Table ‎0.1. Composition of bile.  
Component  % 
Bile salts 41 
Electrolytes 31 
Phospholipids 17 
Proteins  7 
Cholesterol  3 
Bilirubin 1 
(Modified from Vlahcevic, 1996)  
 
 
2.3.3 Bile acid transport  
2.3.3.1 Enterohepatic circulation  
Bile acids, once produced in the liver, transported across the canalicular membrane of the 
hepatocytes into the bile and stored in the gallbladder.  After each meal, bile acids are released 
into the intestinal lumen, where they are efficiently reabsorbed by the enterocytes and 
transported back to the liver via portal blood for re-excretion into the bile.  This process is known 
as enterohepatic circulation of the bile (Chiang, 1998), and it is the main determinant of bile 
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flow.  The hepatocyte depends on the recirculation of bile acids to maintain the bile acid pool, 
which is 3 to 4 g in adult humans.  More than 95% of the bile acids excreted by the hepatocytes 
ultimately returned to the liver and resecreted into bile, and only 5% is lost into the feces.  The 
daily loss of bile acids compensated by de novo synthesis in the liver and thus, a constant bile 
acid pool is maintained (Meier and Stieger, 2002).  Bile acid transporters play important roles in 
this transport process.  The canalicular excretion of bile acids into bile against concentration 
gradient is the major driving force of normal bile flow (Trauner and Boyer, 2003).   
2.3.3.2 Hepatic bile acid transport  
2.3.3.2.1 Hepatic bile acid uptake   
The hepatocytes are polarized epithelial cells with basolateral (sinusoidal) and apical 
(canalicular) membrane domains.  Hepatocytes take up bile acids through the basolateral 
membrane, which is in direct contact with the portal blood plasma, and excrete bile acid at the 
canalicular membrane into the bile (Boyer, 1980).  Unconjugated bile acids are uncharged 
molecules under physiological pH and can pass through the cell membrane via passive diffusion.  
However, majority of the bile acids are conjugated with taurine or glycine and cannot cross the 
cell membrane and need active transport mechanisms for cellular uptake (Meier, 1995).  Two 
bile acid transporters, sodium-dependent taurocholate transporter (NTCP) and organic anion 
transporting polypeptide (OATP) are responsible for basolateral bile acid transport into the 
hepatocytes (Table 2).  The sodium-dependent taurocholate transporter co-transports two Na
+ 
ions down its concentration gradient into the hepatocytes along with one molecule of conjugated 
bile acid.  The trans-membrane Na
+ 
gradient is in turn maintained by the Na
+
- K
+
-ATPase 
(Kullak-Ublick et al., 2000).  Na
+
-dependent bile salt uptake pathway accounts for 80% of the 
total taurocholate uptake and is considered as the major bile acid transport system located at the 
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basolateral membrane (Meier and Stieger, 2002).  The Na
+
-independent bile salt uptake is 
mediated by several members of the OATP family.  Besides conjugated and unconjugated bile 
acids, many amphipathic organic compounds such as bilirubin, selected organic cations and 
numerous drugs are also taken up by these transporters (Meier et al., 1997).  
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Table 2.2.  Function of hepatocyte and cholangiocyte transporters in bile secretion.  
Name Abbreviation Location Function 
  Sodium–potassium     
   ATPase     
 
Na
+
 /K
+
 –
ATPase  
Basolateral 
membrane 
Removal of 2 Na
+
 in exchange for 3 
K
+
, thus creating a favorable 
Na
+
Gradient 
Na
+
-taurocholate 
contransporter 
NTCP 
 
Basolateral   
membrane 
Hepatic uptake of bile acids 
Organic-anion–
transporting 
polypeptide 
 
OATP Basolateral  
 membrane 
 
Multispecific carriers for sodium-
independent uptake of bile salts, 
organic anions, and other 
amphipathic organic solutes from 
portal blood 
Multidrug-resistance–
associated protein 
MRP2 Canalicular   
membrane 
Mediates ATP-dependent 
multispecific organic-anion transport 
(e.g., bilirubin diglucuronide) into 
bile; contributes to bile-salt– 
independent bile flow 
Multidrug-resistance-
3 P-glycoprotein 
(phospholipid 
transporter) 
MDR3 Canalicular  
membrane 
ATP-dependent translocation of 
phosphatidylcholine from inner to 
outer leaflet of membrane bilayer 
Canalicular bile-salt–
export pump 
 
BSEP Canalicular  
membrane 
ATP-dependent canalicular transport 
of bile acid 
Glutathione 
transporter 
 
GSH 
transporter 
Canalicular  
membrane 
Glutathione transport into bile; 
stimulates bile flow independent of 
bile salts 
 
Chloride channel Cl
- 
channel Canalicular 
membrane 
Facilitates chloride entry into bile 
Potassium channel 
 
K
+
  channel 
 
Basolateral  
membrane 
Determines membrane potential  
Cystic fibrosis 
transmembrane 
regulator 
CFTR Apical 
(luminal) 
membrane 
Chloride channel; facilitates chloride 
entry into bile 
Chloride–bicarbonate 
anion exchanger 
isoform 2 
AE2 Apical 
(luminal) 
membrane 
Facilitates bicarbonate secretion into 
bile and contributes 
to bile flow independent of bile salts 
  (Modified from Trauner et al., 1998) 
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2.3.3.2.2 Canalicular bile acid excretion  
Several members of the ATP-binding cassette (ABC) transporter family, driven by ATP 
hydrolysis, are responsible for transporting bile acids and other organic compounds across the 
canalicular membrane against their concentration gradients.  The bile salt export pump (BSEP), 
the major canalicular bile acid transport system, is responsible for monovalent bile acid 
(eg.taurocholate) transport at the canalicular membrane (Childs, 1995).  Divalent bile acids with 
two negative charges such as sulfated taurocholates are transported across the canalicular 
membrane by another ABC transporter called multidrug–resistant associated protein MRP2 
(Buchler, 1996).  MRP2, is also known as the canalicular multispecific organic anion transporter 
(MOAT) (Cui, 1999; Konig et al., 1999), mediates the excretion of glutathione conjugates and 
bilirubin.  Defects in MRP2 gene result in Dubin-Johnson Syndrome characterized by 
hyperbilirubinemia and hepatic accumulation of various endogenous and exogenous organic 
metabolites (Keitel et al., 2000).  
After bile acids are pumped into the bile, they stimulate phospholipid and cholesterol 
secretions into the bile, followed by a passive inflow of water (Oude Elfrink et al., 2000).  The 
excretion of phospholipids is mediated via the MDR3, and the major phospholipid in the bile is 
phosphatidylcholine (Smit, 1993; Langheim et al., 2005).  Bile acids, phospholipids and 
cholesterol are three major organic solutes of the bile and once secreted, they form mixed 
micelles to reduce their toxicity to the bile duct.  Normal bile formation depends largely on 
balanced secretion of these constituents.  Impaired secretions will disrupt the bile flow and result 
in cholestasis.  
2.4 Bilirubin metabolism 
Bilirubin is a catabolic by-product of hemoglobin from hemolyzed red blood cells.   The 
production of bilirubin from hemoglobin takes place in the reticuloendothelial cells.  First, heme 
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is converted to biliverdin by hemeoxygenase, and then biliverdin reductase catalyzes the 
conversion of biliverdin to bilirubin (Figure 2.2).  Unconjugated bilirubin is transported in the 
plasma tightly bound to albumin.  In the liver, despite tight albumin binding, the unconjugated 
bilirubin dissociates from albumin in the sinusoid and diffuses across the unstirred water layer at 
the surface of the hepatocyte (Ananthanarayanan et al., 2001).  The mechanism for transport of 
bilirubin across the plasma membrane into the hepatocyte involves transport proteins, such as the 
organic anion transporter (Knisely, 2004).  In the smooth endoplasmic reticulum of the 
hepatocyte, unconjugated bilirubin is catalyzed by bilirubin uridine diphosphate glucuronyl 
transferase to form bilirubin diglucuronide and monoglucuronide.  Biliary canalicular excretion 
of conjugated bilirubin is mediated by multi-drug resistance protein-2 (MRP2) located in the 
canalicular membrane with the apical region of the hepatocyte (Kuijck et al., 1997).  Biliary 
excretion of glucuronide is the rate-limiting factor in the transport of bilirubin from plasma to 
bile.  In the small bowel, bilirubin diglucuronide is not absorbed.  Further metabolism occurs 
mainly in the large bowel, bacterial β-glucuronidases hydrolyse the conjugated bilirubin, which 
is then reduced to urobilinogens and urobilin which are excreted in the stool.  Most of 
urobilinogen is excreted in feces and the rest is absorbed and re-excreted by the liver 
(enterohepatic circulation) and kidneys.  In case of hepatocellular dysfunction, re-excretion by 
the liver is impaired and more is excreted in the urine.  
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Figure 2.2.  Bilirubin formation and excretion  
Modified from Guyton 2008   
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2.5 Cholestasis 
Cholestasis is defined as the cessation or reduction of bile flow in a pathological 
situation.  It results from either a functional defect in bile formation at the level of the hepatocyte 
or from impairment in bile secretion and flow at the bile duct level (Trauner et al., 1998; Koopen 
et al., 1998).  Cholestasis can be divided into extrahepatic cholestasis and intrahepatic 
cholestasis, which includes obstruction of the intrahepatic bile ducts and hepatocellular 
cholestasis (Erlinger et al., 1999).  Despite the different causes of cholestasis, each of these 
diseases results in marked functional impairment of hepatocellular uptake and canalicular 
excretion of bile salts and various other organic anions (Moseley et al., 1996; Simon et al., 1996; 
Bolder et al., 1997).  Other changes in liver function and structure also occur in many cholestatic 
diseases.  These include changes in cytoskeletal architecture (Song et al., 1996) alterations in 
tight junctional permeability (Rahner et al., 1996) and a decrease in the fluidity of the canalicular 
membrane.   
Cholestasis is defined as serum conjugated bilirubin concentration ≥ 34 mol/L 
(Teitelbaum et al., 1997).  The extent and duration of elevated serum direct bilirubin may predict 
severity and mortality in patients with cholestasis (Beath et al., 1996; Teitelbaum et al., 1996). 
Other biochemical parameters such serum alkaline phosphatase (ALP) and gamma-
glutamyl transpeptidase (GGT) are also sensitive markers for hepatobiliary disease, but they lack 
specificity because their levels may be elevated in other diseases (Kumpf, 2006).  The values for 
ALP and GGT were normal in cholestatic infants.  Serum concentration of aspartate 
aminotransferase (AST) and alanine transferase (ALT) may also elevated after onset of 
cholestasis or jaundice (Vileisis et al., 1981; Ginn-Pease et al., 1985). 
Despite the variation in the features of the histopathological findings of cholestasis 
among patients, there are common pathologic features like presence of bile thrombi in bile 
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canaliculi and periportal fibrosis.  Other features also have been seen in patients with PNAC 
include giant cell transformation, portal inflammation, acute cholangitis, hepatocelluar damage 
and severe fibrosis (Benjamin, 1981; Hodes et al., 1982; Sokol, 1997; Kelly, 1998; Zambrano et 
al., 2004).   
2.5.1 Pathophysiology and molecular mechanisms of cholestasis 
2.5.1.1 Extrahepatic cholestasis 
 Extrahepatic cholestasis results from the physical obstruction of the bile ducts.  In an 
animal model of ligated common bile duct, the inability of bile to enter the intestine results in an 
increase in bile acid concentrations in the bile duct lumen and within the hepatocytes (Setchel et 
al., 1997).  In addition, it causes dilatation of bile canaliculi with a loss of microvilli and 
alteration of intracellular junctions.  Consequently, these alterations lead to regurgitation of bile 
components into blood (Accatino et al., 1981).  As a result, expression of Ntcp and Oatp1 at the 
basolateral membrane is reduced (Gartung et al., 1996) limiting hepatocellular uptake of toxic 
bile acids.  Short-term common bile duct ligation also results in relocation of Mrp2 from the 
apical membrane to a subapical vesicular compartment (Paulusma et al., 2000).  There are also 
specific mechanisms that decrease canalicular efflux.  The expression of Mrp2 (Lee et al., 2000) 
is significantly decreased, and this impairs secretion of sulfated bile acids as well as conjugated 
bilirubin (Moseley et al., 1996).  However, Bsep is reduced by only 20%, and therefore some 
efflux of bile acids into the biliary space continues (Lee et al., 2000).  This serves to protect 
hepatocytes from accumulating toxic levels of bile acids.  In addition, there is up-regulation of 
Mrp1 and Mrp3 at the basolateral membrane of the hepatocytes (Ogawa et al., 2000; Paulusma et 
al., 2000; Hirohashi et al., 2000; Hirohashi et al., 1998) leading to the efflux of bile acids into 
plasma, thus preventing further hepatocellular toxicity.  In the bile duct, there is proliferation of 
cholangiocytes (Alpini et al., 1988) as well as an increase in the expression of the apical sodium-
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dependent bile salt transporter (ASBT) at the apical membrane of the cholangiocytes (Lee et al., 
1999).  This provides a mechanism for the removal of conjugated bile acids from the lumen of 
the bile duct.  Furthermore, up-regulation of Mrp3 expression at the basolateral membrane of the 
cholangiocytes results in efflux of bile acids (Soroka et al., 2001).  Finally, there is a marked 
increase in ductal HCO3- secretion resulting from up-regulation of secretin receptors.  Therefore, 
although ductal obstruction prevents net bile flow, the compensatory mechanisms result in 
limitation of bile acid accumulation within hepatocytes and the duct lumen and profound dilation 
of the obstructed duct.  It is noteworthy that prolonged biliary obstruction leads to bile ductular 
proliferation, fibrosis, and secondary biliary cirrhosis in animals and humans (Erlinger et al., 
1999).   
2.5.1.2 Intrahepatic cholestasis 
Obstruction of intrahepatic bile ducts and alteration of bile secretion by hepatocytes 
(hepatocellular cholestasis) are the main causes of intrahepatic cholestasis.   
In the obstructive intrahepatic bile duct, the mechanism of cholestasis is the same as in 
extrahepatic obstruction with exception of cystic fibrosis disorder, in which the function of cystic 
fibrosis transmembrane conductance regulator (CFTR) is impaired and associated with decreased 
secretion of chloride and bicarbonate (Roy et al., 1982).  The decreased ductal bile flow leads to 
mucous precipitation and obstruction of small bile ducts followed by ductular proliferation, 
inflammation, and ultimately leads to focal biliary fibrosis (Roy et al., 1982).  Hepatocellular 
cholestasis is subdivided into genetic and acquired cholestasis.  There are three genetic forms of 
cholestasis have been identified and named progressive familial intrahepatic cholestasis type 1, 2 
and 3 (PFIC-I, II and III).  Progressive familial intrahepatic cholestasis (PFIC-I) is an autosomal 
recessive disorder caused by mutation in transporter gene (putative aminophospholipid 
transporter) (FIC1/ATP8B1) (Zollner and Trauner, 2008).  Progressive familial intrahepatic 
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cholestasis I patients develop liver cirrhosis in early childhood (Bull, 1998).  Children with 
PFIC-I usually present with elevated levels of serum bile acids, bilirubin, and transaminases in 
the neonatal period and they rapidly progress to end-stage liver disease requiring liver 
transplantation at an early age (Zollner and Trauner, 2008).  In PFIC-II patients, a subtype of 
Byler disease is clinically indistinguishable from PFIC-I, mutations of the bile salt export pump 
gene (BSEP/ABCB11), which encodes BSEP, the major canalicular bile acid export system, 
causes PFIC-II (Strautnieks et al., 1998).  Immunostaining of the liver of these patients shows an 
absence of BSEP at the canalicular membrane (Jansen et al., 1999).  These patients have a near-
total absence of bile acids from the bile and consequently develop bile acid hepatotoxicity 
because of accumulation within the hepatocytes.  The third type of progressive familial 
intrahepatic cholestasis, PFCI-III, is caused by a mutation of the MDR3 gene, and leads to the 
absence of phospholipid secretion in the bile, which is important for forming micelles with bile 
acids.  Its absence increases bile acid concentration in the biliary tract, which consequently leads 
to injury and proliferation of bile ductules (Deleuze et al., 1996).   
Besides the genetic defects, cholestasis also develops during certain pathological 
conditions.  Liver inflammation and sepsis caused by drugs or infection are often associated with 
cholestasis (Rodriguez-Garay, 2003).  In this type of cholestasis, also called inflammatory 
cholestasis, an acquired cholestasis, the mechanism mediated primarily by cytokines, such as 
tumor necrosis factor-α (TNF-α), Interlukin-1 IL-1, and Interlukin-6 (IL-6), that is released in 
response to bacterial lipopolysaccharide, stimulation of activated macrophages and kupffer cells.   
  The effect of these cytokines has been extensively studied in several experimental 
models.  Injection of lipopolysaccharide (LPS), a gram-negative bacteria cell wall component, 
induces inflammation and cholestasis in rodents.  These animals showed reduced Mrp2 
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expression and hyperbilirubinaemia, indicating downregulation of hepatic transporters during 
inflammation might be the cause of cholestasis in these animals (Rodriguez-Garay, 2003).  
Extensive studies have made it clear that nuclear receptors are key regulators for the expression 
of these transporter genes.  For example, PXR regulates the efflux hepatic transporters such as 
MDR1 and MRP2 (Geick et al., 2001; Kast et al., 2002) which are crucial for normal bile 
formation whereas, FXR regulates the canalicular bile acid transporters BSEP, Mrp2, and the 
uptake hepatic transporter NTCP (Ananthanarayanan, 2001; Kast et al., 2002 ).  Studies from 
several groups have shown that some nuclear receptor expression is decreased dramatically by 
cytokines produced during inflammation, which is suggested to be the major cause of reduced 
expression of certain hepatic transporters (Teng and Piquetter-Miller., 2005; Cheng et al., 2005; 
Xu et al., 2004; Kim et al., 2003).  Further studies in patients with hepatic inflammation and 
sepsis may be required to demonstrate the contribution of nuclear receptor down regulation to 
cholestasis.  The cholestatic effects of endotoxin and endotoxin-induced cytokines not only have 
a role in the pathogenesis of inflammatory-induced cholestasis, but it may explain defects in 
hepatobiliary excretory function during total parenteral nutrition (Moseley et al., 1997).   
Another type of acquired cholestasis is intrahepatic cholestasis of pregnancy (ICP).  The 
cause of ICP is hypothesized to result from the hormonal changes during the pregnancy.  Several 
hormones including estrogen and progesterone have been reported to show inhibitory effect on 
canalicular transporters.  This form of intrahepatic cholestasis is reversible and is usually 
resolved after delivery (Riely and Bacq, 2004).   
2.5.1.2.1 PN and hepatic transporter proteins 
During the past decade, the pathogenesis of several forms of cholestasis has been 
attributed to mutations in hepatobiliary transporter proteins especially the canalicular transporters 
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(efflux transporters) and their behaviour during the administration of parenteral nutrition. The 
efflux transporters are members of the ATP- binding cassette (ABC) transporter proteins 
(Trauner, 1998).  These transporters including MDR1, MDR3 (Mdr2 in rodents), MRP2, and 
BSEP are responsible for the transport of bile components from hepatocytes into bile canaliculi 
(Oude Elferink et al., 1995; Muller et al., 1996).  The MDR1 transports chemotherapy drugs, 
MDR3 transports phosphatidylcholine, MRP2 transports conjugated bilirubin and BSEP 
transports bile salts from the hepatocytes to the bile canaliculi.   
Studies on the effect of parenteral nutrition on the hepatobiliary transporter proteins have 
shown that the expression of both human MDR3 (orthologue of rodent Mdr2) and mdr2 in mice 
were reduced when treated with total parenteral nutrition whereas bsep expression in mice is 
increased with administration of PN (deVree et al., 1999; Tazuke et al., 2004).  In another study, 
the expression levels of biliary efflux transporters Mdr2, Mrp2, and Bsep were decreased 
following the administration of PN without fat compared to PN with fat (Nishimura et al., 2005).  
However, few animal models of PN including mice and rats have been used to study 
molecular mechanisms of PN-induced liver injury (deVree et al., 1999; Tazuke et al., 2004; 
Tazuke and Teitelbaum, 2009; Nishimura et al., 2005).   
2.6 Aluminum metabolism 
Al is ubiquitous, the third most abundant element after oxygen and silicon, in the earth’s 
crust.  Humans are exposed to aluminum compounds by eating food, drinking water, ingesting 
drugs containing Al like antacid and aspirin, breathing air or through skin contact by using 
antiperspirants.  In foods, the concentration varies, depending upon the product, the type of 
processing, and the geographical origin (Pennington et al., 1987).  The average intake of Al in a 
normal diet believed to be between 1 and 20 mg/day (Lione, 1983).  The highest sources of Al in 
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foods are herbs and tealeaves; 8 oz of tea would add 1-3 mg Al to the diet (Greger and 
Sutherland, 1997).  Infant milk formulas also contain Al.  In cow’s milk-based formula, the Al 
ranged from 0.03 mg/L to 0.2 mg/L whereas in soya-based formulas, the Al ranged from 0.64 
mg/L to 1.34 mg/L (Baxter et al., 1990).  In drinking water, Al concentration does not exceed 0.1 
mg/L.  The absorption of Al via the gastrointestinal tract is believed to be less than 1% (Greger 
and Sutherland, 1997).  In Wistar rats, the gastrointestinal absorption of Al was 0.1 percent of the 
administered dose (Jouhanneau et al., 1997).   
Although much has been published on intestinal absorption of Al, the mechanism by 
which Al passes through the intestinal wall is not completely understood (Yokel 1994; Exley et 
al., 1996; Lione, 1985; Priest, 1993; Wilhelm et al., 1990).  However, the suggested mechanism 
of Al absorption in the gut includes both paracellular passage of Al through tight junctions by 
passive processes (diffusion) and transcelluar passage across intestinal cells, involving passive, 
facilitated, and active transport processes (Van der voet, 1992).  In the blood, 90% of Al is bound 
to transferrin (Harris and Messori, 2002).  Other elements are believed to be bound to Al include 
citrate and, to a lesser extent, phosphate.  Al uptake by organs is believed to occur from the Al 
bound to transferrin (Ganrot, 1986).   However, transferrin is not the only means by which Al 
enters the cells.  DeVoto and Yokel (1994) assumed that the uptake of Al by cells is via diffusion 
or via pinocytotic uptake of extracellular fluid.   
2.6.1 Aluminum accumulation in the body 
Al occurs normally in all body tissues of humans (Ganrot, 1986).  The total concentration 
of Al in the healthy human body is approximately 30–50 mg (Alfrey, 1984; Cournot-Witmer et 
al., 1981; Ganrot, 1986).  Approximately 50% of total body Al is found in the skeleton and 25% 
in the lungs (Ganrot 1986).   
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In the literature, there are no unified standard normal values of Al in the human serum.  
In a study conducted on 71 office employees, the serum Al levels ranges from 1-3 μg/L with a 
mean of 2.67 μg/L (House, 1992).   A literature review of studies published in the previous 30 
years suggested that the serum concentration of Al ranged from 0.5 to 8 μg/L and 2 to 8 μg/L in 
whole blood (Caroli et al., 1994).  In another study, the serum Al values in the control group 
ranged from 0.03 to 3.12 μg/L with a mean of 0.99 ± 0.97 μg/L, whereas in dialyzed patients 
were from 0.5 to 45.1 μg/L (mean of 4.75 ± 9.23 μg/L) (Razniewska et al., 2005).  In the normal 
newborn, the average concentration of serum Al was reported at 5.17 μg/L (Sedman et al., 1985), 
and 8 to 12 μg/L (Litov et al., 1989).  In normal full-term infants, the mean serum Al 
concentration was 7.8 μg/L, whereas, in preterm infants at gestational age 28 to 32 weeks, the 
average serum Al concentration was 13.2 μg/L (Bougle et al., 1992).  In premature infants who 
received parenteral nutrition, the serum Al concentration averaged 37 μg/L (Sedman et al., 
1985).  In another study, the mean serum Al concentration was 15.9 μg/L in those who received 
parenteral nutrition compared to 8.9 μg/L, which were enterally fed (Bougle et al., 1992). 
Aluminum is unequally distributed throughout the body tissues.  In normal adults, tissue 
Al concentrations in lung, bone, liver, kidney, and brain were 20, 1 to 3, 1, 0.5, and 0.35 mg/kg 
respectively (Nieboer et al., 1995).  In a review of the literature for the past 30 years, similar 
values were obtained; 2.21 to 15.3 mg/kg in the lung, 1.0 to 2.45 mg/kg in the liver and 0.55 to 
1.31 mg/kg in the kidneys (Caroli et al., 1994).  With increased age and accumulation of Al, 
concentrations of Al were 25-50 mg in bone, 20 mg in lung, and 9 to 24 mg in other soft tissues 
(Keith et al., 2002).  In adult patients receiving parenteral nutrition, Al concentration in bone 
tissues of six patients was 14 to 265 mg/kg, and in the plasma was 98 to 214 µg/L (Klein et al., 
1982).  In animals, the results of a study conducted on piglets receiving parenteral nutrition for 
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21 days reported the mean Al concentration in the liver tissues at 0.90 ± 0.37µg/g and in controls 
was 0.05 ± 0.06 µg/g (Li, 2004).   
2.6.2 Aluminum excretion   
The primary route of Al elimination is via the kidneys, and secondarily via bile.  The 
kidneys excrete > 95 % of eliminated Al, presumably as a citrate.  Humans who consume a 
normal diet with no medications and who have normal renal function excrete less than 50 µg 
Al/day in urine (Greger and Sutherland, 1997).  Patients taking Al antacids in the diet had only a 
3-fold increase in urinary Al levels (Gorsky et al., 1979), suggesting that most of the Al 
hydroxide was not absorbed and was excreted directly into the feces.  Fecal Al represents 
unabsorbed Al as well as Al excreted via bile. 
2.6.3 Aluminum concentrations in parenteral nutrition solutions 
              One such proposed etiological factor implicated in the development of PNAC is the 
presence of various contaminants in PN solutions.  Aluminum is a non-essential element, and has 
been known as a significant contaminant in components of PN solutions, including calcium and 
phosphate salts (Stedman et al., 1985; De Vernejoul et al., 1985).  Aluminum concentrations in 
neonatal PN solutions have been found to exceed the safe level (2 g/kg/day) recommended for 
adults by American Society for Clinical Nutrition and American Society of Parenteral Enteral 
Nutrition (ASCN/ASPEN, 1991).  In a study conducted on a group of 26 preterm infants 
receiving parenteral nutrition, the level of Al in PN ranged from 4.1 to 7.2 mol/L, representing 
an average intake of 16.7 µg/kg/day which significantly exceeds the ASCN/ASPEN 
recommendation for safe Al infusion (Moreno et al., 1994).  Also, a retrospective study of 1003 
infants on PN, the total daily Al ranged 30 – 60 μg/kg/d in those weighing < 3 kg.  The 
calculated Al exposure in these infants was approximately 6-12 times greater the recommended 
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safe levels (Poole et al., 2008).  Although many attempts have been made to reduce the overall 
Al content in the components of PN, the currently available parenteral products used to make PN 
solutions for neonatal patients still contain amounts of Al exceeding the recommended safe level 
of Al.  
2.6.4 Aluminum impact on hepatobiliary system  
Aluminum toxicity is well documented but the mechanism of action is still poorly 
understood (Han and Dunn, 2000).  Aluminum present in PN has been shown to accumulate in 
serum, body tissues, and urine of children and infants receiving parenteral nutrition solutions.  
The hepatic Al levels in five children who received PN for 18 to 33 months were five to 27 times 
higher than normal levels.  In addition, they had elevated levels of serum total and direct 
bilirubin.  Moreover, the histopathological observation of the liver showed that all of the five 
children had morphological changes such as bile duct proliferation, inflammatory cells and 
periportal fibrosis (Klein et al., 1984).  In animals, Al present in parenteral nutrition solution 
accumulated in the liver of rats and produced hepatobiliary dysfunction characterized by portal 
inflammation (Demircan et al., 1998).  In our lab, a study conducted on piglets given different 
doses of Al plus PN solution revealed that high doses of Al (1500 g/kg/ day) and the PN 
solutions with Al content 37.8 µg/kg/day caused cholestasis (Li, 2005).  At the cellular level, Al 
accumulation in the liver has been shown to cause ultrastructure changes.  In a study conducted 
by Galle et al on six patients, the results showed that intracellular accumulation of Al caused 
damage to the hepatocytes.  In addition, he reported that Al was deposited in the hepatocytes not 
in the Kupffer cells (Galle et al., 1987).  In a study conducted on mice administered Al chloride 
orally, Al was shown to deposit in the lysosomes of hepatocytes (Kametani et al., 2006).  Besides 
its effect on the morphological structure, Al loading affects the bile acid level in the serum.  
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Klein et al., (1989) showed that Al deposition in the liver cause increased serum bile acids 
concentration.  Despite the relationship between Al loading and liver injury, the exact role of Al 
in the development of PNAC is unknown.  More studies are needed to reveal the exact 
underlying mechanism of Al in causing PNAC.       
2.7 Iron 
Iron (Fe) is an important component of hemoglobin, myoglobin, and many enzymes in 
the body and thus an important micronutrient in the well-balanced human diet (Guyton, 2006).  
The total quantity of iron in the human body averages 4000 to 5000 mg, about 60-70% of which 
is in the form of hemoglobin and myoglobin, while 20-30% is stored in the liver, in the form of 
ferritin and hemosiderin.  The remaining about 10% is in the form of the various heme 
compounds that promote intracellular oxidation, cytochromes and other iron containing enzymes.  
Humans ingest approximately 12-18 mg/day of dietary iron, of which only 1-2 mg is absorbed 
(Crichton et al., 2002).  Maintaining cellular iron homeostasis is vital to the physiological body 
functions.  In the healthy individual, the concentration of free cellular iron is monitored by iron 
regulatory proteins (IRPs) that regulate the transferrin and ferritin receptors.  However, 
individuals with hemochromatosis, a hereditary disorder, or transfusional iron overload have 
difficulties in maintaining iron homeostasis.  The disruption of iron homeostasis can cause 
serious health problems.  Elevated concentrations of cellular iron can cause oxidative damage to 
the cell and are linked to the pathogenesis of various diseases such as cancer and 
neurodegenerative disorders (Adzersen et al., 2003; Deugnier, 2003; Toyokuni, 2002; Jang and 
Surh, 2002; Ng, 2004).  Evidence suggests that iron overload has been shown to result in 
increased lipid peroxidation, DNA lesions, and apoptosis induced by reactive oxygen species 
(Bacon et al., 1983; Kell, 2009).   
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Several studies have suggested that Al can alter iron homeostasis (Ward et al., 2001; 
Contini et al., 2007).  One of the proposed hypotheses is that Al can decrease ferritin synthesis 
and increase the expression of transferrin receptors.  The disruption of the normal synthesis of 
transferrin receptors and ferritin create increased free iron levels in the cell, thus result in an 
increase of oxidative damage (Abreo et al., 1994; Yamanaka et al., 1999).  Another suggested 
mechanism is that Al displaces iron from transferrin and ferritin (discussed in section 2.6.5).  
Parenteral nutrition solutions are contaminated with significant amounts of Al.  Infants and 
children with gastrointestinal problems who need PN therapy are predisposed to disrupted 
cellular iron homeostasis in the liver, which results in oxidative damage and liver injury.  
2.7.1 Intestinal absorption of iron 
There are two main forms of dietary iron, which are absorbed by the digestive tract; heme 
iron from meats, and non-heme iron from plant and dairy products.  Heme iron is more 
efficiently absorbed than non-heme iron.  However, heme iron comprises only about 10% to 15% 
of daily iron intake (Carpenter and Mahoney, 1992).  In the duodenum, the main site of dietary 
iron absorption, heme and non-heme iron pass from the intestinal lumen to the enterocyte across 
the brush border by different pathways (Siah et al., 2005).  Heme iron is more readily absorbed 
and enters the enterocyte as an intact metalloporphyrin (Uzel and Conrad, 1998).  Heme iron is 
taken up into the enterocyte via a heme receptor, heme carrier protein-1 (HCP1), on the brush 
border of intestinal cells (Shayeghi et al., 2005).  Once in the enterocyte, heme is broken down 
into free iron and biliverdin by heme oxygenase that is found on the endoplasmic reticulum 
surface (Raffin et al., 1974).  Iron liberated from heme then enters the intracellular or ‘labile’ 
iron pool.  For non-heme iron, absorption occurs as a multi-step process.  Non-heme iron, which 
occurs mainly in the ferric state (Fe III), is first reduced to ferrous (Fe II) in the intestinal lumen 
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by a ferrireductase at the apical surface of the brush border.  Ferrous iron (Fe II) is then 
transported across the cellular membrane by divalent metal transporter 1 (DMT-1) into the 
enterocytes of the villus tips of the duodenum, which is the site of the major iron absorption 
(Gunshin et al., 1997).  Divalent metal transporter 1, the only known Fe transporter in the 
intestine, also transports other divalent metals including zinc, manganese, cobalt, copper, 
cadmium, nickel and lead (Gunshin et al., 2005).  Once in the cell, the Fe(II) is either stored as 
ferritin, incorporated into iron regulatory proteins (IRP), or is transported to the basolateral 
membrane and excreted by the cell via an iron transporter protein, known as iron-regulated 
protein 1 (IREG1), into the circulation.  The released iron is oxidized to the ferric ion by 
hephaestin and binds apo-transferrin to form Fe (III)-transferrin complex (Vulpe et al., 1999).  
Transferrin is the major iron transporter in the body and can bind 2 molecules of the oxidized 
form of iron (Rouault and Klausner, 1997).   
 2.7.2 Hepatic uptake of iron  
Transferrin (Tf) is responsible for the majority of cellular iron delivery within the body.  
In the hepatic cells, diferric-Tf attaches to the transferrin receptor (TfR) on the surface of the cell 
membrane and the Tf:TfR complex is internalized by receptor- mediated endocytosis via coated 
pits(Richardson and Ponka, 1997).  Once within the cell, the coated-vesicles move within the 
cytoplasm until they fuse with trans-reticular Golgi elements to form an endosome (McClelland 
et al., 1984).  The iron released from Tf is translocated from the endosome to the cytosol by the 
DMT1.  The apoTf:TfR (transferrin without iron) complex is then transported back to the cell 
surface.  The iron released in the cytosol is either stored as ferritin or incorporated into 
mitochondria for the synthesis of heme protein (Beard et al., 1996). 
Non transferrin-bound iron (NTBI) is defined as iron bound to other molecules than 
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transferrin such as citrate, ascorbic acid, or nitrilotriacetic acid.  Irrespective of the form of NTBI 
presented to cells, NTBI taken up first by binding to the cell surface where iron dissociates from 
its ligand; the dissociation possibly involves cell surface reduction by a ferrireductase.  Iron then 
delivered into the cell by a transporter (Graham et al., 1998; Trinder and Morgan, 1998).  The 
identity of the transporter for the NTBI uptake in the hepatocyte is unknown yet.   
2.7.3 Cellular iron homeostasis 
The uptake, sequestration, and export of iron must be properly regulated                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
c.  The regulation of intracellular iron concentration is through the control of iron uptake, and is 
influenced by iron storage capacity.  As the intracellular functional iron concentration drops, iron 
is mobilized from ferritin stores and intracellular ferritin levels are reduced, while transferrin 
receptor synthesis is activated and the transferrin receptor concentration on the cell surface 
increases.  Similarly, as intracellular iron concentrations increases, ferritin molecules are 
synthesized and the number of transferrin receptors on the cell surface is reduced.  This process 
is regulated by two cytosolic IRE (iron responsive elements) - binding proteins known as iron 
regulatory proteins; IRP-1 and IRP-2 (Crichton and Ward, 1995).  They act as iron sensors, 
essentially by existing in two different conformations.  When the supply of iron is increased, the 
IRP-1 is post-transcrptionally inactivated and IRP-2 degraded, both IRP-1 and IRP-2 become 
unavailable for IRE binding, allowing transferrin mRNAs degradation and ferritin mRNA 
translation. (Iwai et al., 1995; Hentze and Kuhn, 1996).  When iron levels are low, the IRPs are 
activated and bind to IRE on both ferritin and transferrin mRNAs (Meneghini, 1997).  This 
binding stabilizes the transferrin mRNA and inhibits translation of the ferritin mRNA.  Hence, 
when iron levels are low there is an increase in the synthesis of transferrin and a decrease in 
ferritin synthesis.  Conversely, when there is an adequate supply of iron, IRP binding is 
42 
 
deactivated and the opposite result is observed.   
2.7.4 Iron and oxidative damage 
Oxidative damage or stress has been defined as an imbalance between the pro-
oxidant/antioxidant steady state in the cell.  Free radicals are highly reactive chemical species 
that maintain one or more unpaired electrons (Halliwell, 1990; Chakravarti et al., 1991).  A 
compound can become a free radical by either gaining or losing an electron.  Although iron is 
important for many normal cellular activities, excess causes devastating toxic effects.  Ferrous 
iron (Fe
2+
) can react with hydrogen peroxide to produce ferric iron (Fe
3+
) leading to the 
formation of hydroxyl radicals; Fe
2+
 + H2O2 → Fe
3+
 + •OH + OH-  (Fenton reaction).  Iron can 
also react with molecular oxygen to yield a variety of toxic chemicals, such as superoxide anions 
(O2-•), hydrogen peroxide (H2O2), and hydroxyl radicals (•OH);  
O2 + Fe
2+
 → O2
-•
 + Fe
3+   
2O2
-•
 + 2H
+
 →O2 + H2O2 
Fe
2+
 + H2O2 → Fe
3+
 + •OH + OH-  (Haber-Weiss reaction). 
  These reactive oxygen species (ROS) are believed to play important pathogenic roles in a 
variety of diseases with excess iron such as Alzheimer's disease and Parkinson's disease (Dexter, 
1989; Good et al., 1992; Mattson,1995; Markesbery, 1997).  Free radical formation can promote 
lipid peroxidation, DNA strand breaks, degradation of biomolecules, and eventually cause cell 
damage (Halliwell and Gutteridge, 1984; Watson et al., 1984; Komara et al., 1986; Siesjo, 1988).  
Therefore, biological systems have evolved specialized iron-transport and management systems 
to maintain iron in a soluble nontoxic form and developed mechanisms to prevent increase of the 
iron-pool while maintaining sufficient levels for metabolic use.  However, these homeostatic 
mechanisms can get dysregulated and cause iron overload or iron deficiency.  
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2.7.5 Aluminum, iron interaction, and oxidative damage 
Al is a non-redox trivalent cation, which is capable of increasing the cellular oxidative 
environment by potentiating the pro-oxidant properties of transition metals such as iron and 
copper (Bjertness et al., 1996).  Under normal physiological conditions, when the cell needs iron, 
transferrin receptor (TfR) production increases allowing for more iron to be brought into the cell 
and the storage protein ferritin decreases enabling more iron to reach the respiratory chain and 
other iron requiring systems.  When the cells have enough iron, TfR decreases and the levels of 
ferritin increase thus allowing iron to be stored in the ferritin which prevents iron-mediated 
oxidative stress (Aisen et al., 2001).  However, when the cell is loaded with Al, the cellular 
accumulation of Al can alter iron metabolism and induce peroxidative injury.  Since Al and iron 
bind to transferrin (Tf) and ferritin, Al could disrupt cellular pathways of iron and thus indirectly 
increasing the intracellular concentration of free iron.  A number of studies conducted on a 
variety of cultured cell lines have shown that Al loading results in abnormal iron accumulation 
and compartmentalization (Abreo et al., 1994; Abreo et al., 1999; Yamanaka et al., 1999).  In 
friend erythroleukaemia cells (FEC), Al loading has been shown to disrupt iron metabolism by 
increasing cellular iron content associated with increased compartmentalization of iron in the 
mitochondria and nuclei, decreased ferritin content, and decreased uptake of iron by ferritin 
(Abreo et al., 1994) which lead to an increased iron to ferritin ratio in the cell.  This increase in 
iron to ferritin ratio would alter the normal compartmentalization of cellular iron, which has been 
shown to be associated with increased membrane lipid peroxidation (Bacon and Britton, 1989; 
Abreo et al., 1994).  It is not clear how Al causes reduction in the ferritin concentrations in the 
tissues.  However, suggested mechanisms include inhibition of translational regulation of ferritin 
synthesis either by sequestration of iron in a cellular compartment that is not accessible to iron 
regulatory protein (IRP) or by competing with iron for binding sites on IRP.  Either mechanism 
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could result in less iron binding to the IRP, thereby inhibiting the synthesis of ferritin (Abreo and 
Glass, 1993).  The decrease in synthesis of ferritin is associated with an increase of iron 
concentrations.  This increase of iron ratio to ferritin would imply that the normal 
compartmentalization of cellular iron is altered, which is associated with increased membrane 
lipid peroxidation.  
Aluminum can facilitate lipid peroxidation in the presence of free iron under acidic 
conditions in vitro (Verstraeten and Oteiza., 1995; Ohyashiki et al., 1996).  Increased 
malondialdehyde (MDA), a by-product of lipid peroxidation, has been shown in Al-loaded 
mouse hepatocytes (Abreo et al., 1990).  Furthermore, in rat liver microsomal fractions, Al ions 
have been shown to accelerate iron induced lipid peroxidation (Quinlan et al., 1988).  In studies 
focused on the correlation between Al accumulation and Alzheimer disease (AD), Al has been 
shown to stimulate lipid peroxidation in the presence of ferrous iron (Fe II) in brain membranes 
(Oteiza, 1993).  Several studies clearly established that the presence of Al in the cell plays a role 
in causing oxidative damage via disrupting normal compartmentalization of iron within the cell, 
however; no work looked at Al and iron interaction in parenteral nutrition infused animals, and 
the mechanisms involved in causing liver injury.  Knowing that would shed the light on the role 
of Al and iron in causing liver damage in parenteral nutrition associated cholestasis.  
2.8 Biomarkers of oxidative stress 
Oxidative stress has been proposed as a significant factor in many diseases.  However, 
definitive evidence for its association with diseases has often been lacking due, in part to the lack 
of biomarkers and/or reliable methods available to assess oxidative stress levels (Mak and 
Newton, 2001).  For instance, previous research has proposed reactive oxygen species (ROS) to 
be short-lived and highly reactive making the accuracy of their in vivo measurement 
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questionable.  A biomarker for oxidative stress is a biological molecule that changes when 
reactive oxygen species and/or free radicals change, and can be objectively measured and 
evaluated (Offord et al., 2000).  Biomarkers have been shown to yield important information on 
the nature of radical damage and antioxidant action in vivo, particularly regarding the nature of 
pro-oxidant effects, compartmentalization, and bioavailability (Bartosz and Bartosz, 1999).  
There are several methods to assess oxidative stress in vivo and in vitro including 
measuring products of oxidative stress.  Such methods include DNA oxidation (Mendez et al., 
2004) and lipid peroxidation (Hsiang et al., 1997), or protein modification (Chirino et al., 2006); 
measurement of the reducing capacity of tissue or cell (Shohami et al., 1999), and trapping the 
superoxide radicals using electron spin resonance trapping reagents (Awasthi et al., 1997).  
However, measuring lipid peroxidation by-products, DNA oxidation markers, and protein 
carbonyls are currently the most commonly used methods. 
2.8.1 Lipid peroxidation 
Lipid peroxidation is a well-established mechanism of cellular injury in both plants and 
animals, and used as an indicator of oxidative stress in cells and tissues (Armstrong and Browne, 
1994; Yagi, 1998).  Masuda and Yamamori (1991) reported increased concentrations of lipid 
peroxidation products in some diseases associated with oxidative stress.  For example, 
peroxidation appears to be important in diseases such as atherosclerosis (Durak et al., 2000), 
tissue injury caused by ischemic or traumatic brain damage (Peker et al., 2004), and hepatic 
damage induced by toxic substances such as trichlorobromomethane (Slater, 1984), chloroform 
(Ekstrom and Hogberg, 1980), and halothane (Tomasi et al, 1983).   
This oxidative degradation process results from the production of free radical reactions 
primarily involving membrane polyunsaturated fatty acids (PUFA) (Slater, 1984; Poli et al, 
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1987).  Highly reactive free radicals are capable of abstracting hydrogen atoms from 
polyunsaturated fatty acids on phospholipid membranes, resulting in the formation of a lipid 
radical (PUFA•).  Reaction with oxygen yields the corresponding peroxy radical (PUFAOO•) 
and chain propagation, leading ultimately to degradation of the lipid to a range of products 
including aldehydes, ethane and pentane.  Malondialdehyde (MDA), an aldehyde, is one of the 
most common lipid peroxidation products that are predictive of oxidative stress (Griffiths et al., 
2002).  It is a physiologic ketoaldehyde produced mainly by peroxidative decomposition of 
unsaturated lipids as a by-product of arachidonic acid metabolism.  Malondialdehyde can be 
measured using thiobarbituric acid-reactive substances (TBARS) assay, a well-established 
method for screening and monitoring lipid peroxidation (Armstrong and Browne, 1994; Yagi, 
1998).  The method based on the reaction of TBA with malondialdehyde (MDA) and other 
reactive aldehydes.  Modifications of the TBARS assay by many researchers have been used to 
evaluate several types of samples including human and animal tissues and fluids, drugs, and 
foods (Ohkawa et al, 1979; Richard et al, 1992; Draper et al, 1993; Scoccia et al, 2001; Dawn-
Linsley et al, 2005).  Even though there remains controversy in the literature regarding the 
specificity of TBARS toward compounds other than MDA (Janero, 1990), it remains the most 
widely employed assay to determine lipid peroxidation (Armstrong and Browne, 1994; 
Esterbauer, 1996; de Zwart et al, 1999).   
  Another product of lipid peroxidation used extensively as a sensitive and specific marker 
of oxidative stress is F2-isoprostane (Morrow et al., 1990).  Isoprostanes are oxidation products 
of arachidonic acid.  A study by Roberts and Morrow (1997) reported that there are two separate 
routes of isoprostane formation, endoperoxide and a dioxethane.  During isoprostane formation, 
8-iso-IPF2-α is used as a marker for oxidative stress (Morrow and Roberts, 1999).  Additionally, 
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in plasma, studies have reported isoprostanes to have a short half-life of approximately 18 
minutes and to be excreted rapidly.  To maintain steady state, it must be formed constantly in 
biological substances (Morrow and Roberts, 1999).  The disadvantage associated with measuring 
isoprostanes in plasma is that it is not possible to measure them over a period of time since the 
half-life is short.  Conjugated dienes have also been proposed to be a product of in vitro lipid 
peroxidation.  Conjugated dienes are primary products of the breakdown of fatty acids.   
However, a disadvantage associated with the diene assay is that many other biological substances 
are absorbed in the same UV region (Corongiu et al., 1986), thus making conjugated diene assay 
not appropriate for determination of lipid peroxidation in vivo. 
2.8.2 Amino acid oxidation 
Lipid peroxidation consequences including amino acid oxidation, denaturation of 
proteins, and loss of function to the proteins are also used as indicators.  For the analysis of 
oxidation products, proteins, urine, plasma, cell, nucleus, mitochondria, and cytoplasm can be 
used.  In a study by Griffiths et al. (2002), it was shown that modifications to histidine and lysine 
in low-density lipoproteins lead to an alteration in the receptor lipoproteins.  Protein oxidation 
stimulates lead to new functional group formation that includes hydroxyls and carbonyls (Dean 
et al., 1997).  Carbonyls have emerged as excellent biomarkers for protein oxidation (Berlett and 
Stadtman, 1997).  They are generated in response to oxidizing stimuli including alkoxy and 
peroxy radicals.  As a biomarker, carbonyls measured by either immunodetection using ELISA 
or Western blot.  Protein carbonyls are a generic marker of oxidation (Pompella et al., 1996).  In 
a review by Chevion et al. (2000), alterations in protein carbonyls were shown to be linked with 
aging.  Previous research has described protein thiols, aliphatic amino acids, oxidized tryptophan 
and tyrosine as biomarkers for oxidative stress (Robinson et al., 1998; Griffiths et al., 1992, and 
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Shigenaga, 1999).  Semi-quantitative analysis of thiols immunohistochemically by Wardman and 
Von Sonntag (1995) showed a correlation with tumor growth (Wardman and Von Sonntag, 
1995).  Regardless of the changes in protein structures and diseases, studies have shown that 
supplementation of diets with antioxidants can reverse impact on some of those modifications in 
protein carbonyls.  Supplementation of a rat diet with flavonoid rutin for 18 days caused a 
reduction in protein carbonyl content (Funabiki et al., 1999).  Srigiridhar and Nair (2000) 
supplemented the diet of rats with αtocopherol or a combination of α-tocopherol (40 mg/day) and 
ascorbic acid (24 mg/day) for 15 days and showed that protection against protein carbonyl 
formation in iron-deficient rats during iron repletion increased.  Tocotrienols reduced the protein 
carbonyl levels in the aging nematode, Caenorhabditis elegans (Adachi and Ishii, 2000).  These 
limited studies are consistent in demonstrating a protective effect against plasma protein 
oxidation through dietary intervention. 
2.9 The piglet as a model for PNAC 
Several animal models of PN including mice, rats, rabbits, and neonatal piglets have been 
used to study liver disorders of PN-induced liver injury.  An ideal animal model of human infant 
should produce viable neonates with maturation characteristics similar to human infant, and have 
a body size that allows comparative monitoring, blood sampling, clinical interventions, and 
easily to handle.  Also, the growth of piglet is very rapid during the neonatal period which can be 
viewed as an accelerated model of postnatal growth and development (Sangild, 2006). 
Numerous studies have used both adult and neonatal piglets to study liver dysfunction 
(Klein et al., 1987; Truskett et al, 1987; Omland and Mathisen, 1991).  The newborn piglet have 
been used as a valid model for studying neonatal metabolism in orally fed animals (Innis, 1993; 
Moughan et al., 1992), and in intravenously fed animals (Wykes et al., 1993; Shulman, 1993; 
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Dureksen et al., 1996; Van-Aerde et al., 1999; Bertolo et al., 1999).  Neonatal piglet is an ideal 
animal for modeling liver function and metabolism as it has a similar hepatic anatomy; 
gastrointestinal physiology, and metabolism to human neonate (Yuan et al., 1996).  Similar 
clinical complications to those observed in human infants on PN have been shown in piglets 
(Tumbleson, 1986; Schantz et al., 1996).  The liver injury observed in piglets receiving PN 
resembled that seen in human neonates (Zambrano et al., 2004; Wang et al., 2006).  In addition, 
the piglet model has been used to screen novel components for parenteral nutrition formulas in 
clinical practice (Hata et al., 1989; Shu et al., 1991; Burrin et al., 2000; Burrin et al., 2003; 
Wykes et al., 1993; Loff et al., 1998; Moran et al., 2005; Cai et al., 2006). 
The newborn piglet provides the opportunity to assess the relative importance of putative 
growth-regulatory and survival factors in a clinically relevant context.  The observed outcomes 
in neonatal piglets that develop PN-induced liver disease would likely more relevant to human 
infants than outcomes demonstrated by experiments in other animal models.  
2.10 Biological imaging techniques 
2.10.1 Overview 
Biological imaging is a demanding field, which requires several important factors to be 
balanced in order to achieve the best result.  Generally, an imaging technique for biological 
samples should achieve high spatial resolution to reveal information at the cellular and sub-
cellular level, require minimal sample preparation to examine samples as close as possible to 
their natural state, and use a radiation dose that is tolerable to minimize sample alterations. 
 Although, light and electron microscopy techniques have been extensively used to identify the 
structural changes in the liver tissues of rats resulting from infusion of aluminum (Klein et al., 
1988; Dermican et al., 1998), there are number of limitations associated with these two 
techniques.  For instance, the low spatial resolution (hundreds of nanometers) by light 
50 
 
microscopy limits identification of sub-cellular changes and extensive sample preparation 
method for electron microscopy alters the sample composition.  A technique that can provide 
high spatial resolution like electron microscopy (~ 2 nm) with minimum sample preparation for 
light microscopy is highly desirable for this study. 
One such technique that provides the advantages of both electron and light microscopy is 
the X-ray microscopy.  The Scanning Transmission X-ray Microscopy (STXM) is a synchrotron 
based technique and has the potential to reveal ultrastructure of intact and hydrated cells at high 
spatial resolution (~30 nm) (Jacobson, 1999).  The spectroscopy associated with microscopy can 
be used to identify and reveal the different states of different elements present in the sample.  
However, other conventional techniques such as Raman and confocal microscopy also have been 
used extensively in biological science for morphological, elemental and chemical imaging of 
cells.  In the following sections, the use of light, Raman, Confocal and electron microscopy and 
comparative advantages of STXM are highlighted with examples related to cholestasis.  
2.10.2 Light Microscopy 
The light microscope is a critical tool in the study of cellular structural and functional 
characterization related to pathology.  Improvements in lens production for higher magnification 
with the parallel development of sample preparation such as fixing, sectioning and staining of 
cells and internal tissues have enabled biologists to use it for wide range of applications, ranging 
from investigations of bacterial cells to human tissues.  Studies of biological structures and 
processes on both fixed and live specimens have led light microscopy to be a vital tool for 
biologists.  The light microscope creates a magnified and detailed image of objects or specimens 
invisible to naked eye.  In light microscopy, objects are enlarged or magnified with a convex lens 
that bends light rays by refraction.  The visibility of the magnified object depends on contrast 
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and resolution.  In general, the contrast or differences in light intensity between an object and its 
background or surroundings make the object distinct.  For colorless or less contrast specimens, as 
in the case of most biological material, contrast is achieved in different ways.  The object itself 
or selected portions of a specimen may be stained, thus enhancing the amplitude of certain light 
waves passing through the stained areas.  However, this usually requires the fixation and staining 
of cells.  Such stained specimens are typically observed using bright-field microscopy.  Despite 
these developments, the detail at the sub-cellular level is very limited in light microscopy.  The 
maximum spatial resolution achieved so far is about 200 nm due to the long wavelengths of 
visible light used in light microscopy (Fernandez-Suarez and Ting, 2008).   
2.10.2.1 Light Microscopy and cholestatic features  
 The histological features of the cholestatic liver are very important for the diagnosis of 
cholestasis.  The common features of cholestasis are bile thrombi in the canaliculi (canalicular 
cholestasis), periportal inflammation, bile duct proliferation and portal fibrosis (Dermican et al., 
1998; Btaiche and Khalidi, 2002).  Fibrosis, portal inflammation, bile duct proliferation, and 
hydropic degeneration are the most prominent histological features of PN-related liver damage 
(Quigley et al., 1993; Merritt, 1986; Benjamin, 1981; Dahms and Halpin, 1981; Hodes et al., 
1982; Moss et al., 1993).  Light microscopy has been used extensively to detect (Figure 2.3) and 
study the histological features of cholestasis (Postuma and Trevenen, 1979; Shu et al., 1991; Loff 
et al., 1998; Cai et al., 2006; Wang, 2006).   Even though light microscopy has been an important 
tool used to detect many structural changes in the cholestatic liver tissues, in some studies, light 
microscopy could not detect some structural changes such as loss of bile canalicular microvilli, 
and swollen mitochondria, as well as some apoptotic changes such as karyoklasis (Shu et al., 
1991; Cai et al., 2006).  
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 Figure 2.3. Light micrograph of liver tissues; 
 A) Control group, no degeneration or cholestasis; B) parenteral nutrition for 7 days, mild   
 inflammatory infiltration and hydropic degeneration; C) PN for 10 days, hepatic intracellular  
 cholestasis; D) PN for 10 days, diffuse fatty degeneration. 
(Source: Cai et al., 2006). 
Reprinted with permission from Journal of Pediatric Surgery. 41, 10, 1663-1668 (2006).    
Copyright © 2006, Elsevier. 
 
 
 
2.10.3. Raman microscopy  
Raman microscopy (RM) is a vibrational spectroscopic technique capable of obtaining 
sensitive measurements of molecular composition, structure, and dynamics of inorganic 
compounds, organic molecules, and minerals.  It is fast becoming one of the most powerful 
analytical techniques that can be applied to many areas of research including materials science, 
forensic research investigation, biological, biomedical materials (Yoshikawa and Nagai, 2001; 
Nishimura and Tsuboi, 1986; Paipetis et al, 1996; Schaeberle et al., 2001; Hodges and Akhavan, 
1990; Cutmore and Skett, 1993).  The main advantages are that the technique is non-destructive 
and there is minimal sample preparation.  The use of Raman spectroscopy in the biological 
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sciences has become incredibly widespread due to its advantages.  Some of the successful 
application of RM includes single-cell analysis (Puppels et al., 1990), characterization of the 
molecular composition of bacteria and other medically relevant microorganisms (Naumann et al., 
1995; Maquelin et al., 2002).  The technique has also been applied to single human tumor cells, 
and has been used successfully to map the distribution of protein and nucleic acids within the 
cytoplasm and nucleus (Krafft et al., 2003; Matthaus et al., 2006).  Many investigators have used 
RM to characterize the spectral differences between normal and cancerous cells and tissues, or to 
distinguish between different types of tumor cells (Nijissen et al., 2002; Choi et al., 2005; Crow 
et al., 2005; Short et al., 2006; Jong et al., 2006).  RM has also been used to investigate the 
spectral differences between living and dead tumor cells (Notingher et al., 2003) and to monitor 
the spectral changes of tumor cells undergoing cell death via apoptosis (Verrier et al., 2004).  
Moreover, RM has been used to differentiate between the Al-treated and untreated brain tissue 
samples (Abubaker et al., 2002).   
Raman spectroscopy is increasingly used to provide chemical structure information on 
tissue specimens.  However, because of the low spatial resolution, details of the histologic 
structure at the sub-cellular level are very limited.  
2.10.4 Confocal microscopy  
Confocal microscopy is an imaging technique used to increase micrograph contrast 
and/or to reconstruct three-dimensional images by using a spatial pinhole to eliminate out-of-
focus light or flare in specimens that are thicker than the focal plane.   In confocal microscopy 
(CM), illumination of the sample is achieved by scanning one or more focused beams of light, 
usually from a laser, across the specimen.  The resulting fluorescence transmission is collected 
by the objective and sent to the detector in the same manner as the wide field illumination mode. 
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Confocal microscopy offers several advantages over conventional optical microscopy, including 
the ability to control depth of field, elimination or reduction of background information away 
from the focal plane, and the capability to collect serial optical sections from thick specimens.  In 
biological and biomedical application, the importance of confocal microscopy as non-destructive 
and sensitive technique made it widely used in a broad range of applications including 
neuroanatomy and neurophysiology, stem cell research, bioluminescent protein and 
photobleaching studies, DNA hybridization and morphological studies of a wide variety of cells 
and tissues (Halbhuber and Konig, 2003).   
One of the most widely used confocal microscopy techniques in biological application is 
the laser scanning confocal microscopy (LSCM).  This technique relies heavily on fluorescence 
as an imaging mode, primarily due to the high degree of sensitivity afforded by the technique 
coupled with the ability to specifically target structural components and dynamic processes in 
chemically fixed as well as living cells and tissues.  Many fluorescent probes designed to bind 
with a biological macromolecule (for example, a protein or nucleic acid) or to localize within a 
specific structural region, such as the cytoskeleton, mitochondria, Golgi apparatus, endoplasmic 
reticulum, and nucleus (Haugland, 2005).  Other probes are employed to monitor dynamic 
processes and localized environmental variables, including concentrations of inorganic metallic 
ions, pH, reactive oxygen species, and membrane potential (Lemasters et al., 1999). 
Fluorescent dyes are also useful in monitoring cellular integrity (live versus dead and 
apoptosis), endocytosis, exocytosis, membrane fluidity, protein trafficking, signal transduction, 
and enzymatic activity (Johnson, 1998).  In addition, fluorescent probes have been widely 
applied to genetic mapping and chromosomes analyses in the field of molecular genetics.  
For elemental mapping, in a study conducted by Uchiumi et al., (1998), laser scanning confocal 
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microscopy was used to detect Al in the liver and tibia of normal and renal failure Wistar rats 
administered intraperitoneally with 1 mg injections of Al potassium sulfate three times for a 
period of 3 or 6 months.   However, using lumogallion as stain, reacts with Al to form 
fluorescent complex, this experiment has enabled the investigator to detect Al in tissues 
containing > 9 µg/g of Al but not < 6.5 µg/g of Al (Uchiumi et al., 1998).  
In previous years, some researchers employed confocal microscopy to investigate the 
mechanisms underlying the development of some hepatobiliary disorders including cholestatic 
diseases.  Kojimi et al., (2007) successfully used confocal microscopy to investigate the 
localization and expression of multidrug resistance protein 2 (MRP2), and radixin, a cross- linker 
between actin filaments and membrane proteins in various cholestatic liver diseases.  Also, Li et 
al., (2009) used this technique to investigate the effect of hepatic ischemia-reperfusion on the 
bile canalicular F-actin microfilaments, main component in the structure of bile canalicular 
microvilli, in rats.  
The use of confocal microscopy, especially the laser scanning confocal microscopy is 
rapidly growing and becoming an invaluable tool for a wide range of investigations in the 
biological and medical sciences.  However, because of the low spatial resolution compared to the 
electron microscopy, the use of this technique is still limited as tool for the histological 
observation in cells and tissues.  
2.10.5 Transmission electron microscopy (TEM) 
The transmission electron microscope (TEM) uses electrons as light source to study 
objects at very high spatial resolution.  TEM provides the means to go beyond the magnification 
and resolution limits of light microscopes, allowing for magnification of up to 100,000 X and 
resolution in the nanometer range.  However, the weakness of electron penetration requires 
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sample thicknesses considerably less than 1 μm (Kirz et al., 1995).  Sectioning samples into thin 
sections can cause structural artifacts or distortion.  The other challenge is the low contrast of 
biological materials which requires staining samples with heavy metal salts that bind to specific 
intracellular organelles to differentiate them which can be an another source of artifact.  There is 
well-documented evidence for the loss of cellular material especially during chemical fixation 
and subsequent dehydration of biological specimens (Coetzee and van der Merwe, 1984, 1989; 
Mersey and McCully, 1978; Salema and Brandao, 1973).  More recent techniques such as cryo-
fixation avoid the need for some of these sample preparation methods like chemical fixation but 
can cause structural disorganization from freezing damage. 
2.10.5.1 Transmission electron microscopy and cholestatic features 
 Similar to light microscopy, transmission electron microscopy has been used extensively 
to study the subcellular structural changes of cells in tissues.  In light microscopy, cell 
membranes and a few internal organelles could be visualized, but the TEM image easily reveals 
much more structures in the organelles (Figure 2.4; Wang et al., 2006).   In detecting the 
cholestatic features in liver tissues, due to its high spatial resolution, electron microscopy has the 
advantage of detecting some cholestatic features that could not be detected using light 
microscopy such as bile plugs, loss of canalicular microvilli, apoptotic changes (Fig 2.5; Cai et 
al., 2006), and swollen mitochondria (Kametani, 2002).  
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Figure 2.4. Transmission electron micrographs showing structure in piglet livers  
of EN (enteral nutrition) group (A) and PN (parenteral nutrition) group (B). 
In EN; nucleus (N), and cytoplasm in hepatocytes and presence of erythrocytes (E);  
arrows indicate mitochondria. In PN liver specimens morphological characteristics  
of fatty liver with swollen and rounded mitochondria and accumulation of the lipid droplets (L) 
and granules of glycogen (G) in cytoplasm are evident. 
(Source: Wang et al., 2006). 
Reprinted with permission from The Journal Society for Nutrition. 136, 2547-2552 (2006).    
Copyright © 2006, American Society for Nutrition. 
 
 
 
 
 
58 
 
 
Figure 2.5. Electron microscopy of rabbit livers; 
A) Control group, normal mitochondria and micro biliary duct (see arrow); B) PN-3 group, 
enlarged micro bile duct (see arrow). C) PN-10 group, high electron density laminar deposition 
in enlarged micro bile duct (see arrow); D) PN-10 group, apoptosis body in hepatic sinusoid (see 
arrow). (Source: Cai et al., 2006) 
Reprinted with permission from Journal of Pediatric Surgery. 41, 10, 1663-1668 (2006).    
Copyright © 2006, Elsevier. 
 
 
 
 
 
2.10.6 Elemental mapping in biological tissues   
The mapping of element distribution in thin sections of biological tissues is a challenging 
task.  Exploring the subcellular metal deposition in the tissues is a key to the understanding of 
many metal-involving disorder mechanisms in biological tissues.  Conventional imaging 
techniques used to gain knowledge about the elemental distribution in tissues or cellular or sub-
cellular level, usually lack sensitivity to detect trace concentrations of elements in the biological 
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tissues.  Recently, imaging the distribution of trace elements in cells (Ortega et al., 2004) and 
tissue sections at the cellular and subcellular compartments is becoming possible using 
synchrotron radiation X-ray techniques.  Moreover, the efficient use of synchrotron beams will 
provide information about oxidation state and metal-site structures at subcellular level (Ortega et 
al., 2005).  
2.10.6.1 Aluminum mapping in biological tissues   
Al is abundantly found in the earth and dissolved into acidic rains thus spreading into the 
earth’s soil and water, which can be absorbed into living bodies of both the animals and plants 
and can be accumulated in cells and tissues (Martin, 1986).  The toxicity of Al accumulation in a 
living body was shown experimentally in plants such as in wheat (Delhaize et al., 1993) and in 
several organs such as the livers, kidneys and brains of experimental animals (Spencer et al., 
1995; Wilhelm et al., 1990; Yokel, 2000).  Many imaging techniques were employed to look at 
the deposition of Al in the biological materials.  Some of these techniques and their use in 
mapping Al will be discussed subsequently.  
2.10.6.1.1 Light microscopy 
There are few studies where light microscopy employed to detect the deposition of Al in 
biological tissues.  In a study conducted on Wistar rats received five intraperitoneal injections at 
dose of 50 mg/kg, Daimon et al., used light microscopy to locate the deposition of Al in liver 
tissues stained with aluminon and he reported that Al was localized in the cytoplasm of Kupffer 
cells (Daimon et al., 1999).  In another study, Al deposits were detected using light microscopy 
in the Kupffer cells and macrophages of Wistar rat’s liver tissues stained with aluminon.  The 
rats were given intraperitoneally daily injections of 50 mg Al for 7 days (Bogdanovic et al., 
2008).  
60 
 
 
2.10.6.1.2 Energy dispersive microanalysis (EDX)  
X-ray microanalysis is a useful method to qualify and quantify basic elements in 
biological specimens.  The term microanalysis was used to mean chemical analysis of very small 
amounts of elements in ultrathin sections in situ by X-rays using either transmission (TEM) or 
scanning electron microscope (SEM) equipped with X-ray analyzers (Chandler and Battersby, 
1976).  With scanning electron microscopy, one can observe and analyze only the surface of 
tissue blocks whereas using transmission electron microscopy, one can observe and analyze the 
inside of the tissues.  In terms of X-ray analyzer, currently there are two types of X-ray analyzers 
available: wave dispersive X-ray analyzer (WDX) and energy dispersive X-ray analyzer (EDX).  
EDX has the potential to analyze all the elements in the sample at a time, whereas, WDX can 
only analyze one element at once.  Thus, transmission electron microscopes equipped with EDX 
for biological specimens would have the potential to analyze all the elements with atomic 
number 11 (sodium) to atomic number 92 (uranium) in the sample at once.  The aim of 
application of X-ray microanalysis to biological specimens is to detect various elements 
localized in the cells and tissues and to determine the kind of elements detected in situ, and 
further to quantify the contents of the elements in the specific cells, cell organelles and tissues 
which contain the elements in relation to their localizations.   
 
2.10.6.1.2.1 Energy dispersive microanalysis (EDX) and aluminum mapping 
Many researchers have explored the distribution of Al in biological tissues using energy 
dispersive microanalysis (EDX).  Spencer et al. (1995) measured Al content in the livers and 
kidneys of rats at the cellular and subcellular level after intravenous administration of Al citrate 
and Al chloride.  They reported that EDX could analyze the Al distribution in the cell organelles.  
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They determined that Al was distributed in all organelles analyzed such as cytoplasm, 
mitochondria, endoplasmic reticulum and nucleus of the liver cells (Spencer et al., 1995).  In 
another study aimed to determine the best conditions of EDX to detect Al deposition in mouse 
tissues, several adult mice at four weeks of age were administered intraperitoneally and orally 
with 2% Al chloride for 2 weeks.  The results suggested that the highest peak of Al was obtained 
at 300 kV when 1.0 µm thick sections were used.  Using TEM-EDX, Kametani et al., (2002) 
reported that Al concentration was found in the lysosomes of hepatocytes in the liver tissues of 
mice administered orally with Al in drinking water for 3-17 weeks (Figures 2.6 & 2.7). 
 
 
 
 
Figure 2.6. TEM micrograph for the hepatocytes of mouse administered with aluminum. 
The high electron density (arrow) represents aluminum deposition in the lysosomes of     
 mouse hepatocytes.  
(Source: Kametani et al., 2002) 
Reprinted with permission from Journal of Electronic Microscopy. 4, 2002, 265-274 (2006).    
Copyright © 2002, Oxford University Press. 
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Figure 2.7. Electron micrograph of transmission electron microscopy showing aluminum 
deposited in the lysosomes of mouse 
 (A) Lysosomes (arrow) in a hepatocyte (HN) found in the liver of a mouse.  
 (B) EDX spectrum obtained from the electron-dense lysosomes (arrow in A). Al;  
      aluminum, BG: background.  
    (Source: Kametani et al., 2002) 
    Reprinted with permission from Journal of Electronic Microscopy. 4, 2002, 265-274 (2006).    
    Copyright © 2002, Oxford University Press. 
 
       
 
2.10.7 Scanning transmission x-ray microscopy (STXM) 
Scanning transmission x-ray microscope (STXM), shown on Fig.2.8, used to record 
pixel-by-pixel images (microscopy and spectroscopy) and point spectra (spectroscopy) with high 
energy and spatial resolution.  It consists of only the objective zone plate lens that focuses the x-
rays to a ~30 nm spot on the sample.  Scanning microscopes minimize the radiation dose to the 
specimen because the low (5-20%) efficiency zone plate is located upstream of the specimen 
rather than between specimen and detector.  The sample is raster scanned pixel by pixel through 
the focal spot.  In this case, the detector records the transmitted intensity for each pixel.  
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Scanning x-ray microscopes show their full power in combining the high spatial resolution 
imaging with high energy resolution for elemental and chemical state mapping.  
 
 
 
 
 
  Figure 2.8. Schematic designs for scanning transmission x-ray microscopy. An objective 
zone plate is used to focus the x-rays on the sample. To generate an image, a thin section of the 
sample is raster-scanned in the focus of the x-rays under computer control. The transmitted 
photons are counted by an x-ray sensitive detector. OSA;order sorting aperture. 
 
 
2.10.7.1 STXM and biological application 
STXM has been used extensively to study biological samples (Kirz and Jacobson, 1995).  
For instance, this technique has been used to quantitatively map the distribution of protein and 
DNA in bull sperm (Williams et al., 1995), and mapping the calcium distribution in tendon 
tissues (Figure 2.9; Buckley, 1995).  Also, STXM has also been used to map the locations of 
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protein and DNA in sperm from different species of (Zhang et al., 1996; Buckley et al., 1997).  
In microbial biofilms, mapping and speciation of metals (nickel, manganese, and ferrous iron) 
have been illustrated using STXM (Figures 2.10, 2.11 & 2.12; Dynes et al., 2006; Hunter, 2008). 
 
 
 
Figure 2.9. Map of calcium distribution in human tendon tissue. 
White spots show the presence of calcium.  
(Source: Buckley, 1995) 
Reprinted with permission from Review of Scientific Instruments. 66, 1322 (1995). Copyright © 
2006, American Institute of Physics. 
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Figure 2.10. STXM micrograph of false color-coded composite map the metal species. 
superimposed on (a) optical density (OD) image recorded at 282 eV (which highlights non-
carbon components), and (b) OD difference image (288.2-282 eV) (Which highlights microbial 
entities) (pale yellow, Fe(II)-rich; red,Fe(III)-rich; green, Mn; blue, Ni; individual intensities 
scaled to fill each color range). The yellow dotted line indicates the area of the detailed metal 
study.(Source: Dynes, 2006)  
Reprinted with permission from Environmental Science & Technology. 5, 1556 (2006). 
Copyright © 2006, American Chemistry Society. 
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Figure 2.11. STXM micrograph and spectra for the speciation of metals in river biofilms. 
 (a) The area of the detailed metals studies is indicated in the yellow box.  
 (b)  X-ray absorption spectra of the mapped metals in the area.  
 (c) The yellow rectangle area is highlighted showing the speciation of metals.  
   (Source: Dynes, 2006) 
   Reprinted with permission from Environmental Science & Technology. 5, 1556 (2006).   
  Copyright © 2006, American Chemistry Society. 
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      Figure 2.12. Mapping of iron speciation in bacterial biofilms. 
      (Source: Hunter, 2008)  
      Reprinted with permission from Environmental Science & Technology. 42, (23), 8766-8772   
      (2008). Copyright © 2008, American Chemistry Society. 
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3.0 ALUMINUM LOADING CAUSES LIVER INJURY IN NEONATAL PIGLETS 
 
 
3.1 Introduction 
Aluminum is a ubiquitous element used extensively in modern daily life.  Food, water, 
and pharmaceutical drugs are the major contributor for human exposure to aluminum (Neiboer et 
al., 1995; Yokel et al., 2001).  In spite of its ubiquity, no biological function has so far been 
attributed to aluminum.  For this reason, aluminum is considered a nonessential metal.  
Aluminum was considered safe to humans until 1975, when high aluminum quantities in the 
brain tissues were found to be associated with encephalopathy in chronic dialysis patients 
(Alfrey and Solomons, 1976).  This encouraged more research on the toxic effects of aluminum 
on humans.  However, a wealth of research suggests that aluminum is toxic not only to humans 
but also to plants and animals (Ganrot, 1986; Yokel, 2000; Nayak, 2000; Pineros and Kochian, 
2001).   
Aluminum toxicity has been linked with neurological disorders such as Alzheimer’s and 
Parkinson’s diseases (Good et al., 1992; Yokel, 2000; Perl et al., 1982).  In bones, aluminum 
overload is believed to be the predominant cause for the development of low-turnover bone 
disease Osteomalacia in dialysis patients (Ott et al., 1982; Nebeker and Coburn, 1986).  Other 
health risks associated with aluminum toxicity includes microcytic anemia, cholestatic changes 
and alterations of the cytochromes P450 system (Klein et al, 1988; Bidlack et al., 1987).   
The objective of this study is to elucidate and detect the early morphological and 
biochemical changes in the liver after the infusion of aluminum at high dose of 1500 μg/kg/day.  
This dose has been chosen because it has shown to cause cholestasis in neonatal piglets (Klein et 
al, 1987).  In our lab, although this high dose has caused increase in serum total bilirubin and 
aluminum, no consistent histological changes were found in neonatal piglet’s liver infused with 
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aluminum for three weeks (Li et al., 2005).  However, the failure to detect the histological signs 
of cholestasis could be attributed to the low spatial resolution of light microscopy used in the 
study, which limits the identification of morphological ultrastructural changes in the liver.  Light 
microscopy could not detect morphological structural changes in the liver such as loss of 
canalicular microvilli and swollen mitochondria (Shu et al., 1991; Cai et al., 2006).  More 
sensitive imaging techniques are necessary to detect such ultrastructural changes in the liver.  
Hence, the study compared low-resolution light microscopy with the various imaging 
technologies currently available to determine which technique(s) may offer improved resolution 
and ability to detect early ultrastructural changes in the liver consistent with the development of 
cholestasis.  The various imaging techniques employed to achieve this objective include light 
microscopy, transmission electron microscopy, Raman microscopy, confocal microscopy, and 
scanning transmission x- ray microscopy.   
  The results obtained will enable us to identify the suitable technique to study and 
understand the morphologic structural changes in the liver tissues that happen during the infusion 
of aluminum and compare these with changes seen in PN infused subjects.  This information 
would help to develop a better understanding on the role of aluminum in causing liver injury.   
3.2 Hypothesis and Objectives 
  The hypothesis of this study is that intravenous infusion of aluminum at a high dose 
(1500 µg/kg/d) to piglets causes liver injury with detectable early ultrastructural changes and 
increasing duration of aluminum exposure causes further deterioration in liver structure and 
function.  Detecting early changes results in early interventions that may reduce the degree of 
liver injury.  
The specific objectives for this study were to: 
70 
 
1-Evaluate the early morphological ultrastructural changes in piglet liver after the intravenous 
administration of aluminum at a dose of 1500 µg/kg/d. 
2-Determine whether the morphological changes deteriorate further with increasing duration of 
exposure and whether these changes correlate with changes in biochemical markers of 
cholestasis.   
3- Identify the appropriate imaging technique for studying the morphological ultrastructural 
changes in the liver associated with aluminum exposure. 
3.3 Materials and Methods 
3.3.1 Animals and Design  
This study was conducted at the Health Science Building at the University of 
Saskatchewan.  This work was approved by the University of Saskatchewan’s Animal Research 
Ethics Board, and adhered to the Canadian Council on Animal Care guidelines for humane 
animal use.  Twenty neonatal piglets were obtained from the Prairie Swine Centre, Saskatoon.  
Piglets were taken from different sows at 2-4 days old and randomly assigned into: 
 I- The Study Group consisted of 16 animals.  In this group, piglets were randomly placed into 
four subgroups, each 4 piglets: one week, two weeks, three weeks, and four weeks group.  
Starting the day after surgery, every morning (9:00 am) the piglets were given daily intravenous 
injections of 1 mL/kg/day of aluminum chloride hexahydrate (1 mL containing 1500 g 
aluminum).  All study animals had free access to food and water.  
II- The Control Group consisted of 4 piglets.  One piglet was assigned as control for each of the 
four study groups.  These piglets were given daily injections of 1 mL/kg/day intravenous sodium 
chloride (0.9%) and had free access to food and water.   
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3.3.2 Surgery  
Upon arrival, piglets were weighed and given milk replacer before the day of the surgery.  
On the day of surgery, the piglets of both study (n=16) and control (n=4) groups underwent 
surgery to insert a central venous access catheter.  All procedures were carried out under general 
anesthesia in a certified operative facility at the Medical Research Building, University of 
Saskatchewan.  Based on body weight (0.09 mg/kg), piglets were given approximately 0.03-0.06 
mL intramuscular (i.m) Atropine (Glaxo Laboratories Inc., Toronto, Ontario, Canada) prior to 
induction of anesthesia.  Anesthesia was induced with Ketamine (Rogarsetic, Rogar STB Inc., 
Montreal, Quebec, Canada), approximately 0.5 mL i.m based on weight (22 mg/kg) and 
Acetpromaxine (Atravet, Ayerst Laboratories, Montreal, Quebec, Canada) 0.5 mg/kg.  Atropine 
and ketamine were combined in the same syringe.  The piglets were maintained with 
spontaneous respiration and manually ventilated if apnea occurred.  Anesthesia was maintained 
by isoflurane at rate of 1-1.5 %, oxygen and nitrous oxide at ratio of 2:1 with total flow of 1.0 
mL/min.  Approximately 0.1-0.2 mL of Excenel (Pharmacia Animal Health, Mississauga, 
Ontario, Canada), (50 mg/mL) at dose of 3 mg/kg/day was administered i.m as a preoperative 
prophylactic antibiotic.  The piglets were placed in dorsal recumbancy and an incision of 
approximately 3 inches was made on the right side of the neck.  A three French silicone venous 
access catheter (Fisher Scientific, Mississauga, Ontario, Canada) was inserted into the central 
venous system via the jugular vein and the catheter was tunneled under the skin to exit dorsally 
between the piglets shoulder blades.  The neck incision was closed with 3-0 Novafil suture.  
Dorsal incision was a small puncture that was not closed with suture material.  Piglets were 
given 6 mL sterile saline i.v through jugular vein.  All the surgical procedures were carried out in 
a sterile environment using aseptic technique.  The piglets were fitted with elastic bandages to 
protect the catheter.   After daily administration of treatment solutions, the catheter was flushed 
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with one mL of saline and then one mL of heparinised 50% dextrose to maintain the patency of 
the catheter.  
3.3.3 Care of animals  
The piglets were housed in the Health Sciences Building, University of Saskatchewan in 
individual cages with a 12-hour light/dark cycle.  The room temperature was maintained at 27
o
C 
with supplemental heat provided by heat lamps.  All piglets were fed milk replacer only for two 
weeks.  After two weeks, starter diet was added to the milk replacer for three and four week 
groups.  All piglets were monitored daily for food intake, weight gain, and body temperature, 
color of mucus membranes, feces, and urine production.  Each piglet had access to a toy for 
entertainment.  The patency of catheter was maintained by daily flushing with 0.9% sodium 
chloride solution (Abbott Laboratories, Montreal, Quebec, Canada).  Piglets were weighed each 
morning and injections of either aluminum chloride hexahydrate for the study group or sodium 
chloride solution (0.9%) for the control group were prepared accordingly.  The incisions were 
cleaned daily until healed and the sutures were removed on postoperative day 7.  The piglets 
were fitted with elastic bandages to protect the catheter.  Cages were cleaned daily.  
3.3.4 Preparation of aluminum injections   
The aluminum injection was in the form of aluminum chloride hexahydrate (Fisher 
Scientific, Mississauga, Ontario, Canada).  To prepare the aluminum injections with a final 
concentration of 1500 μg/mL, 3.3542 g of aluminum chloride hexahydrate was dissolved in 10 
mL of sterile water.  Then, the solution was transferred into an empty 250 mL intravenous bag 
(Abbott Laboratories, Canada) and mixed with normal saline to 250 mL.  Starting the day after 
the surgery, piglets were weighed each morning at 9:00 am and injections of either aluminum 
chloride hexahydrate for study group or sodium chloride solution (0.9%) for control group were 
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prepared accordingly.  The injections for both groups were given once daily for the whole period 
of the study.   
 
3.3.5 Sample collection and analysis   
Daily weight was recorded.  Blood samples (5 mL) were drawn by syringe from the 
vascular access catheter into a metal-free vacutainer tubes from piglets at baseline (prior to 
aluminum and sodium chloride administration) and at the end of the aluminum exposure period 
for each subgroup (7, 14, 21, or 28 days).  The blood was centrifuged, and the obtained serum 
was aliquotted into three parts.  The aliquots were each used to measure the following: 1) direct 
bilirubin using a QuantiChrom bilirubin assay kit (Bioassay Systems, Hayward, CA, USA), and 
spectrophotometric analysis according to manufacturer instructions, 2) total bile acids in the 
serum using a BioQuant bile acid assay kit (San Diego,CA, USA) and spectrophotometric 
analysis according to manufacturer instructions, and 3) aluminum concentration using a 
inductively coupled plasma mass spectrometry (Thermo X Series ICP-MS, Thermo Fisher 
Scientific Inc, Waltham, MA, USA) at the Saskatchewan Research Council (SRC), Saskatoon, 
SK.   
The ICP-MS sample preparation and analysis was done according to the method 
described in Standard Methods for the Examinations of Water and Wastewater, 2005.  At the end 
of the aluminum exposure period for each subgroup, piglets were anesthetized with 5% 
isoflurane in 100% oxygen, and blood sample was collected via cardiac puncture, and then 
sodium pentobarbital was injected via cardiac puncture into the heart.  Once the piglet was 
deceased, urine from the bladder and bile from the gallbladder were collected using syringe 
needles.  Samples from urine, bile, blood, and liver were quickly collected in metal free plastic 
containers and sent to SRC for aluminum determinations by ICP-MS.  For histopathological 
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observation, liver sections were cut and processed for light microscopy, transmission electron 
microscopy (TEM), scanning transmission x ray microscopy (STXM) Raman microscopy, and 
confocal microscopy as indicated below.  The remaining liver tissues were snap frozen and 
stored at -80°C for further studies.  
3.3.6 Inductively coupled plasma-mass spectrometry (ICP-MS) 
  Inductively coupled plasma-mass spectrometry can measure the presence of more than 75 
elements in a single scan, and can achieve detection limits as low as parts per trillion (ppt) levels 
for many elements (Keeler, 1991).  Aluminum level in blood serum was detected down to 0.001 
μg/mL, and in urine to 0.02 μg/mL using ICP-MS (Ward, 1989).  In liver, kidney, and brain, the 
quantification of aluminum was detected at levels as low as 0.04 μg/g (Owen et al. 1994).  Using 
ICP-MS at the Saskatchewan Research Center (SRC), Saskatoon, the quantification limit for 
aluminum in liver is 0.05 μg/g.  In urine, bile and serum, the quantification limit for aluminum is 
0.05 μg/L.  
3.3.7 Microscopic and imaging techniques sample preparation 
In order to achieve the objective of identifying an imaging technique to study the 
structural changes associated with aluminum loading as well as detection of aluminum 
deposition, the following imaging techniques were utilized: Raman microscopy, confocal 
microscopy, transmission electron microscopy, and scanning transmission electron microscopy.  
However, light microscopy was used in all experiments as the conventional technique to evaluate 
the histologic changes in the liver.     
3.3.7.1 Light microscopy sample preparation 
Liver samples were fixed and stored in 10% buffered formalin at room temperature.  The 
fixed sections were trimmed and transferred to coded plastic histology cassettes (Tissue-Tek, 
Miles. Etobicoke, ON, Canada).  Tissues were dehydrated in a graded series of ethanol baths (1 
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hour in each reagent): 2x 70% ethanol, 2x 95% ethanol, 2x 100% ethanol, and 2x 100% xylene, 
using a tissue processor.  Tissues then were embedded in the paraffin wax.  The blocks were 
trimmed, chilled on ice, and sectioned at 5-µm thickness on a rotary microtome.  Sections were 
dried in the oven at 37
o
C for 24 hours.  The liver specimens were stained for routine light 
microscopy with hematoxylin and eosin (H&E) staining, cover slipped and observed using a 
light microscope for structural changes.   
3.3.7.2 Confocal microscopy sample preparation  
Liver samples were prepared and processed (see sample preparation below) in the 
Department of Anatomy and Cell Biology, University of Saskatchewan.  Analysis of the liver 
tissues to evaluate the intrahepatic distribution of aluminum samples was carried out at 
Saskatchewan Structural Sciences Centre (SSSC), University of Saskatchewan.  
Liver samples were fixed with 70% ethanol for 2 days at room temperature and were immersed 
in pure ethanol for 2 days, followed by embedding in methyl methacrylate resin. Thin sections 
(10-µm thickness) were produced manually using a microtome.   Liver sections were stained in 
acetate buffer (pH 4.0) containing 2.5 x10
-5
 mol/L lumogallion for 1 hour at 70°C.  The 
specimens were then examined for aluminum deposition using a confocal microscope. 
3.3.7.3 Raman microscopy sample preparation 
  The liver samples were analyzed using Raman microscope at the Saskatchewan 
Structural Science Center (SSSC), University of Saskatchewan.    
For Raman microscopy sample preparation, frozen liver sections were warmed to room 
temperature and rinsed with phosphate-buffered isotonic saline solution (pH 7.4).  Liver 
specimens (thickness about 1 mm) were cut and placed in a chambered coverslip, and immersed 
in normal saline solution and examined using the Raman microscope. 
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3.3.7.4 Transmission electron microscope - energy dispersive microanalysis (TEM-EDX)    
             sample preparation 
The fixation and embedding of the liver samples was done in the College of Pharmacy 
and Nutrition, University of Saskatchewan.  The liver samples were processed as follow:  liver 
sections were cut with no larger than 1mm
3
 with a sharp razor blade.  The sections were fixed 
primarily with 2.5% glutaraldehyde in 0.1 M sodium phosphate buffer (pH 7.4) and kept in the 
refrigerator for 4 hours. The liver sections were washed with the sodium phosphate buffer three 
times for 30 minutes each.  Then, the samples were fixed (secondary fixation) with 4% osmium 
tetroxide in 0.1 M sodium phosphate buffer and kept in the refrigerator for 4 hours. The samples 
were washed again with cold sodium phosphate buffer for 15 minutes and were dehydrated in a 
graded series of ethanol (25%, 50% 70-75%, 90-95%, 100%) for 10 minutes each.  Then, the 
samples were washed in distilled water for 30 minutes.  The samples were infiltrated with the 
following ratios of resin:solvent (1:2, 1:1, 2:1, 1:0) for one hour each.  The samples were 
embedded in 100% resin in small plastic capped vials.  The plastic vials were placed in oven at 
70 °C for more than 8 hours until the resin is completely polymerized.  Samples were shipped to 
the facility of Electron Microscopy, Faculty of Health Sciences, McMaster University to be cut 
and observed for morphological changes and locating aluminum deposition in the liver samples.  
Transmission electron microscope was equipped with EDX to locate and determine the nature of 
the electron dense materials observed in liver tissues.  We chose to ship the samples to facility of 
Electron Microscopy, Faculty of Health Sciences, McMaster University because their TEM was 
equipped with EDX.  Here, at the University of Saskatchewan, at that time, no TEM equipped 
with EDX. 
3.3.7.5 Scanning Transmission X-ray Microscopy (STXM) Sample Preparation 
Since there is no standard technique for STXM liver sample preparation, we followed a 
similar standard technique used for electron microscopy.  Two sample preparation techniques 
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were followed; 1) the same as TEM sample preparation but unfixed (no gluteraldehyde and 
osmium tetroxide), and the 2) samples were immersed in 70% alcohol only and kept at room 
temperature until shipped to the facility of Electron Microscopy, Faculty of Health Sciences, 
McMaster University.  For preparing the unfixed samples, small pieces of liver tissues (1x1x1 
mm) were cut randomly from different liver areas.  The tissues were dehydrated with different 
concentration (25%, 50% 70-75%, 90-95%, 100%) of ethanol for 20-30 minutes each.  Then, the 
tissues were embedded in epoxy resin, polymerized at 60°C for 24 hours, and sent later to the 
facility of Electron Microscopy, Faculty of Health Sciences, McMaster University.  At 
McMaster University, the liver tissues were cut using ultramicrotome into 90 nm thick.  Sections 
were collected and mounted on copper grids and shipped to the Canadian Light Source (CLS) 
(Saskatoon, Canada) for STXM analysis. 
3.3.8 Statistical analyses 
Descriptive statistics were performed for the variables.  Results were expressed as mean 
± standard deviation (SD).  One-way ANOVA and post hoc test (Student-Newman-Keuls) were 
used to compare the variables in different groups.  However, when the variance was not 
homogenous, values were expressed as median and interquartile range (IQR) and a non 
parametric test (Mann-Whitney U test) was used to compare the difference between the groups.  
The correlation between the variables was evaluated using Pearson correlation.  A p-value less 
than 0.05 were considered significant. 
3.4 Results 
Piglets of the control group (n=4) were assigned randomly into four different period 
groups as follow: one, two, three, and four week.  One piglet was assigned as control for each 
study group.  However, during the experiment, only piglets for one week and two weeks finished 
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the period of the study.  For three and four week piglets, because of catheter-related problems, 
we had to sacrifice the control piglets after one week of the infusion.  
3.4.1 Body weight  
Aluminum infusion was associated with slight decrease in body growth rate of piglets 
throughout the duration of the study (Fig.3.1).  The highest body growth rate was noticed in the 
study one week group (8%) and lowest growth rate was seen in the study four weeks group 
(5.3%).  No significant difference was found between the groups.   
 
 
 
 
  
 
 Figure 3.1. Weight patterns of piglets during the experiment 
Data are expressed as mean ± SD between brackets at the top of the graph. Data series labelled 
with the % growth rate. Number of piglets in each group (n=4). % GR: % growth rate. 
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3.4.2 Biochemical assays 
3.4.2.1 Serum direct bilirubin  
The administration of aluminum in the piglets was associated with slight increase in the 
serum direct bilirubin level (Table 3.1).  Statistically, there is no difference in serum direct 
bilirubin level among controls at day 0 and day 7.  However, the increase in serum direct 
bilirubin level was significant at day 7 in the study group compared to day 0 and day 7 of 
controls, and day 0 of study group (Table 3.1).  The level of the serum direct bilirubin peaked at 
day 21 of infusion and declined at the day 28 of the infusion.  However, the decline in the serum 
direct bilirubin level at day 28 was not statistically significant compared to the other groups.  
 
 
 
 
         Table 3.1. Results of direct bilirubin (µmol/L) in all groups. 
Group Median (IQR) Mean±SD 
Control group    
Day 0 (n=4) 2.0 (1.0-7.0)
 a
 3.4±3.2 
Day 7 (n=4) 2.6 (1.5-7.6)
 a
 3.9±3.5 
Study group   
Day 0 (n=16) 4.1 (2.8-6.8)
 a
 5.0±3.2 
Day 7 (n=16) 7.0 (3.6-11.5)
 b
 7.9±4.2 
   Day 14 (n=11)
1
 8.2 (3.4-17.2)
 b,c
 9.6±6.6 
Day 21 (n=8) 9.9 (2.5-15.3)
 b,c
 9.1±6.4 
Day 28 (n=4) 5.1 (4.8-7.0)
 a,b
 5.6±1.2 
 Values are expressed as median and interquartile range (IQR). Medians with   
 different superscripts (a, b,c) were significantly different (p<0.05) when compared  
 to each other using a non parametric test (Mann-Whitney U test). 
 1-Insufficient sample (piglet # 51, day 14).  
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3.4.2.2 Serum total bile acids 
The median level of serum total bile acids was increased in all the study groups 
throughout the duration of aluminum infusion (Table 3.2).  The aluminum loaded piglets had 
significantly (p<0.05) increased levels of serum total bile acids at day 14, 21, and 28 of the study 
compared to controls at day 0 and 7, and study group at day 0.  The highest increase in the serum 
total bile acids level of study group was seen at day 28 of aluminum infusion (Table 3.2).  
 
 
          Table 3.2. Results of serum total bile acids (µmol/L) in all groups. 
Group Median (IQR) Mean ± SD 
Control group    
Day 0 (n=4) 6.5 (5.0-11.5)
 a
 7.6±4.0 
Day 7(n=4) 11.8 (7.0-13.9)
 a
 10.9±4.0 
Study group   
  Day 0 (n=16) 6.7 (4.6-11.4)
 a
 13.1±18.0 
  Day 7 (n=16) 19.0 (12.1-25.4)
 a,b
 19.9±16.0 
   Day 14 (n=12) 29.3 (19.2-50.4)
b,c
 33.1±16.0 
  Day 21 (n=8) 36.4 (19.4-56.2)
b,c
 37.7±19.0 
  Day 28 (n=4) 48.9 (43.9-56.9)
c,d
 49.9±7.0 
Values are expressed as median and interquartile range (IQR). Medians with                 
different superscripts (a,b,c,d) were significantly different (p<0.05) when  
 compared to each other using a non parametric test (Mann-Whitney U test).   
 
 
 
3.4.2.3 Aluminum content of serum, liver, bile, and urine  
The median level of serum aluminum content was significantly increased at day 7, 14, 21, 
and 28 (p <0.05) in study group compared to day 0 and 7 in the controls and day 0 of the study 
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group (Table 3.3).  For the effect of aluminum loading on the liver, the hepatic aluminum content 
(Table 3.4) was proportionally increased with the duration of the study.  The increase in the 
hepatic aluminum content was significant (p<0.05) among all the study groups.  No correlation 
was found between serum aluminum content, direct bilirubin, and serum total bile acids.  
However, the hepatic aluminum content was positively correlated (Figure 3.2) with the serum 
total bile acids (r = 0.67, p = 0.001).   
  
                Table 3.3. Serum aluminum concentration (µg/L) in all groups. 
Group Median (IQR) Mean±SD  
Control group    
Day 0 (n=4) 25.0 (25.0-25.7)
 a
 25.0±0.5 
Day 7 (n=4) 108 (62.0-615)
 b
 261.6±346 
Study group   
Day 0 (n=16) 84.0 (25.0-290)
 c
 162±169 
Day 7 (n=16) 1013 (754-1500)
d
 1125±124 
  Day 14 (n=12) 1150 (597-1550)
d
 1175±647 
Day 21 (n=8) 990 (574-1436)
d
 1313±1058 
Day 28 (n=4) 1272 (340-1862)
d
 1159±797 
Values are expressed as median and interquartile range (IQR). Medians with        
different superscripts (a,b,c,d) were significantly different (p<0.05) when          
compared to each other using a non parametric test (Mann-Whitney U test).   
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              Table 3.4. Hepatic aluminum concentration (µg/g) in all groups. 
Group 
Median (IQR) Mean±SD 
Control group (n=4) 0.05 (0.05-0.14)
a
 0.08±0.06 
Study group   
One week (n=4) 25.5 (15-28)
b
 22.7±7.5 
Two week (n=4) 44.0 (30-69)
c
 47.7±21.0 
Three week (n=4) 53.5 (43-78)
c
 58.5±19.0 
Four week (n=4) 81.5 (78-85)
d
 81.7±3.8 
Values are expressed as median and interquartile range (IQR). Medians with  
different superscripts (a,b,c,d) were significantly different (p<0.05)when compared  
to each other using a non parametric test (Mann-Whitney U test).   
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            Figure 3.2. Correlation between hepatic aluminum and total serum bile acids (TBA). 
The scatter plot represents the correlation between the concentration of hepatic aluminum 
and the serum total bile acids in the control piglets (n=4) and the piglets of four study 
groups (each has 4 piglets). The controls were give daily injection of 1 mL /kg/day of 
sodium chloride (0.9%). The study groups were given daily injections 1 mL/kg/day of 
aluminum chloride hexahydrate (1 mL contains 1500 µg aluminum). 
 
 
In urine, the median level of aluminum content was proportionally increased in all study 
groups throughout the experiment (Table 3.5).  The increase in the urine aluminum content was 
significant (p<0.05) in the third and fourth week groups compared to the controls and one week 
study group.  In bile, the median levels of aluminum concentrations were increased in the one 
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and two week group of experiment and declined in the third week group.  However, the 
aluminum content in bile was elevated again at the fourth week group (Table 3.6).   
 
         Table 3.5. The concentration of aluminum (µg/L) in urine in all groups. 
Group Median (IQR) Mean ± SD 
Control (n=3)
1
 61.2 (51-155)
 a
 120±112 
Study group   
One week (n=4) 1020.0 (635-1377)
 a
 995±733 
Two week (n=4) 1320.0 (560-4450)
 a,b
 2487±3117 
Three week (n=4) 4335.0 (2652-6324)
 b
 4444±2126 
Four week (n=4) 4913.0 (1105-8262)
 b
 4643±4140 
 Values are expressed as median and interquartile range (IQR). Medians with 
 different superscripts (a, b) were significantly different (p<0.05) when compared  
 to each other using a non parametric test (Mann-Whitney U test).                   
1. Urine sample was not obtained from piglet # 54 (control), the bladder was empty. 
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            Table 3.6. The concentration of aluminum (µg/L) in bile in all groups. 
 
Group 
Median (IQR)  Mean ± SD 
Controls (n=4) 51 (31-51)
 a
 44.5±13.0 
Study group   
One week (n=4) 140 (51-372)
 a,b
 188±176 
Two week (n=4) 227 (198-305)
b
 243±60 
  Three week (n=4) 66 (51-196)
 a,b,c
 104±87 
 Four week (n=4) 146 (97-157)
c,d
 133±35 
              Values are expressed as median and interquartile range (IQR). Medians with                                                 
              different superscripts (a, b,c,d) were significantly different (p<0.05) when         
              compared to each other  using a non parametric test (Mann-Whitney U test).   
 
    
 
 3.4.3 Histopathological observation  
In this study, I aimed to identify an appropriate imaging technique(s) for the early 
detection of ultrastructural changes consistent with cholestatic changes of the liver.  Several 
imaging techniques were employed throughout the study, namely light microscopy, transmission 
electron microscopy equipped with energy dispersive microanalysis (TEM-EDX), Raman 
microscopy, confocal microscopy and scanning transmission x-ray microscopy (STXM).   
 3.4.3.1 Light microscopy 
Light microscopy was used as the starting imaging tool to identify any histopathological 
features seen after the infusion of Al in the piglets.  Liver samples from the study and control 
groups were evaluated for histologic changes blindly by a board- certified Pathologist at the 
Prairie Diagnostics Center in the Western College of Veterinary Medicine.  Inflammation, necrotic 
foci, and hydropic degeneration were the only changes seen in the livers of the piglets (Table 
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3.7).  Morphological evidence characterized with inflammation was seen in all groups.  
Inflammation in the liver samples was more evident after four weeks of Al infusion.  No bile 
plugs were seen in any study or control piglet livers.   
 
 
Table ‎0.7. Histological observations of piglet liver using light microscopy. 
 
Group 
Inflammation Necrotic 
foci 
Bile duct 
proliferation 
Portal 
fibrosis 
Hydropic 
degeneration 
Bile 
plugs 
Control (n=4) 1 0 0 0 0 0 
One week (n=4) 1 0 0 0 1 0 
Two week (n=4) 2 0 0 0 0 0 
Three week (n=4) 2 0 0 0 0 0 
Four week (n=4) 3 1 0 0 0 0 
Numbers (0-3) represent number of subjects.  
 
 
 
3.4.3.2 Raman and Confocal microscopy  
Frozen piglet liver samples from previous work were cut, prepared, and examined for Al 
deposition and morphological changes in the microscope facility at Saskatchewan Structural 
Science Center.  The results showed no clear histological features and no Al deposition was seen 
in the liver samples.  Although significant work was done using Raman and confocal microscopy 
in biological sciences, in our project, we could not utilize the techniques to achieve our 
objectives.  The unsuccessful use of Raman and confocal microscopy to detect Al deposit in the 
liver tissues attributed to the lack of expertise as the scientists who run the confocal and Raman 
microscopes were not familiar with biological samples.  Another reason is that the liver samples 
87 
 
examined were stored improperly, which caused unclear morphological structure to the liver 
sections.  It is worthwhile to mention that Raman microscopy has been used successfully to 
distinguish between normal and cancer cells, and to differentiate between different types of 
tumor cells (Crow et al., 2005; Choi et al., 2005; Jong et al., 2006), and utilizing this imaging 
technique properly with the aid of expertise personnel in the future could help researchers, 
especially in the area of PNAC to distinguish between normal and injured liver, and could detect 
any early structural especially in the livers of patients receiving PN. 
Using both techniques, neither clear morphology nor aluminum deposition was seen in 
the piglet livers using these techniques.  The other techniques to accomplish my objective were 
explored.  
 
3.4.3.3 Transmission electron microscopy energy dispersive spectroscopy (TEM-EDX) 
Transmission electron microscopy equipped with energy dispersive spectroscopy 
demonstrated the presence of aluminum deposits in the lysosomes of hepatocytes of the study 
group (Figure 3.3).  Morphological changes, as evidenced by the loss of canalicular microvilli 
(Figure 3.4) and condensation of mitochondria, were seen in all but the control group.  The loss 
of the canalicular microvilli was observed in the two, three, and four week of infusion groups but 
not in the one week group and controls.  In Table 3.8, the results of semi-quantitative analysis of 
the liver tissues for elemental distribution using EDX showed that aluminum deposition was 
proportionally increased with the duration of infusion.  The highest aluminum levels were 
observed in the four-week group and the lowest was in the control group (Table 3.8).  
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  Figure 133. Electron micrograph and EDX spectra for piglet liver from the study group. 
a) Electron micrograph of liver of piglet from the study group receiving daily injection of 1 
mL/kg/day of aluminum chloride hexahydrate (1 mL 1500μg Al), x50000. b) EDX spectra taken 
from the electron dense in the hepatocyte showing the elemental distribution. Peaks of aluminum 
(Al), copper (cu), osmium (Os), uranium (U), and lead (Pb) were observed. The peaks of Cu are 
originated from the grids. Os, Pb, U peaks are from fixative and staining materials. m: 
mitochondria, n: nucleus. 
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Figure 3.4. Electron micrographs for the liver of control and study piglets.  
The electron micrograph of the control piglet show intact microvilli in the bile canaliculi (arrow), 
x 15000.  The control piglets were given daily injections of mL/kg/day of sodium hydroxide 
(0.9%).  A marked loss of microvilli of bile canaliculi was seen in the study group of piglets 
given daily injections of 1 mL /kg/day of aluminum chloride hexahydrate (each 1 mL contains 
1500 µg Al), x10000.  m: mitochondria, n: nucleus.   
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Table ‎0.8. Results of microanalysis using energy dispersive x-ray microanalysis (EDX) of 
piglet’s‎liver‎presented as peak/background ratios. 
 
Element Al Cu Os P Si 
 
Fe 
 
S 
Group 
Controls (n=2) 0.3±0.1 11.5±3.7 7.4±1.1 2.1±0.4 0.5±0.1 2.6±1.2 0.49±0.25 
One week (n=2) 0.3±0.1 12.0±11.0 2.5±2.9 0.8±0.9 0.6±0.3 0 0 
Two week (n=1) 0.4±0.2 14.8±3.2 7.8±1.3 2.1±0.8 0.1±0.3 0 0.11±0.24 
Three week (n=2) 0.5±0.2 8.8±2.1 5.9±1.4 2.6±0.8 0.3±0.3 4.10±3.51 0.35±0.26 
Four week (n=1) 0.6±0.1 19.1±2.1 0 1.7±0.5 0.5±0.1 1.35±0.95 0 
Al: aluminum, Cu: copper, Os: osmium, P: phosphorus, Si: silicone, S: sulphur. Means are the 
average of the values collected from 6 different sites in the liver tissues for each animal.   
 
 
 
3.4.3.4 Scanning transmission x ray microscopy (STXM) 
 The scanning transmission x-ray microscopy (STXM) was also used in our project as one 
of the prospective advanced imaging techniques to achieve my objectives.  The aim was to 
identify any early morphological changes and to speciate Al in the liver samples.  The piglet 
liver samples were cut, fixed and prepared using the same sample preparation technique as 
Transmission electron microscopy and examined by the beamline scientist at STXM.  The results 
showed no clear morphological structures were seen (Figure 3.5).  Also, Al could not be detected 
in the liver samples.  The failure to detect Al and the unclear morphology led us to try different 
sample preparation techniques.  At this time, unfixed liver samples were cut, prepared and 
examined using STXM.  The results showed damaged tissues and no Al was seen (Figure 3.6).  
The damage was attributed to the lack of fixative in the tissue.   
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Figure 3.5. (A) Scanning transmission x-ray microscopy color-coded composite piglet liver. 
 (B) Spectra extracted from the image demonstrating the distribution of materials in the liver and 
showing no aluminum was found in the liver of the piglet from the study group. Piglets of the 
study group were given daily injections of 1 mL/kg/day aluminum chloride hexahydrate (1 mL 
contains 1500 µg Al). A blue and green color spectrum represents two different fixatives, and red 
color spectra represent the protein distribution. Two fixatives were used in liver tissues; 
glutaraldehyde and osmium tetroxide.  
 
92 
 
 
Figure 3.6. Scanning transmission x-ray microscopy images of unfixed liver tissues taken 
from piglet of the study group.   
Piglets of the study group were given daily injections of 1 mL/kg/day aluminum chloride 
hexahydrate (1 mL contains 1500 µg Al). The unfixed liver sections were damaged and no clear 
morphological structure was seen.   
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3.5 Discussion  
A neonatal piglet model was successfully developed to investigate the effect of aluminum 
loading on the biochemical parameters and histopathological features of the liver.  The main 
objective of this study was to elucidate the early biochemical and ultrastructural changes in the 
liver that are associated with the parenteral administration of high aluminum dose (1500 
µg/kg/d).  This dose has been chosen because it has shown to cause cholestasis in neonatal 
piglets (Klein et al, 1987).  In our lab, although this high dose has caused increase in serum total 
bilirubin and aluminum, no consistent histological changes were found in neonatal piglet livers 
infused with aluminum for three weeks (Li M, 2005).  However, the failure to detect the 
histological signs of cholestasis could be attributed to the low spatial resolution of light 
microscopy used in that study which limits the identification of morphological ultrastructural 
changes in the liver.  Light microscopy could not detect morphological structural changes in the 
liver such as loss of canalicular microvilli and swollen mitochondria (Shu et al., 1991; Cai et al., 
2006).  More sensitive imaging techniques are necessary to detect such ultrastructural changes in 
the liver.  Hence, the study compared low resolution light microscopy with the various imaging 
technologies currently available to determine which technique(s) might offer improved 
resolution and ability to detect early ultrastructural changes in the liver consistent with the 
development of cholestasis.  The various imaging techniques employed to achieve this objective 
include light microscopy, transmission electron microscopy, Raman microscopy, confocal 
microscopy, and scanning transmission x- ray microscopy.   
In our study, using Raman and confocal microscopy, neither clear morphology nor 
aluminum deposition was seen in the piglet livers using these techniques.  The unsuccessful use 
of both techniques in our project attributed mainly to the storage condition of liver samples used.  
The liver sections (from previous work) were frozen at -20°C.  The two commonly used methods 
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of tissue long-term storage are either paraffin embedding or snap-freezing method.  In both 
methods, excised tissues need to be processed immediately to avoid ultrastructural 
morphological damage to the tissue.  Unfortunately, at that time, we did not have fresh liver 
tissues and we had to use the stored liver tissues.  Another reason is that the scientists at 
Saskatchewan Structural Science Center are not familiar with biological samples.   
 
Scanning transmission x-ray microscopy (STXM) has the potential to reveal 
ultrastructure of intact and hydrated cells at high spatial resolution (~30 nm) (Jacobson, 1999).  
The spectroscopy associated with microscopy can be used to identify and reveal the different 
states of different elements present in the sample.  Scanning transmission x-ray microscopes 
show their full power in combining the high spatial resolution imaging with high-energy 
resolution for elemental and chemical state mapping.  Unfortunately, in our work, we could not 
benefit from the powerful imaging characteristics of STXM.  The unsuccessful attempts of 
benefiting from STXM technique in our project could be attributed into two main reasons.  The 
first reason is because of the competitiveness at the Synchrotron and the limited number of 
applications accepted in the beam line which limited our chance of using this technique.  The 
second reason is the lack of proper sample preparation especially liver samples loaded with 
aluminum.  No STXM standard sample preparation for liver tissues is yet established.  In this 
work, liver sample were processed in two different ways.  One using the same sample 
preparation used in TEM; samples were fixed using Glutaraldehyde and osmium tetroxide and 
embedded in epoxy resin.  In the other method, liver samples were immersed in 70% ethanol, 
and embedded in epoxy resin.  However, at observation, no clear morphological structure was 
seen and no Al deposition detected in all the samples.  The failed attempt to detect Al in the liver 
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tissue might attributed to the low thickness (90 nm) of the liver sections.   For the unclear 
morphological structure, the reason could be the absence of fixative in the liver tissue as fixative 
is important to preserve tissue from degradation.  
Transmission electron microscopy (TEM) has also been used extensively to study cellular 
structure in biological materials.  Due to its high spatial resolution and high magnification, 
transmission electron microscopy has the advantage of detecting some morphologic features in 
the liver at the sub-cellular levels that could not be detected using light microscopy such as loss 
of canalicular microvilli and swollen mitochondria (Shu et al., 1991; Cai et al., 2006).  In 
addition, because we aimed to look at the aluminum deposition in the liver samples and where it 
is localized within the cell, TEM can be equipped with energy dispersive microanalysis (EDX) 
which has the potential to analyze all the elements in liver sample at a time.  However, the 
weakness of electron penetration requires sample thicknesses considerably less than 1 μm (Kirz 
et al., 1995).  Sectioning samples into thin sections can cause structural artifacts or distortion.  
The other challenge is the low contrast of biological materials which requires staining samples 
with heavy metal salts that bind to specific intracellular organelles to differentiate them which 
can be an another source of artifact.    
Using transmission electron microscopy equipped with energy dispersive microanalysis 
was very effective in detecting the ultrastructural changes as well as the site of aluminum 
deposition in the liver.  In agreement with previously published results, (Klein et al., 1987; Galle 
and Giudicelli, 1982; Kametani and Nagata, 2006) aluminum was found deposited in the 
lysosomes of the hepatocytes of the study group.  Our work confirms the finding that TEM-EDX 
is superior tool to investigate the trace elements deposition such as aluminum in biological 
materials (Kametani, 2002).  
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The results show that daily parenteral administration of aluminum at high dose (1500 
µg/kg/d) result in accumulation of hepatic aluminum associated with elevated serum total bile 
acids and histopathological changes in the liver.  The significant elevation in serum total bile 
acids level was noticed as early as day 14 of aluminum administration.  Comparable results were 
reported in neonatal piglets and rats infused parenterally with aluminum (Klein et al., 1987; 
Klein et al., 1988), and in rats administered intraperitoneally with aluminum (Demircan et al., 
1998).  This implies that daily chronic intravenous administration of aluminum induces liver 
injury after two weeks.  In addition, elevation in serum bile acids has been seen in early onset of 
parenteral nutrition associated liver injury (Demircan et al., 1998; Tazuke and Teitelbaum, 
2009).  Our results are consistent with those reported that increased levels of bile acids are 
indicative of liver injury, and are in accordance with the suggested proposal by Demircan et al, 
(1998) that serum bile acids might be more sensitive indicator for the early diagnosis of 
parenteral nutrition associated liver disease (Farrell et al., 1984; Demircan et al., 1998; 
D’Apolito et al., 2010).   
The amount of aluminum accumulated in the liver was proportionally correlated with the 
duration of aluminum administration (Klein et al., 1988), and was significantly correlated with 
the increase in total bile acids throughout the duration of the study.  In our study, the effect of 
aluminum loading on the liver was manifested with ultrastructural changes such as loss of bile 
canalicular microvilli and condensation of mitochondria after two weeks of aluminum 
administration.  On the contrary, in study conducted by Klein et al (1987), the electron 
microscopy observation failed to detect ultrastructural changes in the liver of piglets infused with 
the same dose used in our study (1500 µg/kg/d) for 50 days (Klein et al., 1987).  However, in 
agreement with our finding, other investigators were able to demonstrate histopathological 
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changes in liver infused with aluminum.  Stacchiotti et al., (2008) reported that in adult mice 
orally administered Al sulphate (2.5 %) daily for 10 months, the electron microscopy observation 
showed a reduction of hepatic microvillar projections by 60-80 % compared to controls.  Also, 
Demircan et al., (1998) reported that histologic changes such as portal inflammation were 
detected using light microscopy in rats’ liver infused intraperitoneally with aluminum.   
Our data indicates that the intravenous infusion of aluminum at a high dose (1500 
µg/kg/d) in growing neonatal piglets accumulate a significant amount of aluminum in serum, 
bile, urine, and liver tissues.  Marked elevation in serum total bile acids and loss of canalicular 
microvilli were noticed after two weeks of aluminum administration.  For detecting the site of 
aluminum deposition in the liver as well as study the ultrastructural morphology, we found that 
TEM-EDX is the best suitable technique for our purpose and it will be employed in the 
subsequent experiments.  Also, based on elevated total serum bile acids seen after aluminum and 
TPN administration, we may postulate that Al loading may contribute to parenteral nutrition 
induced liver injury.   
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4.0 ALUMINUM-IRON INTERACTION AND ITS ROLE IN CAUSING LIVER 
INJURY IN INTRAVENOUS ALUMINUM INFUSED PIGLETS 
 
4.1 Introduction 
Aluminum toxicity is well documented, but the mechanism of action is poorly 
understood.  Studies have demonstrated that aluminum is a potential toxicant to various body 
systems including central nervous system, hematopoietic system, and skeleton (Yokel and 
McNamara, 2001; Kausz et al., 1999; Alfrey, 1991; Perez et al., 2001; Practico et al., 2002).  
Because aluminum has an ionic structure similar to iron and is known to bind to transferrin, the 
main iron transport protein, interactions between aluminum and iron occur in a variety of cells 
and tissues (DeVoto and Yokel, 1994).  The exact mechanism of aluminum effect on iron 
metabolism is not yet clear.  However, Abreo et al. (1994) proposed that aluminum loading 
causes sequestration of iron in either the mitochondria or nuclei with the resulting reduction in 
cytosolic iron leading to stabilization of iron regulatory proteins (IRP) and suppression of ferritin 
synthesis.  This could lead to increased concentrations of free iron.  Alternatively, Yamanaka et 
al., (1999) proposed that aluminum could modify cellular iron homeostasis by stabilizing the iron 
regulatory protein 2 (IRP2), which would promote the binding of IRP to iron responsive 
elements (IRE), inducing transferrin (TfR) expression while blocking ferritin synthesis. This 
could lead to accumulation of intracellular free iron, and thereby increasing oxidative damage in 
the cell.    
A number of studies conducted on a variety of cultured cell lines have shown that 
aluminum loading results in abnormal iron accumulation in tissues (Abreo, 1990; Abreo, 1994).    
In experimental animals, the increase in tissue aluminum content was paralleled by elevations of 
iron in liver, kidney, heart, spleen, and brain (Ward et al., 2001).  This increase would imply that 
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the normal iron homeostasis in the cell is altered.  Free iron is harmful because of its high redox 
activity and its potential to generate free radicals, thereby inducing cellular toxicity (Halliwell 
and Gutteridge, 1990; Andersson et al., 1999), and tissue damage (Crichton et al., 2002).   
The ability of aluminum to promote iron-induced oxidative stress is not fully understood 
but it is reported that aluminium potentiates the activity of Fe ions to cause oxidative damage 
(Gutteridge et al., 1985; Oteiza et al., 1993; Good et al., 1992; Xie and Yokel, 1996).  Bondy and 
Kristine (1996) observed that in the presence of aluminum salts, there is a potentiation of iron- 
induced reactive oxygen species (ROS), but no stimulation of ROS observed in the presence of 
free aluminum.  Also, Abreo et al. (1990 and 1991) observed that increased iron uptake in 
aluminum-loaded mouse hepatocytes and Friend erythroleukemia cells were associated with 
membrane lipid peroxidation.  This has led to the hypothesis that aluminum loading may lead to 
iron-induced oxidative stress, which, in turn, may explain the pathological changes associated 
with TPN-induced liver injury. 
4.2 Hypothesis and Objective 
The hypothesis of this study was that aluminum loading disrupts iron homeostasis in the 
liver thus resulting in increased free iron and increased oxidative stress in the liver.  The 
objective of this study was to determine if intravenous injection of high dose aluminum into 
neonatal piglets disrupts iron homeostasis in the liver and whether the resulting free iron plays a 
role in the liver injury that is associated with aluminum exposure.   
4.3 Materials and Methods 
Frozen piglet liver tissues (flash frozen in liquid nitrogen and stored at -80°C) from the 
study (16 piglets) and control group (4 piglets) were used in this study.  The study subgroups 
(one,two,three, and four weeks) were given daily intravenous injections of 1 mL/kg/day of 
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aluminum chloride hexahydrate (1 mL containing 1500 g aluminum).  The control group (4 
piglets) were given daily intravenous injections of 1 mL/kg/day intravenous sodium chloride 
(0.9%).  The study and control groups had free access to food and water (Chapter 3). 
4.3.1 Liver homogenization  
Prior to measuring thiobarbituric acid reactive substances (TBARS), nonheme iron, and 
bleomycin detectable iron, liver tissues were crushed into a fine powder under liquid nitrogen 
using BioPulverizer.  The BioPulverizer consists of a hole made in a stainless steel base into 
which fits a special piston.  Typically, up to 1 g of liver tissue is hard-frozen in liquid nitrogen 
and placed in the pre-chilled BioPulverizer, and the tissue is pulverized with a few blows to the 
pestle using a hammer.  The powdered tissues were transferred into cryotubes and stored at -
80°C for subsequent analysis.   
4.3.2 Tissue measurement of oxidative stress  
4.3.2.1 Thiobarbituric acid reactive substances (TBARS) assay 
TBARS was measured in liver tissue as a marker of oxidative stress.  The measurement 
of TBARS was adapted from the method of (Ohkawa et al., 1979).  This method determines 
malondialdehyde (MDA) and other reactive aldehyde levels by heating the samples in the 
presence of thiobarbituric acid (TBA) at low pH, resulting in the formation of a pink 
chromophore with an absorption maximum near 532 nm (Abuja and Albertini, 2001).  The 
procedure was scaled down for use with small samples (100 µL of sample), and the TBA 
reaction products were extracted with an equal volume of butanol/pyridine (15 butanol: 1 
pyridine, v/v). Butylated hydroxytoluene (BHT), and ethylene glycol tetraacetic acid (EGTA), 
previously neutralized to pH 7.2, were included in the tissue homogenization buffers to prevent 
artefact formation of TBARS during sample preparation.  
The TBARS measurement was done in duplicate for all liver tissue samples.  In a micro 
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centrifuge tubes (1.5 ml), 50 mg of liver tissue was homogenized using a tissue grinder (Pellet 
Pestles® cordless motor, Kimble-Knotes # 749521-1590) with 200 µL of 
radioimmunoprecipitation assay (RIPA) buffer.  The tissue grinder grinds soft tissues into a 
homogenous solution.  The homogenate was incubated for 30 minutes at room temperature, and 
centrifuged at 15,000 × g for 10 minutes at 4ºC.  One hundred microliters of the supernatant was 
added to 350 µL of thiobarbituric acid solution containing 12% acetic acid, pH 3.5, 0.6% SDS, 
0.45% thiobarbituric acid, and 0.0002% BHT.  The mixture was heated for 1 hour at 95ºC.  
Then, the heated sample was cooled and centrifuged at 4,000 × g for 10 min.  The absorbance of 
the supernatant was measured at 532 nm using Beckman DU40 spectrophotometer (Beckman 
Coulter, Mississauga, ON, Canada).  The malondialdehyde (MDA) was calculated using a 
standard curve of malondialdehyde prepared from tetraethoxypropane by acid hydrolysis.  The 
amount of MDA in samples was expressed as nmol/mg of protein.   
4.3.2.2 Biuret protein assay  
The biuret protein assay was used to measure the protein content in tissue homogenates in 
order to make other measurements comparable.  The method is based on the formation of a 
purple complex between copper salts and substances containing two or more peptide bonds in an 
alkaline medium.  The procedure used was based on Lyne’s review for the biuret method (1957). 
In the assay, samples were vortexed with biuret reagent (32 mM sodium potassium tartrate, 12 
mM copper sulphate, 30 mM potassium iodide, 0.2 M NaOH) in a ratio of 1 sample: 9 biuret 
reagent (v:v), left for 20 minutes at room temperature .  The copper ions form a complex with the 
amide groups in the proteins and create a blue color that was measured at a wavelength of 550 
nm using a Beckman Coulter DU® 640B spectrophotometer.  Protein concentrations of tissue 
homogenates were measured in duplicate by the biuret method (Layne E, 1957) using bovine 
serum albumin as a calibration standard.   
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4.3.3 Determination of free iron in liver tissues by bleomycin detectable iron  
The free iron level in liver tissues was measured using the bleomycin assay method 
(Gutteridge et al., 1981).  This method is based on the direct complexation of redox-active iron 
with the antibiotic bleomycin.  The iron–bleomycin complex causes degradation of DNA and the 
degradation products can be measured.  The detected iron is generally named bleomycin-
detectable iron.  Concentrations of bleomycin-detectable iron are believed to represent the redox-
active iron pool (Gutteridge et al., 1981).   
A 50 mg of liver tissue was homogenized with 500 µL 20 mM Tris-HCl buffer pH 7.4 
using a small Dounce homogenizer (an apparatus consisting of a glass tube with a tight-fitting 
glass pestle used manually to disrupt tissue suspensions to obtain single cells or subcellular 
fractions) for 1 minute.  The reaction mixture was prepared by the sequential addition of the 
following reagents: 250 µL DNA (1 mg/mL), 25 µL bleomycin (Sigma, USA) (1.5 units/mL), 50 
µL of 50 mM MgCl2, 50 µL of 1 M Tris-HCl pH 7.4, 25 µL of l homogenate/standard, and 50 
µL l7.5 mM ascorbic acid.  The homogenate was incubated at 37°C for 1 hour (to allow the iron 
bleomycin complexes to bind to DNA, releasing malondialdehyde from DNA degradation).   
Fifty microliters of 0.1 mol/L EDTA was added to stop the reaction. Two hundred and fifty 
microliters of 10 g/L thiobarbituric acid and 250 µL of 3 N HCl were added.  The mixture was 
heated at 85°C for 20 minutes (to allow chromogen formation by the reaction of 
malondialdehyde with thiobarbituric acid).  The mixture was cooled at room temperature, 
centrifuged at 10,000 × g for 10 minutes.  The absorbance of the supernatant was measured at 
532 nm using Beckman DU40 spectrophotometer (Beckman Coulter, Mississauga, ON, Canada).   
4.3.4 Non-heme iron assay 
Fifty mg of liver tissue was homogenized with 500 µL high-purity 18 MΩ water using a 
Dounce homogenizer.  In 1.5 mL plastic microcentrifuge tubes, 100 µL of tissue homogenate 
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was added to an equal amount of 1.5 N HCl. The homogenate was heated at 85°C in heating 
blocks for 30 minutes, cooled in water at room temperature for 2 minutes, and centrifuged for 5 
minutes at 10,000 × g.  100 µL of the supernatant aliquot was transferred into another plastic 
centrifuge tube, and 20 µL of 40 % trichloroacetic acid was added. The mixture was heated at 
85°C in heating blocks for 15 minutes, centrifuged for 5 minutes at 10,000 × g at room 
temperature.  200 µL of 1 mM ferrozine solution (1 mM ferrozine in 1.05 M sodium acetate, pH 
4.8) was added to 20 µL of the supernatant aliquot.  The absorbance was measured at 562 nm 
using spectrophotometer (Beckman DU40 spectrophotometer (Beckman Coulter, ON, Canada).   
4.4 Statistical analysis 
Descriptive statistics were performed for the variables.  Results were expressed as mean ± 
standard deviation (SD), and analyzed using one-way ANOVA and post hoc test (Student-
Newman-Keuls).  A p < 0.05 was considered statistically significant.    
4.5 Results 
4.5.1 Measurement of free iron and TBARS levels in liver tissues  
The concentration of bleomycin detectable iron, an indicator of the free iron pool 
(Guttridge, 1981), was measured in the liver tissues.  There was a trend towards increased levels 
of bleomycin in the liver tissues of the study groups throughout the study period (Table 4.1).  
The bleomycin detectable iron levels in the liver tissues were proportionally increased with the 
duration of aluminum exposure.  The increase peaked in the four week group (43%) compared to 
controls, and 39% compared to the one week group (Table 4.1).  Also, aluminum loading caused 
non-significant increases in reactive aldehyde levels in all treatment groups compared to the 
controls (Table 4.1).  The highest increase was seen in the four week treatment group (25 % 
increase), but levels were not significantly higher than controls.  
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Table 4.1. Bleomycin detectable iron and TBARS levels in piglet liver tissues (mean±SD). 
 
 
Group 
Bleomycin 
detectable iron 
 (µg Fe/mg)  
TBARS 
(nmol/mg)  
Controls (n=4) 0.047±0.019 0.71±0.04 
One week (n=4) 0.049±0.018 0.75±0.17 
Two week (n=4) 0.054±0.028 0.76±0.18 
Three week (n=4) 0.065±0.003 0.82±0.05 
Four week (n=4) 0.068±0.014 0.87±0.07 
Data are expressed as mean ±SD. One-way ANOVA and Post Hoc test (Student-Newman-Keuls) 
was used to compare means at significance level (α= 0.05). Bleomycin detectable iron and 
TBARS levels in the liver tissue were measured in all treatment groups (one week, two week, 
three week, and four week) after receiving daily intravenous injection of aluminum chloride 
hexahydrate, 1 mL/kg/day (each 1 mL contains 1500 μg of aluminum). Controls were given 
daily intravenous injections of 1 mL/kg/day sodium chloride (0.9%) for one week.   
 
4.5.2 Measurement of non-heme iron levels in liver tissues 
Non-heme iron levels, which consist of intracellular iron bound to ferritin, hemosiderin, 
and other proteins such as those containing iron-sulfur clusters in the mitochondrial electron 
transport chain, were measured in liver tissues.  The mean levels of non-heme iron in the liver 
were increased in the one, two, and three week groups (Table 4.2).  In the three week group, the 
level of non-heme iron peaked and was significantly (p<0.05) increased by 255% and 175%, 
respectively, when compared to controls and one week aluminum treatment group.  In the four 
week aluminum treatment group, the non-heme iron levels increased by 104% compared to 
controls (Table 4.2).  
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Table 4.2. Non-heme iron (µg Fe/mg) levels in piglets liver tissues. 
 
Group 
(Mean ± SD) 
Controls (n=4) 0.45±0.28
 a
 
One week (n=4) 0.58±0.04
 a
 
Two week (n=4) 1.5±0.90
 a,b
 
Three week (n=4) 1.6±1.20
 b
 
Four week (n=4) 1.0±0.60
 a,b
 
Data are expressed as mean ±SD. One-way ANOVA and Post Hoc test (Student-Newman-Keuls) 
was used to compare means at significance level (α= 0.05). Means with different superscripts (a, 
b) were significantly different (p<0.05) when compared to each other. Non-heme iron levels in 
the liver tissue were measured in all treatment groups (one week, two week, three week, and four 
week) after receiving daily intravenous injection of aluminum chloride hexahydrate, 1 
mL/kg/day (each 1 mL contains 1500 μg of aluminum). Controls were given daily intravenous 
injections of 1 mL/kg/day sodium chloride (0.9%) for one week.   
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4.6 Discussion  
In this study, we hypothesized that aluminum loading disrupts iron homeostasis in the 
piglet’s liver thus resulting in increased free iron and increased oxidative stress in the liver 
tissues.  The present study showed that Al loading caused significant increase in the hepatic non-
heme iron levels after three weeks of Al administration.  Unexpectedly, despite the increasing 
trend seen in levels of hepatic bleomycin detectable iron and TBARS in all the study groups, this 
increase was non-significant in all study groups compared to controls.   
The physiological effects of aluminum have been extensively investigated, but the exact 
mechanism by which aluminum causes damage in the biological system is still speculative.  
However, one of the proposed mechanisms for Al mediated damage is believed to be through 
increased oxidative stress (Flora et al., 2003; Mahieu et al., 2003).  Aluminum can exert its pro-
oxidant effect via either formation of Al superoxide or by its ability to facilitate iron-driven 
biological oxidative reactions (Exley et al., 2004; Bondy et al., 1996).  It has been demonstrated 
in experimental animals that Al exposure has a key impact on tissue iron (Fe) distribution (Ward 
et al., 2001).  The increase in tissue Al content is associated with an increase in tissue Fe in the 
kidney, liver, heart, and spleen, as well as in various brain regions (Ward et al., 2001).  
Aluminum has the potential to increase iron induced oxidative stress to the cell (Clauberg and 
Joshi, 1993; Van Rensberg et al., 1997).  One suggested mechanism is that Al could induce lipid 
peroxidation by increasing the cellular iron uptake paralleled with decreased iron entry into 
ferritin (Abero and Glass, 1993), thereby increasing the free iron level and facilitating iron-
induced oxidative stress.  In support of this mechanism, Xie et al. (1996) reported that increased 
intraneuronal Al potentiated iron-induced oxidative damage and reduced neuronal survival in 
bovine brain.   
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Much research has been done on the effect of aluminum loading on iron-induced 
oxidative damage in various biological tissues.  In mice, aluminum overload was found to be 
associated with lipid peroxidation (Pratico et al., 2002).  In vitro studies, using liposomal and 
brain microsomal systems, suggest the aluminum ion has a stimulating effect on iron-induced 
lipid peroxidation (Oteiza et al., 1993: Quinlan et al., 1988; Verstraeten and Oteiza, 1995; 
Verstraeten et al., 1997).  In hemodialysis patients using a phosphate binder such as aluminum 
hydroxide, higher lipid oxidation had been found in their plasma (Lin et al., 1996; Wratten et al., 
2000; Neiva et al., 2002).  Kapiotis et al. (2005) tested the influence of Al on low-density 
lipoprotein (LDL) oxidation by Fe ions and Cu ions.  The results showed that aluminum ions 
increased the metal ion-induced oxidation of LDL in the presence of Fe ions, but not Cu ions 
(Kapiotis et al., 2005).    
The effect of Al and its role in causing iron-induced oxidative stress is well-documented 
(Harley et al., 1993; Jang and Surth 2002; Walter et al., 2002; Pratico et al., 2002).  However, in 
our study, even though Al loading in serum and liver tissues was significant (section 3), the data 
did not statistically show a significant increase in the levels of free iron and lipid peroxidation in 
all the study groups compared to controls.  Nevertheless, the increasing trend seen in the hepatic 
levels of free iron and lipid peroxidation may reflect the potential of Al to play an important role 
in causing increased free iron and oxidative damage via its pro-oxidative effect.   
At this time, using our data with a low n of 4, we cannot confirm that Al alters cellular 
iron homeostasis in the liver tissue and plays a role in causing oxidative stress via its pro-oxidant 
effect on iron.  
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During the study, a number of important limitations need to be considered.  First, the total 
iron concentration was not analyzed in the serum and liver tissue of the piglets.  Knowing the 
total iron content of serum and liver tissues would help to understand the relationship between Al 
loading and iron content in the piglet’s serum and liver tissue.  The decision to study the effect of 
Al on iron homeostasis in the liver tissues was made after the serum and liver samples were 
already analyzed for Al at the Saskatchewan Research Council.  Further analyses of total iron 
were not done due to limited samples and the high cost of sample analysis using the inductively 
coupled plasma spectrometry (ICP-MS).   Second, the sample size used in the study is small.  We 
had only four animals in each of the five groups.  It is known that sample size is an important 
part of the study, and larger samples tend to minimize the probability of type II errors, maximize 
the accuracy of study estimates, and increase the generalizability of the results obtained in the 
study.  
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5.0 INVESTIGATING THE EFFECT OF LOW ALUMINUM CONTENT IN 
PARENTERAL NUTRITION ON THE DEVELOPMENT OF PARENTERAL 
NUTRITION ASSOCIATED CHOLESTASIS IN NEONATAL PIGLETS 
 
5.1 Introduction  
Aluminum is the third most abundant metal in our environment.  Aluminum is a known 
contaminant of parenteral nutrition solutions and is suspected in the pathogenesis of parenteral 
nutrition associated cholestasis (PNAC).  The PN components that have the highest amounts of 
Al include calcium gluconate, potassium phosphate, and sodium phosphate (Bohrer et al., 2002; 
Smith et al., 2007).  Calcium gluconate alone attributes > 81% of the total aluminum content in 
PN solutions (Mouser et al., 1998).  Aluminum is found not only in raw materials but also is 
incorporated into products during the manufacturing process and from the leaching of aluminum 
from glass containers during autoclaving for sterilization (Bohrer et al., 2002).   
Physiologically, the body has several mechanisms to help reduce the absorption of 
aluminum.  The gastrointestinal tract (GIT) barrier allows only < 1% of ingested aluminum into 
the blood circulation (Sedman et al., 1985).  The major route of aluminum elimination is via 
renal excretion with minor excretion in bile (Sutherland and Greger, 1998).  Consequently, when 
parenterally infused significant aluminum accumulation can occur in neonates, in particular 
premature neonates who have immature renal elimination mechanisms as well as the need for 
more calcium salts for bone mineralization.  The aluminum content in the PN solutions delivered 
to patients in the neonatal intensive care unit may range from 10 – 60 μg/kg/day (Klein et al., 
1991; Mouser et al., 1998; Popinska et al., 1999; Advenier et al., 2003).  This significantly 
exceeds the American Society of Clinical Nutrition/American Society of Enteral and Parenteral 
Nutrition Joint Commission (ASCN/ASPEN 1991) recommendation of 2.0 μg/kg/day, as a safe 
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level for aluminum intake in adults.  Also, it exceeds the safe limit of 5 μg/kg/day Al 
recommended by the Food and Drug Administration and Health Canada (FDA, 2000; Health 
Canada, 2011).  However, for premature neonates with very immature renal elimination 
mechanisms, levels of 2 μg/kg/day may still pose a significant health risk. 
Although research has suggested a correlation between aluminum loading and PNAC in 
neonates, the exact role of aluminum in the development of PNAC is unknown.  A previous 
graduate student in our lab found that 31% of infants with gastrointestinal failure who received 
parenteral nutrition (PN) for 21 days developed cholestasis (Arnold et al., 2002).  Although these 
PN solutions were contaminated with 20 μg/kg/d aluminum (compared to the recommended 
‘safe’ level of 2 μg/kg/d for adults), its causal relationship to PNAC remains speculative.  In a 
neonatal piglet model, infusion of PN solutions with 38 μg/kg/d aluminum for 3 weeks led to 
early cholestasis; but a low aluminum PN was not tested.  Also, infusion of a daily bolus of 1500 
μg/d aluminum in orally fed neonatal piglets has led to cholestasis, but not 20 μg/d, for 3 weeks.  
Although this bolus regimen is less relevant to the PN-fed neonate, it is being used to explore 
more sophisticated imaging techniques in an attempt to identify more subtle histological changes 
in early stages of cholestasis.  In this study, we have used the more clinically relevant TPN-fed 
piglet model and evaluated cholestasis markers after infusing high or low aluminum PN.  This 
study was conducted in Dr Bertolo’s lab, Memorial University of Newfoundland.  The 
collaboration with Dr. Bertolo leverages his extensive experience in studying PN therapy and 
expands his field of research.  The Yucatan miniature pig is smaller and slow growing than 
domestic pigs; the slower growth is more appropriate as a model for infants and allows for 
prolonged PN studies, as well as being easy to care for.  Dr. Bertolo’s laboratory has extensive 
experience administering PN using this model and he is able to handle a large number of subjects 
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at one time providing the opportunity to complete the proposed study in an efficient manner.  
Considering the substantial vulnerability of neonates to Al toxicity, both because of high Al 
exposure from PN and potentially impaired Al elimination, more research needs to be done to 
investigate the exact role of Al in causing parenteral nutrition associated liver injury.  
5.2 Hypothesis and Objective 
 The hypothesis for this study is that reduction in the aluminum content of PN solutions  
causes significant reductions in the incidence and severity of liver injury in neonatal piglets.  The 
main objective for this study was to investigate the role of aluminum as a toxic component of 
parenteral nutrition and as a risk factor in causing liver injury.  The present study utilizes a 
combination of biochemical and morphological methods in order to test our hypothesis.  
 We have evaluated the effects of high and low aluminum levels in PN by measuring 
several biochemical and histologic parameters of liver injury including serum direct bilirubin 
levels, serum total bile acid levels, and morphological changes in the liver tissues.  Also, for 
aluminum loading, we measured the aluminum content in the liver, serum, and bile.  
5.3 Material and Methods 
The Institutional Animal Care Committee at Memorial University of Newfoundland 
approved all animal procedures and protocols used in this study, and all animals were treated in 
accordance with guidelines set by the Canadian Council on Animal Care.   
Sixteen Yucatan miniature pigs were obtained from a breeding herd at Memorial University of 
Newfoundland, St John’s, NL.  Piglets were taken from sows at 2 – 4 days of age and randomly 
assigned into two equal groups:  
 (1) Regular PN group, which consisted of 8 animals.  In this group, piglets received continuous 
PN infusion with a standard PN formulation to meet all nutritional requirements (NRC, 1998) 
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with aluminum contamination at 38 g/kg/ day. 
(2) Low aluminum PN group, which consisted of 8 animals.  The piglets in this group were 
treated identically to regular PN group but with the PN solution modified by substituting the 
standard calcium gluconate additive for an ultrapure form (Sigma Aldrich, Oakville, Canada) 
that reduced the aluminum contamination to 6 g/kg/day. 
 
5.3.1 Surgery 
Piglets at the age of 2-4 days were removed from the sow and transported to the animal 
housing facility in the Biotechnology Center, Memorial University of Newfoundland.  Upon 
arrival, the piglets of both low aluminum PN (n=8) and regular PN (n=8) groups immediately 
underwent surgical implantation of two central venous catheters.  All the procedures were carried 
out under general anesthesia in a certified operative facility at the Biotechnology Center, 
Memorial University of Newfoundland.   Prior to the induction of anesthesia, piglets were pre-
anesthetised with an intramuscular injection of ketamine hydrochloride (0.22 mg/kg, Bimeda 
Canada, Cambridge, Ontario) and acepromizine (0.5 mg/kg, Vetoquinol, Canada, Inc, Quebec, 
Canada).  Anaesthesia was maintained with 1.5 – 2 % isoflurane delivered with oxygen at 1.5 
L/min via an endotracheal tube.  Under general anaesthesia, an incision of approximately 2 
centimeters long was made on the right side of the neck.  An autoclaved silastic catheter (Dow 
Corning Co, Midland, USA; 0.27 inch ID, 0.63 inch OD) was introduced into the external 
jugular vein and advanced to the superior vena cava, just cranial to the heart, to be used for diet 
infusion.  A second catheter (Dow Corning Co, Midland, USA; 0.04 inch ID, 0.08 inch OD), 
used for blood sampling, was introduced into the left femoral vein and advanced to the inferior 
vena cava just caudal to the heart.  Both catheters were tunneled under the skin and exited at the 
back, dorsally between the piglet’s shoulder blades.  Both ends of the catheters were fitted under 
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the bandage on the back of the piglet. Immediately following surgery, all animals were given 
intravenous doses of antibiotic 0.5 mL of Borgal (40 mg trimethorprim & 200 mg 
sulfadoxine/mL) (Intervet Canada Ltd.,) and analgesic (0.03 mg/kg buprenorphine 
hydrochloride) (Temgesic, Reckitt Benckiser Healthcare (UK) Ltd.,).  The neck incisions were 
closed with 3-0 Novafil suture and the incisions sites were treated with a topical antibiotic until 
healed. The piglets were fitted with elastic bandages to protect the catheter.  The catheter was 
flushed with one mL of 0.9% sodium chloride solution and then one mL of heparinised 50% 
dextrose to maintain the patency of the catheter after drawing blood.  
5.3.2 Care of animals 
Piglets were housed in a Canadian Council on Animal Care certified animal care facility 
at Memorial University of Newfoundland in individual circular cages that allow visual and aural 
contact with one another and they had a toy for environmental enrichment.  The cages were 
controlled with a 12 hr light/dark cycle, and ambient temperature was kept at 27
o
C, with 
supplemental heat provided by heat lamps.  Piglets were fitted with cotton jackets that secured 
the catheters to a swivel and tether system.  This system allows for the continuous infusion of 
parenteral fluids while allowing the piglet to move freely about the cage without twisting or 
tangling the tubing.  Hospital-grade, pressure sensitive PN infusion pumps were used to provide 
a continuous, PN infusion.  On the day of surgery (day 0), piglets were adapted to a parenteral 
diet infusion that was initiated immediately after surgery at 50% and slowly advanced over 24 
hours to the goal infusion rate.  Piglets received nothing by mouth and were monitored daily for 
PN intake, weight gain, body temperature, feces and urine production.  Cages were cleaned 
daily.  The piglets were having access to a toy for entertainment, and a blanket for resting.  
114 
 
5.3.3 Parenteral nutrition administration 
 The PN formulation was designed to provide all nutrients required by the neonatal 
piglets.  The intravenous nutrient requirement for piglets has been estimated from orally fed 
piglets (NRC, 1998).  In total, piglets received 1.1 MJ/kg/d, approximately 260 kcal/kg/d and 
200 kcal/kg/d were from non-protein sources.  PN solutions were prepared daily using aseptic 
technique.  Lipid emulsion (Intralipid 20%; Fresenius-Kabi, Germany) and PN solutions were 
mixed and delivered at a rate of 320 mL/kg/d by infusion pumps for 14 days.  All of the PN 
component solutions used in the PN regimen were the same as commercial products used in 
hospitals for infants.  The amount of aluminum content in these PN solutions was measured by 
inductively coupled plasma-mass spectroscopy (ICP-MS) at SRC, Saskatoon, Saskatchewan, 
Canada. 
5.3.4 Sample collection and analysis 
Daily weight was recorded.  Blood samples (5 mL) were drawn by syringe from the 
femoral access catheter into metal-free vacutainer tubes from piglets at baseline (prior to PN 
administration) and at day 7, and 14.  The blood was centrifuged (Clinical 200, VWR, Canada) at 
5000 rpm for 5 minutes, and serum was aliquoted into three parts. The aliquots were each used to 
measure the following: 1) direct bilirubin using a bilirubin assay kit (Bioassay Systems, 
Hayward, CA, USA) and spectrophotometric analysis according to manufacturer instructions, 2) 
total bile acids using a bile acid assay kit (BioQuant, San Diego, CA, USA) and 
spectrophotometric analysis according to manufacturer instructions, and 3) aluminum 
concentration using inductively coupled plasma mass spectrometry (ICP-MS) at the 
Saskatchewan Research Council (SRC), Saskatoon, SK.  Piglets were killed humanely on day 14 
of the study.  Bile from gallbladder was collected using syringe needles and liver samples were 
quickly collected in metal free plastic containers and sent to SRC for aluminum determinations 
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by inductively coupled plasma mass spectrometry (ICP-MS).  For histopathological observation, 
liver sections were cut and processed for light microscopy, transmission electron microscopy 
(TEM), and scanning transmission x- ray microscopy (STXM) as indicated previously in section 
2.  The remaining liver tissues were snap frozen and stored at -80°C for further studies.  
5.3.5 Microscopic and imaging techniques sample preparation 
5.3.5.1 Light microscopy  
Liver tissues were processed and prepared (as mentioned previously) in the Department 
of Anatomy and Cell Biology, University of Saskatchewan.  Sections were stained for routine 
light microscopy with hematoxylin and eosin (H&E) staining, cover slipped and sent to the 
Western College of Veterinary Medicine, University of Saskatchewan, SK, to be evaluated 
blindly by a veterinary pathologist for histological changes.  Samples were evaluated using a 
scoring system as follow (see Table 5.1) (Loff et al., 1998; Cai et al., 2006). 
 
 
            Table ‎0.1. Histologic scoring system for histologic changes in the piglet liver. 
Score Histologic changes  
0  Normal modality without degeneration 
1 Mild to moderate inflammation 
2 Moderate degenerative changes  
3 Cholestasis or mild fibrosis 
 
 
 
 
5.3.5.2 Transmission electron microscopy (TEM) 
The fixation and embedding of liver samples was done in the Faculty of Science, 
Memorial University of Newfoundland.  The liver samples were processed as follows:  liver 
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sections were cut into no larger than 1mm
3
 pieces with a sharp razor blade.  The sections were 
fixed primarily with 2.5 % glutaraldehyde in 0.1 M sodium phosphate buffer (pH 7.4) by 
immersing the liver pieces in the glutaraldehyde fixative and kept in the refrigerator for 4 hours.  
The liver sections were washed with the sodium phosphate buffer three times for 30 minutes 
each.  Then, the samples were fixed (secondary fixation) with 4 % osmium tetroxide in 0.1 M 
sodium phosphate buffer by immersing the liver pieces in the osmium tetroxide fixative and kept 
in the refrigerator for 4 hours. The samples were washed again with cold sodium phosphate 
buffer for 15 minutes and were dehydrated in a graded series of ethanol (25%, 50% 70-75%, 90-
95%, 100%) for 10 minutes each.  Then, the samples were washed in distilled water on ice for 30 
minutes.  The samples were infiltrated with the following ratios of epoxy resin: propylene oxide 
(1:2, 1:1, 2:1, 1:0) simultaneously for one hour each.  The samples were embedded in 100% 
epoxy resin in small plastic capped vials.  The plastic vials were placed in oven at 70°C for more 
than 8 hours until the resin was completely polymerized.  Samples were sent to the Pathology 
Department, College of Veterinary Medicine, University of Saskatchewan to be cut and mounted 
on copper grids.  For histopathological observation, the liver samples were observed using a 
transmission electron microscope at the Department of Biology, University of Saskatchewan.  
Electron micrograph images for the liver cellular ultrastructure were taken.  Films were 
developed and scanned in the Department of Biology, University of Saskatchewan.  However, 
for canalicular microvilli morphology, a grading system for the changes in the bile duct 
microvilli was created to compare the morphological changes in the bile canalicular microvilli 
(Table 5.2) and the liver samples were evaluated blindly by an expert (PhD Anatomy & Cell 
Biology) in liver pathology.  
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          Table ‎0.2. Morphology scoring of bile canalicular microvilli. 
Score  Microvilli morphology  
0 Normal  
1 Short microvilli 
2 Total loss of microvilli 
 
 
5.4 Statistical analyses 
Descriptive statistics were performed for the variables.  Results were expressed as mean ± 
standard deviation (SD), and analyzed using one-way ANOVA and Post Hoc (Student-Newman-
Keuls test).  For non-parametric data, Mann-Whitney U test was used for the analysis.  A p value 
< 0.05 was considered significant.    
5.5 Results  
5.5.1 Body weight  
Mean body weight gain data is summarized in Table 5.3.  At the end of the study, the 
mean body weight in the low aluminum group was higher than the regular PN group, but this 
difference was not statistically different.  
 
Table ‎0.3. Body weight gain (Mean±SD) and growth rate of piglets during the experimental 
period. 
Group  Initial body  
weight 
Final body 
weight 
% Growth rate 
Low Aluminum PN (n=8)  1832±338 3461±468 4.6 
Regular PN (n=8) 1728±282 3312±530 4.7 
Data were expressed as mean ±SD  
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5.5.2 Biochemical assays  
5.5.2.1 Serum direct bilirubin and total bile acid 
The mean serum direct bilirubin level was more elevated in the regular PN group in day 0 
and day 14 compared to the low aluminum PN group (Table 5.4).  However, the difference in 
serum direct bilirubin levels between regular and low aluminum PN groups was not significant.  
The mean total bile acids in the regular PN group were higher at day 7 and 14 compared 
to the low aluminum PN group (Table 5.5).  Despite the marked elevation in the level of serum 
total bile acids in the regular PN group compared to low aluminum PN group, the difference was 
not statistically significant.  
 
 
 
Table ‎0.4. The mean concentration of serum direct bilirubin in piglets during the study. 
  Direct bilirubin (µmol/L) 
 
Group 
  
Day 0 
 
Day 7 
 
Day 14 
     
Low Aluminum PN   8.8±4.9
 
 17.3±6.4 25.9±10.0 
 n 7
1
 8 8 
 
Regular PN  
  
9.7±3.6 
 
17.0±9.6 
 
29.0±9.3 
  
n 
 
8 
 
8 
 
8 
Data were expressed as mean ±SD. One-way ANOVA and Post Hoc test (Student-Newman-
Keuls) was used to compare means at significance level (α= 0.05).  
1. Low aluminum group had one sample with insufficient serum at day 0 (piglet # 25). 
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Table 5.5. The mean concentration of serum total bile acids in piglets during the study. 
  Total Bile acids (µmol/L) 
Group  Day 0 Day 7 Day 14 
     
Low Aluminum PN  45±62 56±58 148±71 
 n 8 6
1
 8 
Regular PN  29±20 61±40 198±75 
 n 7
2
 8 8 
Data were expressed as mean ±SD. One-way ANOVA and Post Hoc test (Student-Newman-
Keuls) was used to compare means at significance level (α= 0.05).    
1. Low aluminum group had two insufficient samples for analysis on day 7 (piglet # 2 & 22). 
2. Regular PN group had one insufficient sample for analysis on day 0 (piglet # 24) 
 
 
 
 
5.5.2.2 Aluminum concentration in serum, liver, and bile 
There was no difference in the mean serum aluminum concentrations between the regular 
PN and low aluminum group on day 0 and 7 (Table 5.6).  On day 14, the mean serum aluminum 
level was significantly (p<0.05) higher in the regular PN group than the low aluminum group 
(Table 5.6).  The mean hepatic aluminum content in the low aluminum PN group was 
significantly (p<0.05) lower compared to the regular PN group (Table 5.7).  The mean bile 
aluminum concentration was lower in the low aluminum PN group compared to the regular PN 
group (Table 5.7), but this was not statistically significant.   
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Table ‎0.6. The concentration of serum aluminum in piglets during the study. 
  Aluminum (µg/L) 
Group  Day 0 Day 7 Day 14 
     
Low Aluminum PN mean±SD 320±261 504±484 218±185
 a
 
 n 6
1
 7
2
 7
2
 
Regular PN  mean±SD 181±119 925±1631 884±630
 b
 
 n 7
3
 7
3
 7
3
 
    Data were expressed as mean ±SD. One-way ANOVA and Post Hoc test (Student-Newman-  
  Keuls) was used to compare means at significance level (p<0.05). Means with different   
  Superscripts (a, b) were significantly different (p<0.05) when compared to each. 
  1. Low aluminum PN group had two samples lost (piglet # 10, 28) for day 0. 
  2. Sample with insufficient serum (piglet # 28, day 7 and piglet # 25, day 14) 
  3. Regular PN group had three samples lost during lab relocation (piglet # 15) for day    
      0,7,14. 
 
 
Table ‎0.7. Liver and bile content of aluminum in the piglets. 
          Group    Liver (µg/g) Bile (µg/L) 
 
Low Aluminum PN 
 
 
 
0.30±0.20
 a
 
 
218±86 
  
n 
 
6
1
 
 
6
2
 
 
Regular PN                
 
 
 
0.77±0.18
 b
 
 
250±131 
  
n 
 
8 
 
7
3
 
Data were expressed as mean ±SD. One-way ANOVA and Post Hoc test (Student-Newman-
Keuls) was used to compare means at significance level (α= 0.05). Means with different 
superscripts (a, b) were significantly different (p<0.05) when compared to each.  
1. Low aluminum PN group had one sample missed (piglet # 6) and one sample insufficient 
for analysis (piglets # 22). 
    2. One bile sample was insufficient for analysis (piglet # 25), and one sample (piglet # 2; 7200 
         µg/L) was considered as outlier. 
    3. One bile sample was considered as outlier (piglet # 8; 3600 µg/L). 
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5.5.3 Histopathological observations 
5.5.3.1 Light microscopy  
Liver tissues of low aluminum PN and regular PN groups were examined for histological 
changes and the morphological changes seen were given scores (see Table 5.1).  Morphological 
evidence of mild to moderate degrees of inflammation was seen in all groups.  Mild to moderate 
inflammation were seen in only one subject in the low aluminum PN, and in 3 subjects in the 
regular PN group (Table 5.8).  More significant (p<0.012) histologic changes were seen in the 
regular PN group compared to low aluminum PN group (Table 5.8).  
 
 
 
         Table ‎0.8. Comparison of histologic scoring for morphological changes in piglet liver. 
 
Group 
Score 
0 1 2 3 
 
Low Aluminum PN (n=7)
1 
 
 
6 
 
1 
 
0 
 
0 
Regular PN  (n=8) 2 3 1 2 
                The differences is significant between the two groups, p < 0.05 (P = 0.012) by  
            Mann-Whitney U test. 
          1. Low aluminum PN group had one missing sample (piglet # 10)  
 
 
 
 
5.5.3.2 Transmission electron microscopy (TEM) 
Transmission electron microscopy was used to examine the morphological changes in the 
liver samples.  Evidence of loss of bile canalicular microvilli and mitochondria condensation 
were observed in most subjects in the regular PN group.  There is a marked loss of canalicular 
microvilli seen in the regular PN group compared to low aluminum PN group (Figure 5.1).  The 
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loss of bile canalicular microvilli was significantly different in the regular PN group from the 
low aluminum PN (Table 5.9). 
a b
c
d
 
Figure 5.1. Electron micrographs showing the bile microvilli on piglet liver. 
a) Microvilli in controls, x 15000 (b) normal microvilli from low aluminum PN group, x 6600 (c) 
short bile microvilli from regular PN group, x 6600 (d) total loss of bile microvilli from regular 
PN group, x 6600.  
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     Table 5.9. Comparison of bile canalicular microvilli changes scoring. 
 
Group 
 
Scorea 
0 1 2  
Low aluminum PN (n=6)
1
 4 2 0  
Regular PN (n=7)
2
 0 3 4  
The difference between the two groups was analyzed using Mann-Whitney U-test.  
The test was significant (p = 0.006). 
1. Low aluminum PN had two samples (sample # 10 and 28) were not included in analysis; 
sample # 10 was lost and # 28 was poorly prepared.   
2. Regular PN group had one sample excluded (sample # 24). The tissue was damaged and    
   morphological structure of the liver was not clear.  
a. Microvilli morphology score: 0, normal microvilli; 1, short microvilli; and 2, total loss of             
    microvilli. 
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5.6 Discussion 
This study demonstrates that reducing the aluminum content of PN decreases the degree 
of PN-associated liver injury.  The severity of canalicular microvilli damage is related to the 
aluminum content of PN infused.  A decrease in size and number of canalicular microvilli is a 
common component of the ultrastructural pathology observed in cholestasis (Phillips et al., 1987; 
Dancygier and Schirmacher, 2010).  These microvilli are the location of bile acid transporter 
proteins, such as bile salt exporter pump (Bsep) and multidrug resistance-associated protein 2 
(Mrp2), which play important roles in bile secretion.  We suspect that the microvilli damage 
causes a loss of bile acid transporter proteins and a reduction in bile flow.  In a study of rats 
administered intraperitoneal aluminum for 3 months, investigators found a loss of structural 
integrity of the canalicular microvilli, decreased Mrp2 content, and decreased bile flow 
(Gonzalez et al., 2007; Klassen, 2002). 
These transporters are important in bile acid metabolism under normal circumstances.  
Premature infants though, may have abnormalities in any or all of the various components of bile 
acid metabolism, including conjugation, uptake, secretion, and recirculation (Carter and 
Shulman, 2007).  The challenges of bile acid metabolism for premature infants may be made 
even more difficult with the loss of bile acid transporters secondary to the microvilli damage.  
Furthermore, they may not be able to up-regulate gene expression to meet the increased demand 
for these proteins.  Variations in the developmental profiles of bile acid transporters among 
infants of varying developments might explain why one infant develops severe PNAC, whereas 
another infant with similar gestational age and feeding history has much less severe PNAC. 
Serum direct bilirubin and total bile acids are early biochemical markers for PN-
associated liver injury. They rise steadily over the course of therapy.  However, we did not find a 
correlation between the levels of these biochemical markers and the amount of aluminum 
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loading.  This is in contrast to studies of intraperitoneal aluminum injection in rats where a 
significant increase in plasma bile salts has been shown (Gonzalez et al., 2007; Klein et al., 
1988).  These subjects, however, were exposed to a much longer duration of aluminum loading.  
In a newborn piglet model administered parenteral aluminum for 4 weeks, we have demonstrated 
a correlation between aluminum loading and rising total bile acid levels (Alemmari et al., 2011).  
The duration of PN therapy is a risk factor for PNAC.  After 6 weeks of PN therapy, 30% of 
children will have signs of liver dysfunction, and this increases to 67% at 16 weeks (Suita et al., 
1982).  It may be that the difference in biochemical markers between our study groups may have 
reached statistical significance with a longer duration of PN therapy. 
The significant difference in the severity of microvilli damage between groups may 
indicate that the loss of structural integrity is an early sign of PNAC and precedes the 
biochemical changes.  It is noteworthy that the onset of neonatal PNAC after starting PN varies 
with the presence or absence of risk factors.  The commonly recognized risk factors for PN-
associated liver injury are as follows: prematurity, duration of PN therapy, lack of enteral 
feeding, repeated bouts of infection or sepsis, and various toxicities or deficiencies in the PN 
solution.  In our model, the piglets did not have the risk factors of prematurity and sepsis.  The 
absence of prematurity and sepsis and a longer duration of therapy may have affected the 
differences in biochemical markers between study groups that could have reached statistical 
significance.  Also, the small number of subjects may have limited the power of the study.  
Similar to our previous study of aluminum loading, we found that the serum aluminum levels 
ranged widely throughout the study in all piglets (Alemmari et al., 2011).  Unbound aluminum in 
the blood is dependent on the renal glomerular filtration rate for excretion.  Aluminum bound to 
proteins such as transferrin is nonfilterable.  Variability in the functional maturity of the renal 
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system in newborn pigs may be a confounding variable.  Other sources of parenteral aluminum, 
such as other pharmaceutical products, cannot be excluded.  In addition, aluminum is ubiquitous 
in nature, and blood specimens are prone to contamination in collection, storage, pre-treatment, 
and analysis (Valkonen et al., 1997).  
For the analysis of the microvilli damage, we used a blinded observer and a 
semiqualitative technique.  To further quantify the degree of microvilli damage, future studies 
will measure the content of cytoskeletal proteins such as radixin and villin.  These proteins are 
important in linking actin to the plasma membrane.  Using proven immunohistochemistry 
techniques (Kojima et al., 2003; Phillips et al., 2003), we may be able to measure differences in 
radixin and villin activity and, in this way, provide more objective evidence to support our 
finding that reducing aluminum contamination of PN reduces the damage to canalicular 
microvilli.   
The problem of aluminum contamination in PN therapy is well known (Poole et al., 2008; 
Klein et al., 1982; Sedman et al., 1985; deVernejoul et al., 1985).  The American Society for 
Clinical Nutrition has recommended that the degree of aluminum contaminating adult PN 
therapy should not exceed 2 μg/kg/day (ASCN/ASPEN).  The US Food and Drug Administration 
warn that levels in excess of 5 μg/ kg/day are potentially toxic (FDA).  Since 2004, they have 
required large-volume parenterals to limit aluminum contamination to no more than 25 μg/L.   
However, there are no such limits for small-volume parenterals, and these are the main 
source of aluminum in PN.  As a result, a typical infant PN therapy results in aluminum 
contamination levels of 10 to 60 μg/ kg/day (Arnold et al., 2004; Poole et al., 2008; Moreno et 
al., 1994; Demircan et al., 1998).  This is well in excess of the toxicity warnings of the Food and 
Drug Administration.  This may be caused by the relatively larger amounts of calcium gluconate 
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that are required for growing infants compared with adults.  In excess of 80% of the aluminum in 
infant PN therapy comes from the calcium gluconate component of the solution (Mouser et al., 
1998).  Infants weighing less than 3 kg on PN therapy receive the largest daily doses of 
aluminum (Poole et al., 2008).  Also, infants may have a decreased capacity to eliminate 
aluminum.  The elimination of aluminum is primarily dependent on urine excretion.  Many 
premature infants have immature renal systems and may not have sufficient glomerular filtration 
to eliminate aluminum loads.  Parenteral nutrition–associated cholestasis is a multifactorial 
problem.  For this reason, it will require multiple strategies to both prevent and treat this 
problem.  We propose that this study provides further evidence of the hepatotoxic effect of 
parenteral aluminum and that reducing the aluminum contamination of PN therapy is one 
important strategy in preventing or reducing the severity of PNAC. 
 
Finally, two important limitations need to be considered in this study.  The small number 
of piglets used in this study.  A larger sample would provide a better statistical power and 
produce estimates that are more precise.  Also, because of the lack of instruments needed 
(inductively coupled plasma-mass spectrometry) to analyze Al content in serum and liver tissues 
in St John’s, NL, samples had to be shipped from there to our lab in Saskatoon.  A better setup of 
lab equipped with the necessary instruments and equipments to conduct research would save 
time, money, and more importantly minimize any problems may emerge because of handling and 
storage during the shipping of the frozen samples.  
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6.0 DISPLACEMENT OF IRON AND ASSOCIATED OXIDATIVE STRESS IN THE       
HEPATOTOXICITY OF ALUMINUM-CONTAINING PARENTERAL SOLUTIONS 
DELIVERED TO PIGLETS 
 
 
6.1 Introduction  
 Parenteral nutrition associated cholestasis (PNAC) is primarily a pediatric disease with 
the smallest and most premature infants being particularly vulnerable.  It is estimated that 40-
60% of infants on long-term parenteral nutrition (PN) for intestinal failure develop PNAC 
(Kelly, 2006).  Of those infants born at < 1 kg, overall 23% developed PNAC, and with 
prolonged therapy, 80% and 90% developed PNAC after 60 and 90 days, respectively.   
Over the past 30 years, there has been very little progress in the development of preventative 
or therapeutic strategies for treating PNAC.  The complexities of PNAC is impacted by 
numerous factors such as prematurity, sepsis, lack of enteral feeding, and toxic or deficient 
components of the infused solutions.  As a result, there has been a great deal of research to 
understand how PN therapy can cause PNAC.   
One area of investigation has been an evaluation of the components of the PN solution that 
may be toxic to the liver (hepatotoxic).  Aluminum is a non-essential element that contaminates 
PN solutions, and is suspected in the pathogenesis of PNAC.  Most of the components of PN 
currently used are contaminated with aluminum with the greatest contamination occurring in 
calcium and phosphate solutions, as well as dextrose and trace element preparations (Greger and 
Sutherland, 1997; Davis et al., 1999; Li et al., 2004).  Once aluminum (Al) is absorbed, it can 
either remain free (aluminum ions), form complex with organic acids or bound to the plasma 
protein transferrin, which is thought to be the mechanism by which Al is delivered to the liver 
(Klein et al., 1993, DeVoto and Yokel, 1994).  Thus, Al could interfere with uptake, 
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homeostasis, and transport of iron.  In cultured glial cells Al has been shown to increase the 
uptake of non-transferrin-bound and transferrin bound iron (Fe), likely by an effect on cellular 
transporters (Kim et al., 2007).   
Ferritin is a ubiquitous intracellular protein that stores iron and releases it in a controlled 
fashion.  In cultured erythroleukemia cells, Al has been shown to increase the uptake and cellular 
iron content while decreasing ferritin (Abreo et al., 1994).  In experimental animals, Al exposure 
has an impact on tissue iron distribution; the increase in tissue Al content was paralleled by 
elevations of tissue iron in the liver, kidney, heart, and spleen, brain tissues (Ward et al., 2001, 
Turgut et al., 2004).  Another study in chicks however, found that dietary Al decreased liver total 
iron but also decreased ferritin, resulting in increased non-heme iron to ferritin ratios (Han and 
Dunn, 2000).   Interactions between Al and iron can theoretically also occur in cells and tissues 
due to an interaction of Al with ferritin (Fleming and Joshi 1991, Sakamoto et al., 2004; Kim et 
al., 2007).   As a result, free iron may accumulate in body tissues.  Free Fe is harmful because of 
its high redox activity and its potential to generate free radicals, thereby inducing cellular 
toxicity (Halliwell and Gutteridge, 1990; Andersson et al., 1999) and tissue damage (Crichton et 
al., 2002).   
6.2 Hypothesis and objectives 
 We hypothesize that contamination of parenteral solutions with aluminum disrupts iron 
homeostasis in the liver resulting in an increased free iron pool, thus increasing oxidative stress 
and liver injury in neonatal piglets.  The main objectives of this study were to evaluate the effect 
of reducing the aluminum contamination of parenteral nutrition on liver iron homeostasis and to 
determine if reducing the aluminum content of PN would reduce the free iron pool in the liver 
and reduce the signs of liver injury in newborn piglets.   
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6.3 Materials and methods  
Frozen liver tissues from piglets of both low aluminum PN and regular PN groups were 
used in this study.  The piglets (n=8) from the regular PN group received PN solutions with 
aluminum contamination at 38 g/kg/ day for 14 days, and piglets (n=8) from the low Al PN 
groups received PN with reduced aluminum contamination to 6 g/kg/day for 14 days.   The 
liver tissues were used for TBARS, non-heme iron, and bleomycin detectable iron assays.  
Aluminum content in liver, serum, and bile and iron content in liver and serum was assayed 
using (ICP-MS).  
6.3.1 Thiobarbituric acid reactive substances (TBARS) assay 
The measurement was done in duplicate for all liver tissue samples, using a method 
adapted from Ohkawa et al. (1979).  In microcentrifuge tubes (1.5 ml), 50 mg of liver tissue was 
homogenized using a tissue grinder (Pellet Pestles® cordless motor, Kimble-Knotes # 749521-
1590) with 200 µL of radioimmunoprecipitation assay (RIPA) buffer.  The tissue grinder grinds 
soft tissues into a homogenous solution.  The homogenate was stood for 30 minutes at room 
temperature, and centrifuged at 15,000 × g for 10 minutes at 4ºC.  100 µL of the supernatant was 
added to 350 µL of thiobarbituric acid solution containing 12% acetic acid, pH 3.5, 0.6% SDS, 
0.45% thiobarbituric acid, and 0.0002% BHT.  The mixture was heated for 1 hour at 95ºC.  
Then, the heated sample was cooled and centrifuged at 4,000 × g for 10 minutes.  The 
absorbance of the supernatant was measured at 532 nm using a Beckman DU40 
spectrophotometer (Beckman Coulter, Mississauga, ON, Canada).  The malondialdehyde (MDA) 
was calculated using a standard curve of malondialdehyde prepared from tetraethoxypropane by 
acid hydrolysis. The amount of MDA in samples was expressed as nmol/mg of protein.   
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6.3.2 Biuret protein assay  
Biuret protein assay was used to measure the protein concentration in tissue homogenates 
in order to make other measurements comparable.  In the biuret assay, protein samples were 
combined with biuret reagent (32 mM sodium potassium tartrate, 12 mM copper sulphate, 30 
mM potassium iodide, 0.2 M NaOH).  The copper ions form a complex with the amide groups in 
the proteins and create a blue color that was measured at 550 nm using a Beckman Coulter DU® 
640B spectrophotometer.  Protein concentrations of tissue homogenates were measured in 
duplicate by the biuret method (Layne, 1957) using bovine serum albumin as a calibration 
standard.   
6.3.3 Determination of free iron in liver tissues by bleomycin detectable iron  
About 50 mg of liver tissue was homogenized with 500 µL 20 mM Tris-HCl buffer, pH 
7.4 using small Dounce homogenizer for one minute.  The reaction mixture was prepared by the 
sequential addition of the following reagents: 250 µL DNA (1 mg/mL), 25 µL bleomycin 
(Sigma, USA) (1.5 units/mL), 50 µL 50 mM MgCl2, 50 µL 1 M Tris-HCl, pH 7.4, 25 µL l 
homogenate/standard, and  50 µL l 7.5 mM ascorbic acid.  The homogenate was incubated at 
37°C for 1 hour (to allow the iron bleomycin complexes to bind to DNA, causing reactive 
aldehyde formation).  Then, 50 µL of 0.1 mol/L EDTA was added to stop the reaction and 250 
µL of 10 g/L thiobarbituric acid and 250 µL of 3 N HCl were added.  The mixture was heated at 
85°C for 20 minutes (to allow chromogen formation by the reaction of malondialdehyde with 
thiobarbituric acid).  The mixture was cooled at room temperature, and centrifuged at 10,000 × g 
for 10 minutes.  The absorbance of the supernatant was measured at 532 nm using Beckman 
DU40 spectrophotometer (Beckman Coulter, Mississauga, ON, Canada).   
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6.3.4 Non-heme iron assay 
Fifty mg of liver tissue was homogenized with 500 µL high-purity 18 MΩ water using a 
Dounce homogenizer.  In 1.5 mL plastic microcentrifuge tubes, 100 µL of tissue homogenate 
was added to an equal amount of 1.5 N HCl.  The homogenate was heated at 85°C in heating 
blocks for 30 minutes, cooled in water at room temperature for 2 minutes, and centrifuged for 5 
minutes at 10,000 × g.  One hundred µL of the supernatant aliquot was transferred into another 
plastic centrifuge tube, and 20 µL of 40 % trichloroacetic acid was added. The mixture was 
heated at 85°C in heating blocks for 15 minutes, centrifuged for 5 minutes at 10,000 × g at room 
temperature.  200 µL of 1 mM ferrozine solution (1 mM ferrozine in 1.05 M sodium acetate, pH 
4.8) was added to 20 µL of the supernatant aliquot.  The absorbance was measured at 562 nm 
using spectrophotometer (Beckman DU40 spectrophotometer (Beckman Coulter, ON, Canada).   
6.4 Statistical analyses 
Descriptive statistics were performed for the variables.  Results were expressed as mean ± 
standard deviation (SD), and analyzed using parametric test (one-way ANOVA and post hoc test 
Student-Newman-Keuls).  A p < 0.05 was considered statistically significant.  The correlation 
between the variables was evaluated using Pearson’s correlation coefficient. 
6.5 Results   
6.5.1 Aluminum and iron concentration in serum  
After two weeks of PN administration, the elevation in serum Al in the regular PN group 
was statistically significant (p<0.05) on day 14 compared to the low aluminum PN group (Table 
6.1).  For serum iron concentration, the mean iron content in the regular PN group was higher 
than in the low aluminum PN group on days 7 and 14, but only on day 14 was it significant 
(p<0.05) (Table 6.2).  In the regular PN group, the increase in serum Al was significantly 
correlated (r=0.731, p=<0.001) with serum iron (Figure 6.1).   
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  Table 6.1. The concentration of serum aluminum in piglets during the study. 
                         Aluminum (µg/L) 
Group  Day 0 Day 7 Day 14 
     
Low Aluminum PN mean±SD 320±261 504±484 218±185
 a
 
 n 6
1
 7
2
 7
2
 
Regular PN  mean±SD 181±119 925±1631 884±630
 b
 
 n 7
3
 7
3
 7
3
 
  Data was expressed as mean ±SD. One-way ANOVA and Post Hoc test (Student-Newman-  
  Keuls) was used to compare means at significance level (p<0.05). Means with different   
  Superscripts (a, b) were significantly different (p<0.05) when compared to each. 
  1. Low aluminum PN group had two samples lost (piglet # 10, 28) for day 0. 
  2. Sample with insufficient serum (piglet # 28, day 7 and piglet # 25, day 14) 
  3. Regular PN group had three samples lost (piglet # 15) for day 0,7,14. 
 
 
 
 
     Table 6.2. The concentration of serum iron in piglets during the study. 
 Iron (µg/L) 
Group Day 0 Day 7 Day 14 
    
Low Aluminum PN 2348±1072 4701±3025 6014±2318
a
 
 
                                     n 6
1
 7
2
 7
2
 
Regular PN  2542±1111 6332±3285 9290±3583
b
 
                                      n 7
3
 7
3
 7
3
 
        Data was expressed as mean ±SD. One-way ANOVA and Post Hoc test (Student- 
         Newman-Keuls) was used to compare means at significance level (p<0.05). Means 
         with different superscripts (a, b) were significantly different (p<0.05) when compared to  
         each. 
         1. Low aluminum PN group had had two samples missed at day 0 (piglet 10&28). 
         2. Sample with insufficient serum (piglet # 28, day 7 and piglet # 25, day 14) 
         3. Regular PN group had serum samples (piglet # 15) for day 0,7,14 lost. 
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            Figure 6.1. Correlation between serum aluminum and serum iron in the regular PN  
            group.  
             
 
6.5.2 Aluminum and iron concentration in liver  
The mean hepatic aluminum content in the low aluminum PN group was significantly 
(p<0.05) lower compared to the regular PN group (Table 6.3).  The mean hepatic iron content in 
the regular PN group was higher than the low aluminum PN but it wasn’t significant (Table 6.3).  
The hepatic Al level was significantly correlated with non-heme iron and total hepatic iron 
(Table 6.4).  
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Table 6.3. Mean hepatic concentration of aluminum and iron in the piglets. 
          Group   Aluminum (µg/g) Iron (µg/g) 
Low Aluminum PN  
n 
0.30±0.20
a  
6
1
 
237±78 
7
2
 
Regular PN  
n 
0.77±0.18
b 
8 
268±62 
8 
 Values are expressed as means ±SD. Means with different superscripts (a, b) were    
  significantly different (p<0.05) when compared to each other by one way-ANOVA/Student-  
  Newman-Keuls test.   
1. Low aluminum PN group had one sample missed (piglet # 6) and one sample insufficient 
for analysis (piglets # 22). 
  2. One liver sample (piglet # 6) missed. 
 
 
 
Table 6.4 Correlation between hepatic aluminum and hepatic levels of TBARS, non-heme 
iron, bleomycin detectable iron, and total iron. 
  
               
                 
 
 
 
 
 
 
 
 
            P-value < 0.05 considered significant                   
            r: Pearson correlation coefficient  
 
 
 
 
 
 
 
 
 
 
 
Parameter  
Low aluminum PN Regular PN 
r p-value r p-value 
TBARS  0.440 0.229 0.440 0.162 
Bleomycin Detectable iron  -0.449 0.448 0.387 0.195 
Non- heme iron 0.294 0.315 0.825 0.011 
Hepatic iron  0.349 0.249 0.809 0.008 
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6.5.3 Measurement of bleomycin detectable iron, non-heme iron and TBARS levels in liver 
tissues  
Concentration of bleomycin detectable iron, an indicator of the free iron pool (Gutteridge 
et al., 1981), was measured in the piglet liver tissues of all the groups (Table 6.5).  Bleomycin 
detectable iron levels were decreased non-significantly in the low aluminum PN group by 25% 
compared to regular PN group (Table 6.5).   
Non-heme iron levels in the piglet liver tissues were measured in the low aluminum PN 
and regular PN (Table 6.5).  The levels of non-heme iron in the liver of low aluminum PN group 
were non-significantly decreased by 18% compared to regular PN group, (p = 0.355) (Table 6.5).  
Non-heme iron was significantly correlated with hepatic Al concentration in the regular PN 
group (r = 0.825, p = 0.011) (Table 6.4).   
The oxidative stress TBARS assay which is used to detect malondialdehyde (MDA) level 
in samples was used to assess piglet liver tissues in the two groups; the low aluminum PN and 
regular PN group (Table 6.5).  The MDA level in the low aluminum PN group was reduced non-
significantly by 54% compared to regular PN group (p = 0.116) (Table 6.5).   
 
Table 6.5. TBARS, non-heme iron, and bleomycin detectable iron levels in piglet liver*. 
 
Group 
TBARS (MDA 
nmol/mg) 
Non-heme iron 
(µg Fe/mg tissue) 
Bleomycin detectable 
iron (µg Fe/mg tissue) 
Low Aluminum PN (n=7)
1
 1.1±0.4 0.9±0.2 0.26±0.11 
Regular PN (n=7)
2
 2.4±2.0 1.1±0.2 0.35±0.05 
p-value 0.116 0.355 0.105 
Values are expressed as means ±SD. Groups were compared to each other using one way-
ANOVA/Student- Newman- Keuls test (p<0.05).   
1. Insufficient sample (piglet # 2).  
2. Insufficient sample (piglet # 9). 
*liver was harvested at the end of the study (day 14). 
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6.6 Discussion 
The main objectives of this study were to evaluate the effect of reducing the aluminum 
contamination of parenteral nutrition on liver iron homeostasis and to determine if reducing the 
aluminum content of PN would decrease the free iron pool in the liver and reduce the signs of 
oxidative stress in liver tissues.   
This study demonstrated that compared to regular PN, the administration of a low Al PN 
to newborn piglets for 14 days caused a significant decrease in Al levels in serum and liver 
tissues, but no significant reduction in hepatic free iron oxidative stress.  
It is known that prolonged administration of PN to infants and children is associated with 
liver injury and hepatobiliary dysfunction, but still the exact mechanism that leads to liver injury 
is unknown.  Several PN studies conducted in different models of animals reported that oxidative 
stress plays an important role in developing liver injury (Sokol et al., 1996; Sola et al., 2002; 
Weinberger et al., 2002; Cai et al., 2006).  However, the investigators could not identify the 
source of oxidative stress in their models.   
 Al has evidently been established as a hepatotoxic metal.  In our study, Al contamination 
in the regular PN solutions provide Al intakes in the range of 38 µg/kg/d which exceeds the Food 
and Drug Administration recommended exposure limit of 5 µg/kg/d.  It is clear that Al 
contamination in the regular PN solutions led to significant accumulation of Al in the piglet’s 
liver of regular PN group.  A similar finding of hepatic Al accumulation has been observed in 
animals administered with PN (Klein, 1993; Demircan et al., 1998).   
Al is a non redox-active metal with a high pro-oxidant activity that has been shown to 
facilitate lipid peroxidation in the presence of free iron (Oteiza et al., 1993; Verstraeten et al., 
1995; Ohyashiki et al., 1996; Verstraeten et al., 1997).   In vitro studies using liposomal and 
brain microsomal systems, Al ions were reported to have stimulating effect on lipid peroxidation 
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induced by iron ions (Quinlan et al., 1988; Verstraeten et al., 1994).  Interestingly, Al ions were 
found to increase oxidation of low density lipoproteins (LDL) in the presence of Fe but not Cu 
(Kapiotis et al., 2005).   
In our study, no significant difference was observed in the levels of hepatic free iron, 
non-heme iron, and TBARS between the two groups; however, these levels were non-
significantly higher in the regular PN group compared to low Al PN group.  Various animal 
studies conducted on different animal models have shown that administration of PN resulted in 
significantly increased levels of lipid peroxidation products (a measure of oxidative stress) in the 
liver tissues (Sokol et al., 1996; Cai et al., 2006; Hong et al., 2007).  The lack of statistical 
significance could be attributed to the small number of animals used in the current study, and 
with a larger sample size differences may be detected.   
In summary, the present study indicates that the administration of lower aluminum 
content PN led to less aluminum loading in the serum and liver tissues.  However, we did not 
find significant reduction in the levels of free iron, non-heme iron, and lipid peroxidation 
products in the low Al PN compared to the regular PN therapy.  
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7.0 ALUMINUM CONTENT IN TOTAL PARENTERAL NUTRITION CAUSES 
DOWNREGULATION OF KEY CANALICULAR TRANSPORTERS 
 
7.1 Introduction  
Parenteral nutrition-associated cholestasis (PNAC) predisposes patients to the 
development of irreversible liver injury (Teitelbaum, 1997; Beath et al., 1996; Moss and Amii, 
1999).  Cholestasis may either result from a functional defect in bile formation at the level of the 
hepatocyte or from impairment in bile secretion and flow at the bile duct level.  Despite the 
recognition of illness for more than 30 years, the mechanism responsible for PNAC is unknown.  
In the past decade, research in the area has attributed the pathogenesis of some forms of 
cholestasis to mutations in members of ATP binding cassette (ABC) transporter family of 
proteins (Trauner et al., 1998; Balistreri et al., 2005) or to the inhibition of transporters involved 
in maintenance of bile flow.  Other forms include drug-induced cholestasis caused by drug or its 
metabolites (Stieger et al., 2000; Funk et al., 2001; Fattinger et al., 2001; Bode et al., 2002).  
Hepatobiliary transport proteins are responsible for the transport of various components of bile 
into the hepatocytes and/or the bile canaliculi (Trauner et al., 1998).  Exposure to cholestatic 
injury (e.g., drugs, hormones, pro-inflammatory cytokines, and biliary obstruction) results in 
reduced expression and function in hepatobiliary transport proteins.  Changes in the expression 
of hepatobiliary transporters provide a crucial mechanism to regulate bile acid homeostasis and 
to prevent hepatic bile acid toxicity in hepatocytes during cholestasis.  The basolateral 
transporters, sodium-taurocholate co-transporting polypeptide (NTCP) and organic anion-
transporting polypeptide (OATP) are the major transporters for the uptake of bile acids and 
organic solutes from blood into the hepatocyte (Kullak- Uplick et al., 2000; Meier and Stieger, 
2002).  The canalicular transporters bile salt export pump (BSEP), multidrug resistance-
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associated protein 2 (MRP2) and multidrug resistance protein (MDR3) are responsible for the 
excretion of bile salts, organic anions and phospholipids into bile (Trauner and Boyer, 2003).  
The nuclear receptors, farnesoid X receptor (FXR) and pregnane X receptor (PXR), also play an 
important role in the regulation of bile acid metabolism.  High bile acid levels can activate FXR, 
which directly or indirectly induces Bsep expression (Ananthanarayanan et al., 2001; Plass et al., 
2002).  The canalicular transporters, BSEP and MRP2, (Trauner and Boyer, 2003) are 
responsible for elimination of bile acids and conjugated bilirubin and, hence, play an important 
role in the hepatic detoxification processes.  In addition, these two transporters are involved 
simultaneously in hepatic excretion of diverse drugs and their metabolites into bile.  Thus, 
functional disruption of BSEP and MRP2 may result in accumulation in the liver of materials 
that are toxic and cause liver injury.   
Aluminum, a non-essential element, has been a known significant contaminant in the 
components of PN solutions (Stedman et al., 1985; De Vernejoul et al., 1985).  In 2004, 
Gonzalez et al investigated the effect of aluminum exposure on biliary secretory function in a rat 
model and concluded that intraperitoneal administration of Al led to downregulation of Mrp2 
and no specific mechanism through which Al exerts its deleterious effects was defined (Gonzalez 
et al., 2004).  However, an involvement of Al-induced oxidative stress was suggested as a 
mechanism to cause liver injury (Gonzalez et al., 2007).     
7.2 Hypothesis and Objective 
We hypothesize that aluminum content in PN causes down-regulation of canalicular 
transport proteins, Bsep and Mrp2.  The objective of this study was to investigate the effect of 
low aluminum and high aluminum PN (regular PN) on the mRNA expression of Bsep and Mrp2.   
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7.3 Material and Methods 
 
Frozen liver tissues (flash frozen in liquid nitrogen and stored at -80°C) from Yucatan 
piglets were used in this study.  The sixteen Yucatan piglets (3-4 days old) were obtained from a 
breeding herd facility at Memorial University of Newfoundland, St John’s, NL.  The piglets 
assigned randomly into; regular PN (8 piglets) and low Al PN group (8 piglets).  The piglets 
from the regular PN group received PN formulation with aluminum contamination at 38 g/kg/ 
day, and piglets from the low Al PN groups received PN with reduced aluminum contamination 
to 6 g/kg/day (section 5).  Both groups were administered PN (either low Al or regular PN) for 
14 days.  At the end of the study, piglets were killed humanly, and samples of bile, blood, and 
liver were collected.  Liver samples were snap frozen with liquid nitrogen and stored at -80°C.  
The liver tissues (n=11); 5 from regular PN and 6 from low Al PN were used for quantitative 
reverse transcription-polymerase chain reaction (QRT-PCR) analysis for the following apical 
(canalicular) transporters: Bsep, Mrp2.  However, five liver specimens (3 from regular PN and 2 
from low Al PN group) were not suitably preserved for QRT-PCR analysis.  The Institutional 
Animal Care Committee at Memorial University of Newfoundland, and University of 
Saskatchewan’s Animal Research Ethics Board approved all animal procedures and protocols 
used in this study.  
 
7.3.1‎mRNA‎expression‎levels‎of‎Bsep‎and‎Mrp2‎in‎piglet’s‎liver‎with‎regular‎PN‎and‎low 
aluminum PN solution. 
 
7.3.1.1 Total mRNA Isolation and Quantitative RT-PCR Analysis.  
Total mRNA was extracted from frozen piglet’s liver tissues using RNeasy Mini Kits 
according to manufacturer instructions (Qiagen Inc., Mississauga, ON).  The mRNA purity and 
quantity were determined spectrophotometrically by measurement at 260 nm and the 
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OD260/OD280 ratio, respectively, with a UV/VIS spectrophotometer (8453E, Agilent 
Technologies, Palo Alto, CA).  Total RNA was stored at -80°C until analysis. Gene sequences 
for each transporter were obtained from the National Center for Biotechnology Information 
GeneBank (NCBI) and specific primers were designed using Primer3 software (Whitehead 
Institute for Medical Research) (Table 7.1).  Quantitative RT-PCR (QRT-PCR) analysis was 
carried out using a QuantiTect SYBR Green RT-PCR kit (Applied Biosystems, Foster City, CA) 
and an Applied Biosystems 7300 Real-Time PCR system.  The QRT-PCR protocol was carried 
out according to manufacturer’s instructions.  The protocol consisted of reverse transcription (1 
cycle at 48°C, 30 minutes), PCR initial activation step (1 cycle at 95°C, 15 minutes), three-step 
thermal-cycling (50 cycles; denaturing at 94°C, 15 seconds, annealing at 60°C, 30 seconds, and 
primer extension at 60°C for 30 seconds), and a melt curve analysis from 65°C-95°C at 
0.5°C/second.  
7.3.1.2 Validation of the 2
-ΔΔCT
 Method.  
QRT-PCR assays were initially optimized to give a PCR efficiency between 1.9-2.1 (as 
determined by a 4-point standard curving using serial dilutions of control RNA with a slope 
range of -2.9 to -3.5) and a single melt-peak corresponding to the appropriate PCR product as 
verified by 2% agarose gel electrophoresis.  The reactions were further optimized for usage of 
the 2
-ΔΔCT
 method using β-actin as an internal standard.  The amplification efficiency of each 
target and β-actin was determined by constructing a standard curve from CT and RNA 
concentration.  The target genes and β-actin were then amplified using same diluted samples. 
The ΔCT were calculated (i.e. the difference between the target gene CT and β-actin CT).  The 
slope from log RNA concentration versus ΔCT was close to zero (<0.1).  Only primers giving 
PCR amplification close to 100% and the relative efficiencies between the target and β-actin that 
were approximately equal were used in our experiment.  Fold differences in mRNA expression 
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between control and treated samples were then calculated. 
 
Table 7.1. Primer sequence for RT-PCR of Bsep, β-actin and Mrp2. 
 
Gene 
 
Accession number 
Primers 
Forward Reverse 
Bsep (pig) SSU20587 tcacccagcactttctcc tgaccttggtccagttcg 
Mrp2 (pig) NM000392 ctgcaacttgggttgtcc catgatggtgtgcagtcg 
β-actin (pig) DQ845171 gtggcaccaccatgtacc cgtcgtactcctgcttgc 
Bsep: bile salt export pump; Mrp2: multidrug resistance-associated protein 2; β-actin: beta-actin.  
 
 
 
7.4 Results  
 
 7.4.1 Evaluation of the expression of Mrp2 and Bsep in piglet liver. 
 
The effect of regular PN and low aluminum PN solutions on canalicular transport proteins, Mrp2 
and Bsep, were tested using QRT-PCR.  In the regular PN group, the Mrp2 mRNA expression 
levels were significantly (p<0.05) reduced compared to low aluminum PN group (Figure 7.1).  
Expression levels of Bsep mRNA could not be analyzed, as the Bsep primer used could not be 
validated.  This could be attributed to using SYBR® Green dye assay (Applied Biosystems, 
Foster City, CA).  The disadvantage of this dye is its lack of specificity as it detects all amplified 
double-stranded DNA sequence, including non-specific reaction products (Hardikat et al., 2014).  
Using a probe such as TaqMan assays (a fluorophore-tagged probe-based chemistry) which 
detects only specific amplification products, may help to overcome this problem and produce 
reliable results.  Future work includes designing and validating another Bsep primer.  
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Figure 7.1. Expression levels of Mrp2 mRNA in piglet liver of both Low Aluminum and 
Regular PN group measured using QRT-PCR.  
Regular PN group (n=5) received continuous PN infusion with aluminium contamination at 38 
g/kg/day for 14 days.  The low aluminum PN group (n=6) received continuous PN infusion 
with aluminum contamination at 6 g/kg/day. * indicates that using independent t test, decrease 
in Mrp2 expression of regular PN group is significantly (p< 0.05) different compared to low 
aluminum PN group.  
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7.5 Discussion 
In the present study, the effect of low and high Al content PN on the canalicular 
transporter Mrp2 was investigated by measuring mRNA expression levels in the liver of the 
Yucatan neonatal piglets after 14 days of PN administration.    
In our previous work, we showed that administration of regular PN to newborn piglets for 
14 days resulted in high hepatic and serum aluminum levels.  The elevation was associated with 
liver injury evidenced by the loss of canalicular microvilli.  These results supported our main 
hypothesis of the study that Al content could play an important role in causing liver damage, and 
encouraged us to proceed in our work to study molecular changes, specifically the bile 
canalicular transport system, and how it is affected by the administration of regular PN as 
compared with the low Al PN.   
The overall results of the this experiment showed that regular PN infusion for 14 days 
caused downregulation of the Mrp2, an efflux transporter, in the liver of the neonatal piglets.  In 
the literature, few studies investigated bile canalicular transporters in PN animal models.  There 
are conflicting results about the mRNA expression levels of canalicular transporters in TPN 
administered animals.  For example, a study on adult mice (10-12 weeks) administered with TPN 
for 7 days showed a decline in the mRNA expression of mdr2, but no significant changes in 
mrp2 and bsep (Tazuke and Teitelbaum, 2009).  In another study, three weeks old rats received 
TPN for 4 days had significant declines in the mRNA expression levels of Mrp2.  The etiologyy 
behind the changes observed in this study was unknown (Nishimura et al., 2005); however, in a 
study for the effect of Al loading on canalicular transporters reported that Al could alter the bile 
canalicular transporter proteins and cause downregulation of Mrp2 (Gonzalez et al., 2004; 
Gonzalez et al., 2009).  However, the authors suggested that Al exerts its toxic effects through 
oxidative stress.   
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In our study, although the TBARS levels, a marker of oxidative stress, were high in liver 
tissues of the regular PN group compared to low Al group, these levels did not reach statistical 
significance.  Therefore, we cannot claim that the downregulation of Mrp2 seen in our study was 
associated with oxidative stress.    
The underlying mechanisms by which Al contamination in regular PN resulted in the 
downregulation of Mrp2 are far from being understood and cannot be addressed by our results.  
Nonetheless, our experiment indicates that Al content in the regular PN might be involved in the 
downregulation of Mrp2.    
Generally, in injured livers, the expression levels of basolateral transporters (uptake 
transporters) are reduced, and the levels of canalicular transporters (efflux transporters) are 
increased as a compensatory mechanism to maintain the bile flow and protect the liver from 
further injury (Trauner and Boyer, 2003; Slitt et al., 2007).  In our study, it is possible that the 
reduced levels of Mrp2 with increased total bile acids reflecting the development of cholestasis 
in the neonatal piglets (Nishimura et al., 2005).  
In conclusion, our results show that regular PN administration to newborn piglets for 14 
days caused decreased mRNA expression of the bile canalicular transporter Mrp2.  It is likely 
that Al content in PN plays a major role in the downregulation of Mrp2, however, in this study, 
using our results we could not determine the exact mechanisms that led to the downregulation of 
Mrp2.  More research is needed to explore the underlying mechanisms that cause downregulation 
of bile canalicular transporter proteins during administration of parenteral nutrition in neonates.    
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8.0 General conclusion and future studies 
 
The overall aim of this dissertation was to investigate the role of aluminum as a toxic 
component of PN and as a risk factor in developing parenteral nutrition associated liver injury.  
The study objectives were carried out using a variety of biochemical, histological, and biological 
imaging techniques to test our hypotheses.   
 Using a pig model, we have demonstrated that parenteral aluminum administration results 
in significant deposition of aluminum in the liver.  This resulted in hepatocyte injury as 
demonstrated by significant increases in serum total bile acid levels.  Interestingly, this was not 
reflected in a significant increase in serum direct bilirubin which is the biochemical marker used 
in clinical practice to indicate cholestasis.  It may be that the duration of aluminum exposure was 
not sufficient to cause an increase in bilirubin.  This may also be a reflection of the experimental 
model.  We used newborn pigs born at full term gestation.  We know that premature infants are 
at a much greater risk for parenteral nutrition associated cholestasis.  Furthermore, aluminum is 
primarily excreted by the kidneys and the findings of our study may be confounded by relatively 
mature renal function compared to that seen in premature infants.  
A troubling issue in this study was the finding of serum aluminum levels on day 0 that 
were markedly different between the study and control groups.  We have not found a satisfactory 
answer for this difference.  This may be a reflection of specimen contamination.  Aluminum is 
ubiquitous in nature and there is always the potential of contamination during the animal care as 
well as the handling and processing of specimens.  The study subject numbers were very small 
so outliers may confound the results due to statistical errors. 
It is particularly significant that we discovered parenteral aluminum caused marked 
damage to the bile canalicular microvilli.  This is the anatomical location of the bile acid 
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transport proteins, Mrp2 and Bsep, that are critical to the normal bile physiology.  This 
canalicular microvilli damage seen with aluminum administration mirrors that which has been 
seen in association with PNAC (Shu et al., 1991; Moran et al., 2005; Cai et al., 2006),  and this 
finding helps to support our hypothesis that aluminum contaminating PN is a contributing factor 
in PNAC.  The pathophysiology of how aluminum causes the canalicular microvilli damage is 
unclear.  It is also unclear if the rise in serum bile acids is a reflection of the microvilli damage or 
if other mechanism might be at play.  It is possible that the intracellular accumulation of bile 
acids causes a downregulation in the expression of those genes responsible for the production of 
these bile acid transport proteins.  We recognize that the dose of aluminum used for these studies 
was far in excess of that seen in PN therapy however we wanted to first demonstrate the toxic 
effects of aluminum and in our later work we would evaluate aluminum in doses that reflected 
that seen in clinical practice. 
 In trying to understand the pathophysiology of the hepatic toxicity of aluminum, we were 
interested in oxidative stress.  Aluminum competes with iron for binding to transferrin and we 
were interested if the aluminum was negatively effecting iron homeostasis leading to the 
production of toxic free radicals.  Contrary to our expectations, the significant elevation in Al 
levels in the serum and liver tissues of piglets of all study groups did not cause a significant 
increase in the levels of bleomycin detectable iron and oxidative stress as determined by 
measuring the lipid peroxidation by-product, TBARS in the liver tissues.   There was an 
increasing trend in the hepatic levels of free iron and TBARS and this may reflect the disruptive 
effect of Al loading on tissue iron homeostasis.  At this time, we can only speculate that Al 
disrupts iron homeostasis and plays a role in causing oxidative stress through its disrupting effect 
on iron homeostasis or its pro-oxidant effect resulting in increased tissue free iron thus 
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stimulating lipid peroxidation leading to liver injury.  Our results don’t support this however, it is 
possible that a larger sample size may help to conclude whether Al loading disrupts iron 
homeostasis in the liver tissues or not.   
Looking at the issue of the aluminum induced canalicular microvilli damage seen in our 
earlier work we then approached the question; if we reduce the amount of aluminum in PN 
would it result in less microvilli damage?  To study this we chose to use a newborn Yucatan 
miniature piglet model.  These animals grow at a slower rate than the previous study pigs and 
more closely mimic the growth rate of a human infant.  We administered PN to one group with 
the aluminum contamination level typical of that seen in human infant PN therapy.  This was 
compared to a group receiving PN with a much lower aluminum contamination level.  After 14 
days the serum and hepatic aluminum levels were much lower in the low Al exposure group.  
This correlated with a significant reduction in the degree of microvilli damage. This was 
encouraging as it seemed to support our hypothesis.  These results were not reflected in the 
serum total bile acid levels. We expected to see a higher serum bile acid level in the serum of 
piglets with greater aluminum exposure.  While there may be a trend in this regard the 
differences were not significant.  Our subject numbers may have been too low to demonstrate a 
real difference or it may be that a longer duration of aluminum exposure is required to show a 
significant result.  Our study was only 2 weeks duration and clinically significant liver injury 
may take longer to manifest. It may be that the canalicular microvilli damage is the earliest 
evidence of the hepatotoxic effects of aluminum.  
We found there was less serum and hepatic accumulation of Al in the low aluminum 
group compared to the regular PN group.  As we expected, the reduction in the serum and 
hepatic Al content was associated with lower serum total bile acids in the low aluminum PN 
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group compared to regular PN group.  These findings support our hypothesis that reducing 
aluminum content in the PN solutions reduces liver injury in the piglets administered with PN.  
Also, it indicates that Al might, in part, be responsible for the liver injury seen in piglets infused 
with PN.  Moreover, this study’s results showed that reducing Al content in PN solutions has led 
to significant reduction of Al accumulation in the serum and liver of newborn piglets.  This 
reduction was associated with less morphological changes and damage in the bile canalicular 
microvilli.   
It has been demonstrated in other types of cholestasis that there is a reduction in the 
hepatic expression of mRNA for the bile transport proteins Mrp2.  We were interested in seeing 
if aluminum had a deleterious effect on the expression of the bile acid transport proteins Mrp2 
and Bsep.  Due to technical challenges we were not able to obtain results for Bsep.  We did find 
that the higher aluminum exposure in PN resulted in a greater reduction in the expression of 
Mrp2.  This may help to explain at least one mechanism by which aluminum may contribute to 
PNAC.  Unfortunately, our study did not demonstrate a corresponding rise in serum bile acid 
levels.  Again, this may be a reflection of small subject numbers or it may be too short a study 
period to demonstrate a rise in bile acids.  The decrease in Mrp2 expression may be an early sign 
of the hepatotoxic effect of aluminum.   
8.1 Future study 
This work has discovered that aluminum in PN significantly accumulates in the liver and 
this is associated with both canalicular microvilli damage and a reduction in the expression of the 
bile acid transport protein Mrp2.  From these findings there are opportunities expand these 
investigations into the potential role of aluminum as a contributing factor in PNAC.  Additional 
work to look at the potential for aluminum to lead to cholestasis through oxidative stress is 
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worthwhile.  Employing a greater sample size or using a different research model may help to 
reveal a true role for oxidative stress in the pathophysiology of PNAC and a potential for 
antioxidant therapy in the prevention and treatment of this disease.   
While we found that aluminum caused damage to the canalicular microvilli how this 
occurs and the mechanisms involved deserves further study.  Some types of cholestatic disease 
have demonstrated that bile acid transport proteins are displaced from the microvilli apex surface 
to a more sub-apical location.  Radixin is the dominant erizin-radixin-moesin protein in bile 
canalicular membrane, and a cross-linker between actin filaments that forms the cores of 
canalicular membranes and plasma membrane proteins, and known as an important component 
in the formation of canalicular microvilli of hepatocytes (Amieva et al., 1994; Kondo et al., 
1997).  A study on mice lacking radixin demonstrated that the mice develop conjugated 
hyperbilirubinemia associated with loss of microvilli and Mrp2 from the canalicular membrane, 
indicating that radixin is required for the secretion of conjugated bilirubin through the efflux 
transporter Mrp2 (Kikuchi et al., 2002).  A future study investigating the effect of Al in PN on 
radixin may elucidate the mechanisms behind the loss of canalicular microvilli and 
downregulation of Mrp2 in the piglet’s liver.  
The effect of aluminum on the downregulation of the bile acid transport proteins is open 
for more investigation.  We could look at what levels this is occurring such as mRNA level, 
initiation of transcription, and promoter activity.  This will help to unravel the molecular 
mechanisms involved not only in the hepatotoxicity of aluminum but also of other factors in 
PNAC .  
Outside of the role of aluminum the effect of different fat emulsions specifically Omega-
3 based versus Omega-6 based is the current area of most interest in understanding PNAC.  The 
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anti-inflammatory nature of Omega-3 fatty acids has been shown to reduce the cholestasis of PN 
therapy.  Our work with imaging of the canalicular microvilli may prove very useful in 
evaluating the effects of these different fat emulsions in relationship to PNAC.  Likewise the 
study of the molecular expression of bile acid transport proteins with the different fat emulsions 
may help to further understand PNAC including how to prevent and treat it.   
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10.0 Appendices  
 
 
Appendix A 
      
 
     Table 10.1 Oral nutrient requirements for piglets (NRC, 1998).   
 
Nutrient Requirement* 
 
Metabolizable energy, kcal 
 
820 
Amino acids, g 65.0 
Essential amino acids, g 24 
Dextrose, g ND 
Sodium, mmol 27.4 
Potassium, mmol 19.2 
Calcium, mmol 56.1 
Magnesium, mmol 4.1 
Chloride, mmol 17.7 
Phosphate, mmol 56.5 
Zinc, µmol 382 
Manganese, µmol 18.2 
Copper, µmol 23.6 
Chromium, µmol ND 
Selenium, µmol 1.0 
Iodine, µmol 0.3 
Iron, mg 25.0 
Cobalamin, µg 5.0 
Biotin, µg 20.0 
Retinol, µg 189 
Ergocalciferol, µg 1.4 
α-Tocopherol, mg 2.7 
Phylloquinone, µg 130 
Ascorbic acid, mg ND 
Thiamin, µg 380 
Riboflavin, µg 1000 
Pyridoxine, µg 500 
Pantothenate, mg 3.0 
Folate, µg 80 
Niacinamide, mg 5.0 
Lipid g 32 
 
    * based on piglets weighing 3 to 5 kg 
 
